U.S. patent application number 14/579819 was filed with the patent office on 2015-12-03 for compositions and methods for treatment of cervical dysplasia.
The applicant listed for this patent is Advaxis, Inc., The Trustees of the University of Pennsylvania. Invention is credited to Yvonne PATERSON, John Rothman.
Application Number | 20150343047 14/579819 |
Document ID | / |
Family ID | 46455430 |
Filed Date | 2015-12-03 |
United States Patent
Application |
20150343047 |
Kind Code |
A1 |
PATERSON; Yvonne ; et
al. |
December 3, 2015 |
COMPOSITIONS AND METHODS FOR TREATMENT OF CERVICAL DYSPLASIA
Abstract
The present invention provides methods of treating, protecting
against, and inducing an immune response against cervical dysplasia
and cancer, comprising the step of administering to a subject a
recombinant Listeria strain, comprising a fusion peptide that
comprises an LLO fragment and an E7 and/or E6 antigen. The present
invention also provides methods for inducing an anti-E7 CTL
response in a human subject and treating HPV-mediated diseases,
disorders, and symptoms, comprising administration of the
recombinant Listeria strain.
Inventors: |
PATERSON; Yvonne;
(Philadelphia, PA) ; Rothman; John; (Lebanon,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Trustees of the University of Pennsylvania
Advaxis, Inc. |
Philadelphia
Princeton |
PA
NJ |
US
US |
|
|
Family ID: |
46455430 |
Appl. No.: |
14/579819 |
Filed: |
December 22, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13314583 |
Dec 8, 2011 |
8956621 |
|
|
14579819 |
|
|
|
|
11715497 |
Mar 8, 2007 |
8114414 |
|
|
13314583 |
|
|
|
|
11415271 |
May 2, 2006 |
8791237 |
|
|
11715497 |
|
|
|
|
11373528 |
Mar 13, 2006 |
7662396 |
|
|
11415271 |
|
|
|
|
10835662 |
Apr 30, 2004 |
7588930 |
|
|
11373528 |
|
|
|
|
10239703 |
Aug 7, 2003 |
7635479 |
|
|
PCT/US01/09736 |
Mar 26, 2001 |
|
|
|
10835662 |
|
|
|
|
11223945 |
Sep 13, 2005 |
7820180 |
|
|
11415271 |
|
|
|
|
10949667 |
Sep 24, 2004 |
7794729 |
|
|
11223945 |
|
|
|
|
Current U.S.
Class: |
424/190.1 ;
536/23.4 |
Current CPC
Class: |
A61K 39/00 20130101;
A61K 39/12 20130101; A61K 2039/53 20130101; A61K 2039/585 20130101;
C07K 2319/00 20130101; A61K 39/0011 20130101; C12N 2710/20034
20130101; C07K 14/70503 20130101; C07K 14/195 20130101; A61K
2039/6068 20130101; A61P 35/00 20180101; A61K 2039/523
20130101 |
International
Class: |
A61K 39/07 20060101
A61K039/07 |
Claims
1. A polynucleotide encoding a fusion protein comprising: a. a
PEST-like sequence from a prokaryotic organism; and b. a tumor
antigen.
2. The polynucleotide of claim 1, wherein the prokaryotic organism
is a Listeria bacterium.
3. The polynucleotide of claim 2, wherein the Listeria bacteria is
Listeria monocytogenes.
4. The polynucleotide of claim 1, wherein the PEST-like sequence is
selected from the sequences set forth in SEQ ID NOs: 2-5.
5. The polynucleotide of claim 1, wherein the polynucleotide is
operably linked to a promoter.
6. The polynucleotide of claim 5, wherein the promoter is selected
from the group consisting of Listerial prfA, Listerial hly
promoter, Listerial actA promoter, and Listerial p60 promoter.
7. The polynucleotide of claim 1, wherein the tumor antigen is a
self-antigen.
8. A method of enhancing immunogenicity of a tumor antigen in a
Listeria bacteria, the method comprising introducing a
polynucleotide into the Listeria bacteria, wherein the
polynucleotide encodes a fusion protein comprising the tumor
antigen and a PEST-like sequence from the Listeria bacteria.
9. The method of claim 8, wherein the Listeria bacteria is Listeria
monocytogenes.
10. The method of claim 8, wherein the PEST-like sequence is
selected from the sequences set forth in SEQ ID NOs: 2-5.
11. The method of claim 8, wherein the polynucleotide is operably
linked to a promoter.
12. The method of claim 11, wherein the promoter is selected from
the group consisting of Listerial prfA promoter, Listerial hly
promoter, Listerial actA promoter, and Listerial p60 promoter.
13. The method of claim 8, wherein the tumor antigen is a
self-antigen.
14. The method of claim 8, wherein the Listeria bacteria is
Listeria monocytogenes.
15. A polynucleotide encoding a fusion protein comprising: c. a
fragment of ActA protein from a Listeria bacterium, wherein the
fragment of ActA protein comprises one or more PEST-like sequences;
and d. a tumor antigen.
16. The polynucleotide of claim 15, wherein the polynucleotide is
operably linked to a promoter.
17. The polynucleotide of claim 16, wherein the promoter is
selected from the group consisting of Listerial prfA promoter,
Listerial hly promoter, Listerial actA promoter, and Listerial p60
promoter.
18. The polynucleotide of claim 15, wherein the fragment of ActA
protein has an amino acid sequence at least 80% homologous with the
amino acid sequence set forth in SEQ ID NO: 23.
19. The polynucleotide of claim 15, wherein the fragment of ActA
protein has an amino acid sequence as set forth in SEQ ID NO:
23.
20. The polynucleotide of 15, wherein the PEST-like sequences are
selected from the sequences set forth in SEQ ID NOs: 2-5.
21. The polynucleotide of claim 15, wherein the tumor antigen is a
self-antigen.
22. A method of enhancing immunogenicity of a tumor antigen in a
first Listeria bacterium, the method comprising introducing a
polynucleotide into the first Listeria bacterium, wherein the
polynucleotide encodes a fusion protein comprising the tumor
antigen and a fragment of ActA protein from a second Listeria
bacterium, wherein the fragment of ActA protein comprises one or
more PEST-like sequences.
23. The method of claim 22, wherein the polynucleotide is operably
linked to a promoter.
24. The method of claim 23, wherein the promoter is selected from
the group consisting of Listerial prfA promoter, Listerial hly
promoter, Listerial actA promoter, and Listerial p60 promoter.
25. The method of claim 22, the fragment of ActA protein has an
amino acid sequence at least 80% homologous with the amino acid
sequence set forth in SEQ ID NO: 23.
26. The method of claim 22, wherein the fragment of ActA protein
has an amino acid sequence as set forth in SEQ ID NO: 23.
27. The method of claim 22, wherein the tumor antigen is a
self-antigen.
28. The method of claim 22, wherein the first Listeria bacterium
and the second Listeria bacterium belong to the same subtype of
Listeria monocytogenes.
29. The method of claim 23, wherein the first Listeria bacterium
and the second Listeria bacterium belong to different subtypes of
Listeria monocytogenes.
30. The method of claim 22, wherein the PEST-like sequences are
selected from the sequences set forth in SEQ ID NOs: 2-5.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation of U.S. application Ser.
No. 13/314,583, filed Dec. 8, 2011, which is a Continuation-in-Part
of co-pending U.S. application Ser. No. 11/715,497, filed Mar. 8,
2007, now U.S. Pat. No. 8,114,414; which is a Continuation-in-Part
of co-pending U.S. application Ser. No. 11/415,271, filed May 2,
2006, now U.S. Pat. No. 8,791,237; and is (1) a
Continuation-in-Part of co-pending U.S. application Ser. No.
11/373,528, filed Mar. 13, 2006 now U.S. Pat. No. 7,662,396, which
is a Continuation-in-Part of co-pending U.S. application Ser. No.
10/835,662, filed Apr. 30, 2004 now U.S. Pat. No. 7,588,930, which
is a Continuation-in-Part of co-pending U.S. application Ser. No.
10/239,703, filed Aug. 7, 2003 now U.S. Pat. No. 7,635,479, which
is a National Phase Application of PCT International Application
No. PCT/US01/09736, International Filing Date Mar. 26, 2001, now
expired; and is (2) a Continuation-in-Part of co-pending U.S.
application Ser. No. 11/223,945, filed Sep. 13, 2005 now U.S. Pat.
No. 7,820,180, which is a Continuation-in-Part of co-pending U.S.
application Ser. No. 10/949,667, filed Sep. 24, 2004 now U.S. Pat.
No. 7,794,729. These applications are hereby incorporated in their
entirety by reference herein.
FIELD OF INVENTION
[0002] The present invention provides methods of treating,
protecting against, and inducing an immune response against
cervical pre-cancer or dysplasia, comprising the step of
administering to a subject a recombinant Listeria strain,
comprising a fusion peptide that comprises an LLO fragment and an
E7 and/or E6 antigen. The present invention also provides methods
for inducing an anti-E7 CTL response in a human subject and
treating HPV-mediated diseases, disorders, and symptoms, comprising
administration of the recombinant Listeria strain.
BACKGROUND OF THE INVENTION
[0003] Worldwide, approximately 500,000 cases of cervical cancer
are diagnosed each year. Cancer of the cervix (cervical cancer)
begins in the lining of the cervix and is the result of
infection-induced mutations of cervical cells by the human
papilloma virus (HPV). Early manifestations of persistent HPV
infection are reflected when normal cervical cells gradually
develop pre-cancerous changes that turn into cancer. Several terms
are used to describe these pre-cancerous changes, including
cervical intraepithelial neoplasia (CIN), squamous intraepithelial
lesion (SIL), and neoplasia in situ, dysplasia.
[0004] There are 2 major types of cervical cancers: squamous cell
carcinoma and adenocarcinoma. Cervical cancers and cervical
precancers are classified by microscopic appearance. About 80%-90%
of cervical cancers are squamous cell carcinomas, which are
composed of cells that resemble the flat, thin cells called
squamous cells that cover the surface of the endocervix. Squamous
cell carcinomas most often begin where the ectocervix joins the
endocervix.
[0005] The remaining 10%-20% of cervical cancers are
adenocarcinomas. Adenocarcinomas are becoming more common in women
born in the last 20 to 30 years. Cervical adenocarcinoma develops
from the mucus-producing gland cells of the endocervix. Less
commonly, cervical cancers have features of both squamous cell
carcinomas and adenocarcinomas. These are called "adenosquamous
carcinomas" or "mixed carcinomas."
[0006] Improved therapies for cervical pre-cancer or dysplasia are
urgently needed in the art.
SUMMARY OF THE INVENTION
[0007] The present invention provides methods of treating,
protecting against, and inducing an immune response against
cervical pre-cancer or dysplasia, comprising the step of
administering to a subject a recombinant Listeria strain,
comprising a fusion peptide that comprises an LLO fragment and an
E7 and/or E6 antigen. The present invention also provides methods
for inducing an anti-E7 CTL response in a human subject and
treating HPV-mediated diseases, disorders, and symptoms, comprising
administration of the recombinant Listeria strain.
[0008] In one embodiment, the present invention provides a method
of treating a cervical dysplasia in a human subject, comprising the
step of administering to the subject a recombinant Listeria strain,
the recombinant Listeria strain comprising a recombinant
polypeptide comprising an N-terminal fragment of an LLO protein
fused to an Human Papilloma Virus (HPV) E7 antigen, whereby the
recombinant Listeria strain induces an immune response against the
E7 antigen, thereby treating a cervical pre-cancer or dysplasia in
a human subject.
[0009] In another embodiment, the present invention provides a
method of protecting a human subject against a cervical cancer
comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a
recombinant polypeptide comprising an N-terminal fragment of an LLO
protein fused to an HPV E7 antigen, whereby the recombinant
Listeria strain induces an immune response against the E7 antigen,
thereby protecting a human subject against a cervical cancer. In
another embodiment, the recombinant Listeria strain comprises a
plasmid that encodes the recombinant polypeptide. In another
embodiment, the method further comprises the step of boosting the
human subject with a recombinant Listeria strain of the present
invention. In another embodiment, the method further comprises the
step of boosting the human subject with an immunogenic composition
comprising an E7 antigen. In another embodiment, the method further
comprises the step of boosting the human subject with an
immunogenic composition that directs a cell of the subject to
express an E7 antigen. Each possibility represents a separate
embodiment of the present invention.
[0010] In another embodiment, the present invention provides a
method for inducing an immune response against a cervical dysplasia
in a human subject, comprising the step of administering to the
subject a recombinant Listeria strain, the recombinant Listeria
strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an LLO protein fused to an HPV E7 antigen,
whereby the recombinant Listeria strain induces an immune response
against the E7 antigen, thereby inducing an immune response against
a cervical pre-cancer or dysplasia in a human subject. In another
embodiment, the recombinant Listeria strain comprises a plasmid
that encodes the recombinant polypeptide. In another embodiment,
the method further comprises the step of boosting the human subject
with a recombinant Listeria strain of the present invention. In
another embodiment, the method further comprises the step of
boosting the human subject with an immunogenic composition
comprising an E7 antigen. In another embodiment, the method further
comprises the step of boosting the human subject with an
immunogenic composition that directs a cell of the subject to
express an E7 antigen. Each possibility represents a separate
embodiment of the present invention.
[0011] In another embodiment, the present invention provides a
method for inducing an anti-E7 cytotoxic T cell response against a
cervical dysplasia in a human subject, comprising the step of
administering to the subject a recombinant Listeria strain, the
recombinant Listeria strain comprising a recombinant polypeptide
comprising an N-terminal fragment of an LLO protein fused to an HPV
E7 antigen, whereby the recombinant Listeria strain induces an
immune response against the E7 antigen, thereby inducing an anti-E7
cytotoxic T cell response against a cervical dysplasia in a human
subject. In another embodiment, the recombinant Listeria strain
comprises a plasmid that encodes the recombinant polypeptide. In
another embodiment, the method further comprises the step of
boosting the human subject with a recombinant Listeria strain of
the present invention. In another embodiment, the method further
comprises the step of boosting the human subject with an
immunogenic composition comprising an E7 antigen. In another
embodiment, the method further comprises the step of boosting the
human subject with an immunogenic composition that directs a cell
of the subject to express an E7 antigen. Each possibility
represents a separate embodiment of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1. Lm-E7 and Lm-LLO-E7 use different expression systems
to express and secrete E7. FIG. 1A. Lm-E7 was generated by
introducing a gene cassette into the orfZ domain of the L.
monocytogenes genome. FIG. 1B. The hly promoter drives expression
of the hly signal sequence and the first five amino acids (AA) of
LLO followed by HPV-16 E7. Lm-LLO-E7 was generated by transforming
the prfA-strain XFL-7 with the plasmid pGG-55. pGG-55 has the hly
promoter driving expression of a nonhemolytic fusion of LLO-E7.
pGG-55 also contains the prfA gene to select for retention of the
plasmid by XFL-7 in vivo.
[0013] FIG. 2. Lm-E7 and Lm-LLO-E7 secrete E7. Lm-Gag (lane 1),
Lm-E7 (lane 2), Lm-LLO-NP (lane 3), Lm-LLO-E7 (lane 4), XFL-7 (lane
5), and 10403S (lane 6) were grown overnight at 37.degree. C. in
Luria-Bertoni broth. Equivalent numbers of bacteria, as determined
by OD at 600 nm absorbance, were pelleted and 18 ml of each
supernatant was TCA precipitated. E7 expression was analyzed by
Western blot. The blot was probed with an anti-E7 mAb, followed by
HRP-conjugated anti-mouse (Amersham), then developed using ECL
detection reagents.
[0014] FIG. 3. Tumor immunotherapeutic efficacy of LLO-E7 fusions.
Tumor size in millimeters in mice is shown at 7, 14, 21, 28 and 56
days post tumor-inoculation. Naive mice: open-circles; Lm-LLO-E7:
filled circles; Lm-E7: squares; Lm-Gag: open diamonds; and
Lm-LLO-NP: filled triangles.
[0015] FIG. 4. Splenocytes from Lm-LLO-E7-immunized mice
proliferate when exposed to TC-1 cells. C57BL/6 mice were immunized
and boosted with Lm-LLO-E7, Lm-E7, or control rLm strains.
Splenocytes were harvested 6 days after the boost and plated with
irradiated TC-1 cells at the ratios shown. The cells were pulsed
with .sup.3H thymidine and harvested. Cpm is defined as
(experimental cpm)-(no-TC-1 control).
[0016] FIG. 5. Listeria constructs containing PEST regions induce a
higher percentage of E7-specific lymphocytes within the tumor. FIG.
5A. representative data from 1 experiment. FIG. 5B. average and SE
of data from all 3 experiments.
[0017] FIG. 6. E6/E7 transgenic mice develop tumors in their
thyroid, where the E7 gene is expressed. Mice were sacrificed at 3
months and had their thyroids removed, sectioned, and stained by
hematoxylin and eosin. FIG. 6A. Normal thyroid at 20.times.
magnification. Follicles are of normal size and lined with cuboidal
cells with abundant pink cytoplasm (arrow). FIG. 6B. E6/E7
transgenic mouse thyroid. Note the greatly enlarged follicles
because of the increased production of colloid. The cuboidal cells
lining the follicles are smaller with very little cytoplasm.
[0018] FIG. 7. E7 message is expressed in the thyroid and medullary
thymic epithelial cells of the E6/E7 transgenic mouse. FIG. 7A.
Tissue-specific expression of the E7 transgene is detected in the
thyroid only but not the liver, spleen, or whole thymus. Lane 1:
Liver; Lane 2: Spleen; Lane 3: Thyroid; Lane 4: Whole Thymus. FIG.
7B. Medullary thymic epithelial cells (mTECs) express E7. RT-PCR
results are as shown for equivalent amounts of cDNA loaded for 40
cycles. Lane 5: Cathepsin S; Lane 6: E7; Lane 7: Actin; Lane 8:
Negative Control.
[0019] FIG. 8. RAHYNIVTF peptide plus CpG adjuvant does not protect
against TC-1 challenge in E6/E7 transgenic mice. Two groups of
transgenic mice received either E7 peptide plus adjuvant or PBS. A
third group of wild type C57B1/6 control mice received E7 peptide
plus adjuvant. The mice were vaccinated twice intraperitoneally
(i.p.), 7 days apart and challenged with 5.times.10.sup.4 TC-1
cells 7 days later. Tumors were measured every 5 days until
unimmunized mice needed to be sacrificed. Error bars: standard
deviations from the mean value.
[0020] FIGS. 9A-9B. Vaccines of the present invention induce
regression of solid tumors in the E6/E7 transgenic mice in
wild-type mice and transgenic mice immunized with LM-LLO-E7 (FIG.
9A), or LM-ActA-E7 (FIG. 9B), left naive, or treated with LM-NP
(control).
[0021] FIGS. 10A-10B. FIG. 10A. IV immunization of LM-LLO-E7 is
effective at inducing the regression of established tumors at doses
as low as 1.times.10.sup.6 CFU per mouse. FIG. 10B. Tumors loads
for the 2 cohorts in the LM-LLO-E7 clinical trial.
[0022] FIGS. 11A-11B. FIG. 11A. Effect of passaging on bacterial
load (virulence) of recombinant Listeria vaccine vectors. Top
panel. Lm-Gag. Bottom panel. Lm-LLO-E7. FIG. 11B. Effect of
passaging on bacterial load of recombinant Lm-E7 in the spleen.
Average CFU of live bacteria per milliliter of spleen homogenate
from four mice is depicted.
[0023] FIG. 12. Induction of antigen-specific CD8.sup.+ T-cells for
HIV-Gag and LLO after administration of passaged Lm-Gag versus
unpassaged Lm-Gag. Mice were immunized with 10.sup.3 (Figure A,
Figure B, Figure E, Figure F) or 10.sup.5 (Figure C, Figure D,
Figure G, Figure H) CFU passaged Listeria vaccine vectors, and
antigen-specific T-cells were analyzed. Figures B, D, F, H:
unpassaged Listeria vaccine vectors. Figures A-D immune response to
MHC class I HIV-Gag peptide. Figures E-H: immune response to an LLO
peptide. Figure I: splenocytes from mice immunized with 10.sup.5
CFU passaged Lm-Gag stimulated with a control peptide from HPV
E7.
[0024] FIGS. 13A-10B. FIG. 13A. Plasmid isolation throughout LB
stability study. FIG. 13B. Plasmid isolation throughout TB
stability study. C. Quantitation of TB stability study.
[0025] FIG. 14. Numbers of viable bacteria chloramphenicol
(CAP)-resistant and CAP-sensitive colony-forming units (CFU) from
bacteria grown in LB. Dark bars: CAP.sup.+; white bars: CAP.sup.-.
The two dark bars and two white bars for each time point represent
duplicate samples.
[0026] FIG. 15. Numbers of viable bacteria CAP-resistant and
CAP-sensitive CFU from bacteria grown in TB. Dark bars: CAP.sup.+;
white bars: CAP. The two dark bars and two white bars for each time
point represent duplicate samples.
[0027] FIG. 16. Growth of L. monocytogenes following short-term
cryopreservation.
[0028] FIG. 17. Viability of LB RWCB following storage at
-70.degree. C.
[0029] FIG. 18. Viability of TB RWCB following storage at
-70.degree. C.
[0030] FIG. 19. Growth curve of 200 mL LB and TB cultures of
Lm-LLO-E7.
[0031] FIG. 20. Growth of Lm-LLO-E7 in 4 defined media with and
without AA, vitamins and trace elements, at the 50 mL stage.
"AA+Vits+TE+" denotes bulk medium, essential components, AA,
vitamins and trace elements; "AA+Vits+TE-" denotes bulk medium,
essential components, AA, and vitamins; "AA+Vits-TE-" denotes bulk
medium, essential components, and AA; "AA-Vits-TE-" denotes bulk
medium and essential components.
[0032] FIG. 21. Growth of Lm-LLO-E7 in 4 defined media with and
without amino acids, vitamins and trace elements, at the 200 mL
stage. Groups are labeled as for FIG. 23.
[0033] FIG. 22. Growth of Lm-LLO-E7 in 200 mL cultures of defined
media with different concentrations of supplements, with and
without inorganic nitrogen.
[0034] FIG. 23. Growth of Lm-LLO-E7 in 200 mL cultures of defined
media supplemented with different concentrations of supplements,
with and without glutamine and iron.
[0035] FIGS. 24A-C. FIG. 24A. Growth curves of Lm-LLO-E7 in 5 L
fermenters in TB and defined media. FIG. 24B. Viability of
Lm-LLO-E7 grown in 5 L fermenters in TB to different densities.
FIG. 24C. Viability of Lm-LLO-E7 grown in 5 L fermenters in defined
media to different densities.
[0036] FIG. 25. Percentage of viable cells remaining after storage
at -20.degree. C. for 3 days.
[0037] FIG. 26. Percentage of viable cells remaining after storage
at -70.degree. C. for 3 days
[0038] FIGS. 27A-C. FIG. 27A. Percentage of viable cells remaining
following snap freezing in liquid nitrogen and storage at
-70.degree. C. for 3 days. FIG. 27B. Summary of viability studies
for several conditions. FIG. 27C. Growth kinetics of cryopreserved
samples after thawing.
[0039] FIG. 28. Listeria vaccine vectors grown in defined media
effectively protect mice against growth of established tumors. "BHI
cultured"--vectors cultured in Brain-Heart Infusion media "Terrific
Broth cultured" and "defined media cultured"--vectors cultured in
indicated media.
DETAILED DESCRIPTION OF THE INVENTION
[0040] The present invention provides methods of treating,
protecting against, and inducing an immune response against
cervical pre-cancer or dysplasia, comprising the step of
administering to a subject a recombinant Listeria strain,
comprising a fusion peptide that comprising a listeriolysin O (LLO)
fragment and an E7 antigen. The present invention also provides
methods for inducing an anti-E7 CTL response in a human subject and
treating HPV-mediated diseases, disorders, and symptoms, comprising
administration of the recombinant Listeria strain.
[0041] In one embodiment, the present invention provides a method
of treating a cervical dysplasia in a human subject, comprising the
step of administering to the subject a recombinant Listeria strain,
the recombinant Listeria strain comprising a recombinant
polypeptide comprising an N-terminal fragment of an LLO protein and
an Human Papilloma Virus (HPV) E7 antigen, whereby the recombinant
Listeria strain induces an immune response against the E7 antigen,
thereby treating a cervical pre-cancer or dysplasia in a human
subject. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. In another embodiment, the method further
comprises the step of boosting the human subject with a recombinant
Listeria strain of the present invention. In another embodiment,
the method further comprises the step of boosting the human subject
with an immunogenic composition comprising an E7 antigen. In
another embodiment, the method further comprises the step of
boosting the human subject with an immunogenic composition that
directs a cell of the subject to express an E7 antigen. Each
possibility represents a separate embodiment of the present
invention.
[0042] The N-terminal LLO protein fragment and HPV E7 antigen are,
in another embodiment, fused directly to one another. In another
embodiment, the genes encoding the N-terminal LLO protein fragment
and HPV E7 antigen are fused directly to one another. In another
embodiment, the N-terminal LLO protein fragment and HPV E7 antigen
are attached via a linker peptide. In another embodiment, the
N-terminal LLO protein fragment and HPV E7 antigen are attached via
a heterologous peptide. In another embodiment, the N-terminal LLO
protein fragment is N-terminal to the HPV E7 antigen. In another
embodiment, the N-terminal LLO protein fragment is the
N-terminal-most portion of the fusion protein. Each possibility
represents a separate embodiment of the present invention.
[0043] In another embodiment, the present invention provides a
method of protecting a human subject against a cervical cancer,
comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a
recombinant polypeptide comprising an N-terminal fragment of an LLO
protein and an HPV E7 antigen, whereby the recombinant Listeria
strain induces an immune response against the E7 antigen, thereby
protecting a human subject against a cervical cancer. In another
embodiment, the recombinant Listeria strain expresses the
recombinant polypeptide. In another embodiment, the recombinant
Listeria strain comprises a plasmid that encodes the recombinant
polypeptide. In another embodiment, the method further comprises
the step of boosting the human subject with a recombinant Listeria
strain of the present invention. In another embodiment, the method
further comprises the step of boosting the human subject with an
immunogenic composition comprising an E7 antigen. In another
embodiment, the method further comprises the step of boosting the
human subject with an immunogenic composition that directs a cell
of the subject to express an E7 antigen. Each possibility
represents a separate embodiment of the present invention.
[0044] In another embodiment, the present invention provides a
method for inducing an immune response against a cervical dysplasia
in a human subject, comprising the step of administering to the
subject a recombinant Listeria strain, the recombinant Listeria
strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an LLO protein and an HPV E7 antigen,
thereby inducing an immune response against a cervical dysplasia in
a human subject. In another embodiment, the recombinant Listeria
strain expresses the recombinant polypeptide. In another
embodiment, the recombinant Listeria strain comprises a plasmid
that encodes the recombinant polypeptide. In another embodiment,
the method further comprises the step of boosting the human subject
with a recombinant Listeria strain of the present invention. In
another embodiment, the method further comprises the step of
boosting the human subject with an immunogenic composition
comprising an E7 antigen. In another embodiment, the method further
comprises the step of boosting the human subject with an
immunogenic composition that directs a cell of the subject to
express an E7 antigen. Each possibility represents a separate
embodiment of the present invention.
[0045] As provided herein, recombinant Listeria strains expressing
LLO-antigen fusions induce anti-tumor immunity (Example 1), elicit
antigen-specific T cell proliferation (Example 2), generate
antigen-specific, tumor-infiltrating T cells (Example 3), and
abrogate central and peripheral tolerance to antigens such as E6
and E7 (Examples 4-11). Thus, vaccines of the present invention are
efficacious at inducing immune responses against E7 and E6.
Further, the recombinant Listeria strains are safe and improve
disease indicators in human subjects (Example 9).
[0046] In another embodiment, the present invention provides a
method of treating a cervical dysplasia in a human subject,
comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a
recombinant polypeptide comprising an N-terminal fragment of an LLO
protein and an HPV E7 antigen, whereby the recombinant Listeria
strain induces an immune response against the E7 antigen, thereby
treating a cervical pre-cancer or dysplasia in a human subject. In
another embodiment, the recombinant Listeria strain expresses the
recombinant polypeptide. In another embodiment, the recombinant
Listeria strain comprises a plasmid that encodes the recombinant
polypeptide. Each possibility represents a separate embodiment of
the present invention.
[0047] In another embodiment, the present invention provides a
method of protecting a human subject against a cervical cancer,
comprising the step of administering to the subject a recombinant
Listeria strain, the recombinant Listeria strain comprising a
recombinant polypeptide comprising an N-terminal fragment of an LLO
protein and an HPV E7 antigen, whereby the recombinant Listeria
strain induces an immune response against the E7 antigen, thereby
protecting a human subject against a cervical pre-cancer or
dysplasia. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. Each possibility represents a separate
embodiment of the present invention.
[0048] In another embodiment, the present invention provides a
method for inducing an immune response against a cervical dysplasia
in a human subject, comprising the step of administering to the
subject a recombinant Listeria strain, the recombinant Listeria
strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an LLO protein and an HPV E7 antigen,
thereby inducing an immune response against a cervical dysplasia in
a human subject. In another embodiment, the recombinant Listeria
strain expresses the recombinant polypeptide. In another
embodiment, the recombinant Listeria strain comprises a plasmid
that encodes the recombinant polypeptide. Each possibility
represents a separate embodiment of the present invention.
[0049] As provided herein, recombinant Listeria strains expressing
LLO-antigen fusions induce anti-tumor immunity (Example 3),
generate antigen-specific, tumor-infiltrating T cells (Example 3),
and abrogate central and peripheral tolerance to antigens such as
E6 and E7 (Examples 4-11). Further, recombinant Listeria strains of
the present invention are safe and improve disease indicators in
human subjects (Example 9).
[0050] The N-terminal LLO protein fragment and HPV E7 antigen are,
in another embodiment, fused directly to one another. In another
embodiment, the genes encoding the N-terminal LLO protein fragment
and HPV E7 antigen are fused directly to one another. In another
embodiment, the N-terminal LLO protein fragment and HPV E7 antigen
are attached via a linker peptide. In another embodiment, the
N-terminal LLO protein fragment and HPV E7 antigen are attached via
a heterologous peptide. In another embodiment, the N-terminal
protein fragment is N-terminal to the HPV E7 antigen. In another
embodiment, the N-terminal LLO protein fragment is the
N-terminal-most portion of the fusion protein. Each possibility
represents a separate embodiment of the present invention.
[0051] In another embodiment, the present invention provides a
method for vaccinating a human subject against an HPV, comprising
the step of administering to the subject a recombinant Listeria
strain, the recombinant Listeria strain comprising a recombinant
polypeptide comprising an N-terminal fragment of an LLO protein and
an HPV E7 antigen, thereby vaccinating a human subject against an
HPV. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. Each possibility represents a separate
embodiment of the present invention.
[0052] In another embodiment, the present invention provides a
method for vaccinating a human subject against an HPV, comprising
the step of administering to the subject a recombinant Listeria
strain, the recombinant Listeria strain comprising a recombinant
polypeptide comprising a PEST-like sequence-containing peptide and
an HPV E7 antigen, thereby vaccinating a human subject against an
HPV. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. Each possibility represents a separate
embodiment of the present invention.
[0053] In another embodiment, the present invention provides a
method for vaccinating a human subject against an HPV, comprising
the step of administering to the subject a recombinant Listeria
strain, the recombinant Listeria strain comprising a recombinant
polypeptide comprising an N-terminal fragment of an LLO protein and
an HPV E7 antigen, thereby vaccinating a human subject against an
HPV. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. Each possibility represents a separate
embodiment of the present invention.
[0054] As provided herein, recombinant Listeria strains expressing
fusions of an antigen to LLO, -induce anti-E6 and E7 immunity
(Example 3), and abrogate central and peripheral tolerance to
antigens such as E6 and E7 (Examples 4-11). Further, recombinant
Listeria strains of the present invention are safe and improve
disease indicators in human subjects (Example 9). Thus, Listeria
strains of the present invention can be used to vaccinate a subject
against an HPV, thereby preventing or inhibiting HPV-mediated
carcinogenesis.
[0055] In another embodiment, the subject is at risk for developing
an HPV-mediated carcinogenesis (e.g. a cervical pre-cancer or
dysplasia). In another embodiment, the subject is HPV-positive. In
another embodiment, the subject's husband is HPV-positive. In
another embodiment, the subject exhibits cervical intraepithelial
neoplasia. In another embodiment, the subject exhibits a squamous
intraepithelial lesion. In another embodiment, the subject exhibits
a dysplasia in the cervix. Each possibility represents a separate
embodiment of the present invention.
[0056] The HPV that is the target of methods of the present
invention is, in another embodiment, an HPV 16. In another
embodiment, the HPV is an HPV-18. In another embodiment, the HPV is
selected from HPV-16 and HPV-18. In another embodiment, the HPV is
an HPV-31. In another embodiment, the HPV is an HPV-35. In another
embodiment, the HPV is an HPV-39. In another embodiment, the HPV is
an HPV-45. In another embodiment, the HPV is an HPV-51. In another
embodiment, the HPV is an HPV-52. In another embodiment, the HPV is
an HPV-58. In another embodiment, the HPV is a high-risk HPV type.
In another embodiment, the HPV is a mucosal HPV type. Each
possibility represents a separate embodiment of the present
invention.
[0057] In another embodiment, the present invention provides a
method for inducing a regression of a cervical dysplasia in a human
subject, comprising the step of administering to the subject a
recombinant Listeria strain, the recombinant Listeria strain
comprising a recombinant polypeptide comprising an N-terminal
fragment of an LLO protein and an HPV E7 antigen, thereby inducing
a regression of a cervical pre-cancer or dysplasia in a human
subject. In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide. In another embodiment, the
recombinant Listeria strain comprises a plasmid that encodes the
recombinant polypeptide. Each possibility represents a separate
embodiment of the present invention.
[0058] In another embodiment, the present invention provides a
method for reducing an incidence of relapse of a cervical
pre-cancer or dysplasia in a human subject, comprising the step of
administering to the subject a recombinant Listeria strain, the
recombinant Listeria strain comprising a recombinant polypeptide
comprising an N-terminal fragment of an LLO protein and an HPV E7
antigen, thereby reducing an incidence of relapse of a cervical
pre-cancer or dysplasia in a human subject. In another embodiment,
the recombinant Listeria strain expresses the recombinant
polypeptide. In another embodiment, the recombinant Listeria strain
comprises a plasmid that encodes the recombinant polypeptide. Each
possibility represents a separate embodiment of the present
invention.
[0059] In another embodiment, the present invention provides a
method for suppressing a formation of a cervical dysplasia in a
human subject, comprising the step of administering to the subject
a recombinant Listeria strain, the recombinant Listeria strain
comprising a recombinant polypeptide comprising an N-terminal
fragment of an LLO protein and an HPV E7 antigen, thereby
suppressing a formation of a cervical dysplasia in a human subject.
In another embodiment, the recombinant Listeria strain expresses
the recombinant polypeptide. In another embodiment, the recombinant
Listeria strain comprises a plasmid that encodes the recombinant
polypeptide. Each possibility represents a separate embodiment of
the present invention.
[0060] In another embodiment, the present invention provides a
method for inducing a remission of a cervical pre-cancer or
dysplasia in a human subject, comprising the step of administering
to the subject a recombinant Listeria strain, the recombinant
Listeria strain comprising a recombinant polypeptide comprising an
N-terminal fragment of an LLO protein and an HPV E7 antigen,
thereby inducing a remission of a cervical pre-cancer or dysplasia
in a human subject. In another embodiment, the recombinant Listeria
strain expresses the recombinant polypeptide. In another
embodiment, the recombinant Listeria strain comprises a plasmid
that encodes the recombinant polypeptide. Each possibility
represents a separate embodiment of the present invention.
[0061] In another embodiment, the present invention provides a
method for impeding a growth of a cervical tumor in a human
subject, comprising the step of administering to the subject a
recombinant Listeria strain, the recombinant Listeria strain
comprising a recombinant polypeptide comprising an N-terminal
fragment of an LLO protein and an HPV E7 antigen, thereby impeding
a growth of a cervical tumor in a human subject. In another
embodiment, the recombinant Listeria strain expresses the
recombinant polypeptide. In another embodiment, the recombinant
Listeria strain comprises a plasmid that encodes the recombinant
polypeptide. Each possibility represents a separate embodiment of
the present invention.
[0062] The cervical tumor targeted by methods of the present
invention is, in another embodiment, a squamous cell carcinoma. In
another embodiment, the cervical tumor is an adenocarcinoma. In
another embodiment, the cervical tumor is an adenosquamous
carcinoma. In another embodiment, the cervical tumor is a small
cell carcinoma. In another embodiment, the cervical tumor is any
other type of cervical tumor known in the art. Each possibility
represents a separate embodiment of the present invention.
[0063] In another embodiment, an HPV E6 antigen is utilized instead
of or in addition to an E7 antigen in a method of the present
invention for treating, protecting against, or inducing an immune
response against a cervical pre-cancer or dysplasia.
[0064] In another embodiment, the present invention provides a
method for inducing an anti-E7 cytotoxic T cell (CTL) response
against a cervical dysplasia in a human subject, comprising the
step of administering to the subject a recombinant Listeria strain,
the recombinant Listeria strain comprising a recombinant
polypeptide comprising an N-terminal fragment of an LLO protein and
an HPV E7 antigen, thereby inducing an anti-E7 CTL response in a
human subject. In another embodiment, the recombinant Listeria
strain comprises a plasmid that encodes the recombinant
polypeptide. In another embodiment, the method further comprises
the step of boosting the subject with a recombinant Listeria strain
of the present invention. In another embodiment, the method further
comprises the step of boosting the subject with an immunogenic
composition comprising an E7 antigen. In another embodiment, the
method further comprises the step of boosting the subject with an
immunogenic composition that directs a cell of the subject to
express an E7 antigen. In another embodiment, the CTL response is
capable of therapeutic efficacy against an HPV-mediated disease,
disorder, or symptom. In another embodiment, the CTL response is
capable of prophylactic efficacy against an HPV-mediated disease,
disorder, or symptom. Each possibility represents a separate
embodiment of the present invention.
[0065] In another embodiment, the present invention provides a
method of treating or ameliorating an HPV-mediated disease,
disorder, or symptom in a subject, comprising the step of
administering to the subject a recombinant Listeria strain, the
recombinant Listeria strain comprising a recombinant polypeptide
comprising an N-terminal fragment of an LLO protein and an HPV E7
antigen, whereby the recombinant Listeria strain induces an immune
response against the E7 antigen, thereby treating or ameliorating
an HPV-mediated disease, disorder, or symptom in a subject. In
another embodiment, the subject is a human subject. In another
embodiment, the subject is any other type of subject known in the
art. Each possibility represents a separate embodiment of the
present invention.
[0066] The HPV causing the disease, disorder, or symptom is, in
another embodiment, an HPV 16. In another embodiment, the HPV is an
HPV-18. In another embodiment, the HPV is an HPV-31. In another
embodiment, the HPV is an HPV-35. In another embodiment, the HPV is
an HPV-39. In another embodiment, the HPV is an HPV-45. In another
embodiment, the HPV is an HPV-51. In another embodiment, the HPV is
an HPV-52. In another embodiment, the HPV is an HPV-58. In another
embodiment, the HPV is a high-risk HPV type. In another embodiment,
the HPV is a mucosal HPV type. Each possibility represents a
separate embodiment of the present invention.
[0067] In another embodiment, an HPV E6 antigen is utilized instead
of or in addition to an E7 antigen in a method of the present
invention for treating or ameliorating an HPV-mediated disease,
disorder, or symptom.
[0068] In another embodiment, an HPV E6 antigen is utilized instead
of or in addition to an E7 antigen in a method of the present
invention for treating or ameliorating an HPV-mediated disease,
disorder, or symptom.
[0069] The antigen of methods and compositions of the present
invention is, in another embodiment, an HPV E7 protein. In another
embodiment, the antigen is an HPV E6 protein. In another
embodiment, the antigen is any other HPV protein known in the art.
Each possibility represents a separate embodiment of the present
invention.
[0070] "E7 antigen" refers, in another embodiment, to an E7
protein. In another embodiment, the term refers to an E7 fragment.
In another embodiment, the term refers to an E7 peptide. In another
embodiment, the term refers to any other type of E7 antigen known
in the art. Each possibility represents a separate embodiment of
the present invention.
[0071] The E7 protein of methods and compositions of the present
invention is, in another embodiment, an HPV 16 E7 protein. In
another embodiment, the E7 protein is an HPV-18 E7 protein. In
another embodiment, the E7 protein is an HPV-31 E7 protein. In
another embodiment, the E7 protein is an HPV-35 E7 protein. In
another embodiment, the E7 protein is an HPV-39 E7 protein. In
another embodiment, the E7 protein is an HPV-45 E7 protein. In
another embodiment, the E7 protein is an HPV-51 E7 protein. In
another embodiment, the E7 protein is an HPV-52 E7 protein. In
another embodiment, the E7 protein is an HPV-58 E7 protein. In
another embodiment, the E7 protein is an E7 protein of a high-risk
HPV type. In another embodiment, the E7 protein is an E7 protein of
a mucosal HPV type. Each possibility represents a separate
embodiment of the present invention.
[0072] "E6 antigen" refers, in another embodiment, to an E6
protein. In another embodiment, the term refers to an E6 fragment.
In another embodiment, the term refers to an E6 peptide. In another
embodiment, the term refers to any other type of E6 antigen known
in the art. Each possibility represents a separate embodiment of
the present invention.
[0073] The E6 protein of methods and compositions of the present
invention is, in another embodiment, an HPV 16 E6 protein. In
another embodiment, the E6 protein is an HPV-18 E6 protein. In
another embodiment, the E6 protein is an HPV-31 E6 protein. In
another embodiment, the E6 protein is an HPV-35 E6 protein. In
another embodiment, the E6 protein is an HPV-39 E6 protein. In
another embodiment, the E6 protein is an HPV-45 E6 protein. In
another embodiment, the E6 protein is an HPV-51 E6 protein. In
another embodiment, the E6 protein is an HPV-52 E6 protein. In
another embodiment, the E6 protein is an HPV-58 E6 protein. In
another embodiment, the E6 protein is an E6 protein of a high-risk
HPV type. In another embodiment, the E6 protein is an E6 protein of
a mucosal HPV type. Each possibility represents a separate
embodiment of the present invention.
[0074] In another embodiment, the present invention provides a
method of vaccinating a human subject against an antigen of
interest, the method comprising the step of administering
intravenously to the human subject a recombinant Listeria strain
comprising or expressing the antigen of interest, wherein the first
peptide is selected from an N-terminal fragment of an LLO protein,
thereby vaccinating a human subject against an antigen of
interest.
[0075] In another embodiment, the present invention provides a
method of vaccinating a human subject against an antigen of
interest, the method comprising the step of administering
intravenously to the human subject an immunogenic composition,
comprising a fusion of a first peptide to the antigen of interest,
wherein the first peptide is an N-terminal fragment of an LLO
protein of interest.
[0076] In another embodiment, the present invention provides a
method of vaccinating a human subject against an antigen of
interest, the method comprising the step of administering
intravenously to the human subject a recombinant Listeria strain
comprising a recombinant polypeptide, the recombinant polypeptide
comprising a first peptide fused to the antigen of interest,
wherein the first peptide is an N-terminal fragment of an LLO
protein.
[0077] In another embodiment, the present invention provides a
method of inducing a CTL response in a human subject against an
antigen of interest, the method comprising the step of
administering to the human subject a recombinant Listeria strain
comprising or expressing the antigen of interest, thereby inducing
a CTL response in a human subject against an antigen of interest.
In another embodiment, the step of administering is intravenous
administration. Each possibility represents a separate embodiment
of the present invention.
[0078] As provided herein, recombinant Listeria strains expressing
LLO-antigen fusions induce anti-tumor immunity (Example 1), elicit
antigen-specific T cell proliferation (Example 2), generate
antigen-specific, tumor-infiltrating T cells (Example 3), and
abrogate peripheral tolerance to antigens such as E6 and E7
(Examples 4-11). Thus, vaccines of the present invention are
efficacious at inducing immune responses against E7 and E6.
Further, the recombinant Listeria strains are safe and improve
disease indicators in human subjects (Example 9).
[0079] In another embodiment, the antigen of interest is HPV-E7. In
another embodiment, the antigen is HPV-E6. In another embodiment,
the antigen is human papilloma virus antigens E1 and E2 from type
HPV-16, -18, -31, -33, -35 or -45 human papilloma viruses
[0080] Each antigen represents a separate embodiment of the present
invention.
[0081] The immune response induced by methods and compositions of
the present invention is, in another embodiment, a T cell response.
In another embodiment, the immune response comprises a T cell
response. In another embodiment, the response is a CD8.sup.+ T cell
response. In another embodiment, the response comprises a CD8.sup.+
T cell response. Each possibility represents a separate embodiment
of the present invention.
[0082] The N-terminal LLO protein fragment of methods and
compositions of the present invention comprises, in another
embodiment, SEQ ID No: 1. In another embodiment, the fragment
comprises an LLO signal peptide. In another embodiment, the
fragment comprises SEQ ID No: 15. In another embodiment, the
fragment consists approximately of SEQ ID No: 15. In another
embodiment, the fragment consists essentially of SEQ ID No: 15. In
another embodiment, the fragment corresponds to SEQ ID No: 15. In
another embodiment, the fragment is homologous to SEQ ID No: 15. In
another embodiment, the fragment is homologous to a fragment of SEQ
ID No: 15. The ALLO used in some of the Examples was 416 AA long
(exclusive of the signal sequence), as 88 residues from the amino
terminus which is inclusive of the activation domain containing
cysteine 484 were truncated. It will be clear to those skilled in
the art that any ALLO without the activation domain, and in
particular without cysteine 484, are suitable for methods and
compositions of the present invention. In another embodiment,
fusion of an E7 or E6 antigen to any ALLO, including the PEST-like
AA sequence, SEQ ID NO: 1, enhances cell mediated and anti-tumor
immunity of the antigen. Each possibility represents a separate
embodiment of the present invention.
[0083] The LLO protein utilized to construct vaccines of the
present invention has, in another embodiment, the sequence:
TABLE-US-00001 (GenBank Accession No. P13128; SEQ ID NO: 17;
nucleic acid sequence is set forth in GenBank Accession No.
X15127). MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSMAPPASPPASPK
TPIEKKHADEIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIV
VEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKRD
SLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPNV
SAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS
FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGR
QVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGG
SAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDNELAVI
KNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYDPEGNEIVQH
KNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRN
LPLVKNRNISIWGTTLYPKYSNKVDNPIE
The first 25 AA of the proprotein corresponding to this sequence
are the signal sequence and are cleaved from LLO when it is
secreted by the bacterium. Thus, in this embodiment, the full
length active LLO protein is 504 residues long. In another
embodiment, the above LLO fragment is used as the source of the LLO
fragment incorporated in a vaccine of the present invention. Each
possibility represents a separate embodiment of the present
invention.
[0084] In another embodiment, the N-terminal fragment of an LLO
protein utilized in compositions and methods of the present
invention has the sequence:
TABLE-US-00002 (SEQ ID NO: 15)
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPK
TPIEKKHADEIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIV
VEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKRD
SLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYSNV
SAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS
FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGR
QVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGG
SAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDNELAVI
KNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYD.
[0085] In another embodiment, the LLO fragment corresponds to about
AA 20-442 of an LLO protein utilized herein.
[0086] In another embodiment, the LLO fragment has the
sequence:
TABLE-US-00003 (SEQ ID NO: 16)
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPK
TPIEKKHADEIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIV
VEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKRD
SLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYSNV
SAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVIS
FKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGR
QVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGG
SAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDNELAVI
KNNSEYIETTSKAYTD.
[0087] In another embodiment, "truncated LLO" or "ALLO" refers to a
fragment of LLO that comprises the PEST-like domain. In another
embodiment, the terms refer to an LLO fragment that comprises a
PEST sequence.
[0088] In another embodiment, the terms refer to an LLO fragment
that does not contain the activation domain at the amino terminus
and does not include cysteine 484. In another embodiment, the terms
refer to an LLO fragment that is not hemolytic. In another
embodiment, the LLO fragment is rendered non-hemolytic by deletion
or mutation of the activation domain. In another embodiment, the
LLO fragment is rendered non-hemolytic by deletion or mutation of
cysteine 484. In another embodiment, the LLO fragment is rendered
non-hemolytic by deletion or mutation at another location. Each
possibility represents a separate embodiment of the present
invention.
[0089] In another embodiment, the LLO fragment consists of about
the first 441 AA of the LLO protein. In another embodiment, the LLO
fragment consists of about the first 420 AA of LLO. In another
embodiment, the LLO fragment is a non-hemolytic form of the LLO
protein.
[0090] In another embodiment, the LLO fragment contains residues of
a homologous LLO protein that correspond to one of the above AA
ranges. The residue numbers need not, in another embodiment,
correspond exactly with the residue numbers enumerated above; e.g.
if the homologous LLO protein has an insertion or deletion,
relative to an LLO protein utilized herein, then the residue
numbers can be adjusted accordingly.
[0091] In another embodiment, the LLO fragment is any other LLO
fragment known in the art. Each possibility represents a separate
embodiment of the present invention.
[0092] In another embodiment, the recombinant Listeria strain is
administered to the human subject at a dose of
1.times.10.sup.9-3.31.times.10.sup.10 CFU. In another embodiment,
the dose is 5-500.times.10.sup.8 CFU. In another embodiment, the
dose is 7-500.times.10.sup.8 CFU. In another embodiment, the dose
is 10-500.times.10.sup.8 CFU. In another embodiment, the dose is
20-500.times.10.sup.8 CFU. In another embodiment, the dose is
30-500.times.10.sup.8 CFU. In another embodiment, the dose is
50-500.times.10.sup.8 CFU. In another embodiment, the dose is
70-500.times.10.sup.8 CFU. In another embodiment, the dose is
100-500.times.10.sup.8 CFU. In another embodiment, the dose is
150-500.times.10.sup.8 CFU. In another embodiment, the dose is
5-300.times.10.sup.8 CFU. In another embodiment, the dose is
5-200.times.10.sup.8 CFU. In another embodiment, the dose is
5-150.times.10.sup.8 CFU. In another embodiment, the dose is
5-100.times.10.sup.8 CFU. In another embodiment, the dose is
5-70.times.10.sup.8 CFU. In another embodiment, the dose is
5-50.times.10.sup.8 CFU. In another embodiment, the dose is
5-30.times.10.sup.8 CFU. In another embodiment, the dose is
5-20.times.10.sup.8 CFU. In another embodiment, the dose is
1-30.times.10.sup.9 CFU. In another embodiment, the dose is
1-20.times.10.sup.9 CFU. In another embodiment, the dose is
2-30.times.10.sup.9 CFU. In another embodiment, the dose is
1-10.times.10.sup.9 CFU. In another embodiment, the dose is
2-10.times.10.sup.9 CFU. In another embodiment, the dose is
3-10.times.10.sup.9 CFU. In another embodiment, the dose is
2-7.times.10.sup.9 CFU. In another embodiment, the dose is
2-5.times.10.sup.9 CFU. In another embodiment, the dose is
3-5.times.10.sup.9 CFU.
[0093] In another embodiment, the dose is 1.times.10.sup.9
organisms. In another embodiment, the dose is 1.5.times.10.sup.9
organisms. In another embodiment, the dose is 2.times.10.sup.9
organisms. In another embodiment, the dose is 3.times.10.sup.9
organisms. In another embodiment, the dose is 4.times.10.sup.9
organisms. In another embodiment, the dose is 5.times.10.sup.9
organisms. In another embodiment, the dose is 6.times.10.sup.9
organisms. In another embodiment, the dose is 7.times.10.sup.9
organisms. In another embodiment, the dose is 8.times.10.sup.9
organisms. In another embodiment, the dose is 10.times.10.sup.9
organisms. In another embodiment, the dose is 1.5.times.10.sup.10
organisms. In another embodiment, the dose is 2.times.10.sup.10
organisms. In another embodiment, the dose is 2.5.times.10.sup.10
organisms. In another embodiment, the dose is 3.times.10.sup.10
organisms. In another embodiment, the dose is 3.3.times.10.sup.10
organisms. In another embodiment, the dose is 4.times.10.sup.10
organisms. In another embodiment, the dose is 5.times.10.sup.10
organisms.
[0094] Each dose and range of doses represents a separate
embodiment of the present invention.
[0095] In another embodiment, the recombinant polypeptide of
methods of the present invention is expressed by the recombinant
Listeria strain. In another embodiment, the expression is mediated
by a nucleotide molecule carried by the recombinant Listeria
strain. Each possibility represents a separate embodiment of the
present invention.
[0096] In another embodiment, the recombinant Listeria strain
expresses the recombinant polypeptide by means of a plasmid that
encodes the recombinant polypeptide. In another embodiment, the
plasmid comprises a gene encoding a bacterial transcription factor.
In another embodiment, the plasmid encodes a Listeria transcription
factor. In another embodiment, the transcription factor is prfA. In
another embodiment, the transcription factor is any other
transcription factor known in the art. Each possibility represents
a separate embodiment of the present invention.
[0097] In another embodiment, the plasmid comprises a gene encoding
a metabolic enzyme. In another embodiment, the metabolic enzyme is
a bacterial metabolic enzyme. In another embodiment, the metabolic
enzyme is a Listerial metabolic enzyme. In another embodiment, the
metabolic enzyme is an amino acid metabolism enzyme. In another
embodiment, the amino acid metabolism gene is involved in a cell
wall synthesis pathway. In another embodiment, the metabolic enzyme
is the product of a D-amino acid aminotransferase gene (dat). In
another embodiment, the metabolic enzyme is the product of an
alanine racemase gene (dal). In another embodiment, the metabolic
enzyme is any other metabolic enzyme known in the art. Each
possibility represents a separate embodiment of the present
invention.
[0098] In another embodiment, a method of present invention further
comprises the step of boosting the human subject with a recombinant
Listeria strain of the present invention. In another embodiment,
the recombinant Listeria strain used in the booster inoculation is
the same as the strain used in the initial "priming" inoculation.
In another embodiment, the booster strain is different from the
priming strain. In another embodiment, the same doses are used in
the priming and boosting inoculations. In another embodiment, a
larger dose is used in the booster. In another embodiment, a
smaller dose is used in the booster. Each possibility represents a
separate embodiment of the present invention.
[0099] In another embodiment, a method of present invention further
comprises the step of inoculating the human subject with an
immunogenic composition comprising the E7 antigen. In another
embodiment, the immunogenic composition comprises a recombinant E7
protein or fragment thereof. In another embodiment, the immunogenic
composition comprises a nucleotide molecule expressing a
recombinant E7 protein or fragment thereof. In another embodiment,
the non-Listerial inoculation is administered after the Listerial
inoculation. In another embodiment, the non-Listerial inoculation
is administered before the Listerial inoculation. Each possibility
represents a separate embodiment of the present invention.
[0100] "Boosting" refers, in another embodiment, to administration
of an additional vaccine dose to a subject. In another embodiment
of methods of the present invention, 2 boosts (or a total of 3
inoculations) are administered. In another embodiment, 3 boosts are
administered. In another embodiment, 4 boosts are administered. In
another embodiment, 5 boosts are administered. In another
embodiment, 6 boosts are administered. In another embodiment, more
than 6 boosts are administered. Each possibility represents a
separate embodiment of the present invention.
[0101] The recombinant Listeria strain of methods and compositions
of the present invention is, in another embodiment, a recombinant
Listeria monocytogenes strain. In another embodiment, the Listeria
strain is a recombinant Listeria seeligeri strain. In another
embodiment, the Listeria strain is a recombinant Listeria grayi
strain. In another embodiment, the Listeria strain is a recombinant
Listeria ivanovii strain. In another embodiment, the Listeria
strain is a recombinant Listeria murrayi strain. In another
embodiment, the Listeria strain is a recombinant Listeria
welshimeri strain. In another embodiment, the Listeria strain is a
recombinant strain of any other Listeria species known in the art.
Each possibility represents a separate embodiment of the present
invention.
[0102] In another embodiment, a recombinant Listeria strain of the
present invention has been passaged through an animal host. In
another embodiment, the passaging maximizes efficacy of the strain
as a vaccine vector. In another embodiment, the passaging
stabilizes the immunogenicity of the Listeria strain. In another
embodiment, the passaging stabilizes the virulence of the Listeria
strain. In another embodiment, the passaging increases the
immunogenicity of the Listeria strain. In another embodiment, the
passaging increases the virulence of the Listeria strain. In
another embodiment, the passaging removes unstable sub-strains of
the Listeria strain. In another embodiment, the passaging reduces
the prevalence of unstable sub-strains of the Listeria strain. In
another embodiment, the Listeria strain contains a genomic
insertion of the gene encoding the antigen-containing recombinant
peptide. In another embodiment, the Listeria strain carries a
plasmid comprising the gene encoding the antigen-containing
recombinant peptide. In another embodiment, the passaging is
performed as described herein (e.g. in Example 12). In another
embodiment, the passaging is performed by any other method known in
the art. Each possibility represents a separate embodiment of the
present invention.
[0103] In another embodiment, the recombinant Listeria strain
utilized in methods of the present invention has been stored in a
frozen cell bank. In another embodiment, the recombinant Listeria
strain has been stored in a lyophilized cell bank. Each possibility
represents a separate embodiment of the present invention.
[0104] In another embodiment, the cell bank of methods and
compositions of the present invention is a master cell bank. In
another embodiment, the cell bank is a working cell bank. In
another embodiment, the cell bank is Good Manufacturing Practice
(GMP) cell bank. In another embodiment, the cell bank is intended
for production of clinical-grade material. In another embodiment,
the cell bank conforms to regulatory practices for human use. In
another embodiment, the cell bank is any other type of cell bank
known in the art. Each possibility represents a separate embodiment
of the present invention.
[0105] "Good Manufacturing Practices" are defined, in another
embodiment, by (21 CFR 210-211) of the United States Code of
Federal Regulations. In another embodiment, "Good Manufacturing
Practices" are defined by other standards for production of
clinical-grade material or for human consumption; e.g. standards of
a country other than the United States. Each possibility represents
a separate embodiment of the present invention.
[0106] In another embodiment, a recombinant Listeria strain
utilized in methods of the present invention is from a batch of
vaccine doses.
[0107] In another embodiment, a recombinant Listeria strain
utilized in methods of the present invention is from a frozen stock
produced by a method disclosed herein.
[0108] In another embodiment, a recombinant Listeria strain
utilized in methods of the present invention is from a lyophilized
stock produced by a method disclosed herein.
[0109] In another embodiment, a cell bank, frozen stock, or batch
of vaccine doses of the present invention exhibits viability upon
thawing of greater than 90%. In another embodiment, the thawing
follows storage for cryopreservation or frozen storage for 24
hours. In another embodiment, the storage is for 2 days. In another
embodiment, the storage is for 3 days. In another embodiment, the
storage is for 4 days. In another embodiment, the storage is for 1
week. In another embodiment, the storage is for 2 weeks. In another
embodiment, the storage is for 3 weeks. In another embodiment, the
storage is for 1 month. In another embodiment, the storage is for 2
months. In another embodiment, the storage is for 3 months. In
another embodiment, the storage is for 5 months. In another
embodiment, the storage is for 6 months. In another embodiment, the
storage is for 9 months. In another embodiment, the storage is for
1 year. Each possibility represents a separate embodiment of the
present invention.
[0110] In another embodiment, a cell bank, frozen stock, or batch
of vaccine doses of the present invention is cryopreserved by a
method that comprises growing a culture of the Listeria strain in a
nutrient media, freezing the culture in a solution comprising
glycerol, and storing the Listeria strain at below -20 degrees
Celsius. In another embodiment, the temperature is about -70
degrees Celsius. In another embodiment, the temperature is about
.sup.-70-.sup.-80 degrees Celsius.
[0111] In another embodiment, a cell bank, frozen stock, or batch
of vaccine doses of the present invention is cryopreserved by a
method that comprises growing a culture of the Listeria strain in a
defined media of the present invention (as described below),
freezing the culture in a solution comprising glycerol, and storing
the Listeria strain at below -20 degrees Celsius. In another
embodiment, the temperature is about -70 degrees Celsius. In
another embodiment, the temperature is about .sup.-70-.sup.-80
degrees Celsius. In another embodiment, any defined microbiological
media of the present invention may be used in this method. Each
defined microbiological media represents a separate embodiment of
the present invention.
[0112] In another embodiment of methods and compositions of the
present invention, the culture (e.g. the culture of a Listeria
vaccine strain that is used to produce a batch of Listeria vaccine
doses) is inoculated from a cell bank. In another embodiment, the
culture is inoculated from a frozen stock. In another embodiment,
the culture is inoculated from a starter culture. In another
embodiment, the culture is inoculated from a colony. In another
embodiment, the culture is inoculated at mid-log growth phase. In
another embodiment, the culture is inoculated at approximately
mid-log growth phase. In another embodiment, the culture is
inoculated at another growth phase. Each possibility represents a
separate embodiment of the present invention.
[0113] In another embodiment of methods and compositions of the
present invention, the solution used for freezing contains glycerol
in an amount of 2-20%. In another embodiment, the amount is 2%. In
another embodiment, the amount is 20%. In another embodiment, the
amount is 1%. In another embodiment, the amount is 1.5%. In another
embodiment, the amount is 3%. In another embodiment, the amount is
4%. In another embodiment, the amount is 5%. In another embodiment,
the amount is 2%. In another embodiment, the amount is 2%. In
another embodiment, the amount is 7%. In another embodiment, the
amount is 9%. In another embodiment, the amount is 10%. In another
embodiment, the amount is 12%. In another embodiment, the amount is
14%. In another embodiment, the amount is 16%. In another
embodiment, the amount is 18%. In another embodiment, the amount is
222%. In another embodiment, the amount is 25%. In another
embodiment, the amount is 30%. In another embodiment, the amount is
35%. In another embodiment, the amount is 40%. Each possibility
represents a separate embodiment of the present invention.
[0114] In another embodiment, the solution used for freezing
contains another colligative additive or additive with anti-freeze
properties, in place of glycerol. In another embodiment, the
solution used for freezing contains another colligative additive or
additive with anti-freeze properties, in addition to glycerol. In
another embodiment, the additive is mannitol. In another
embodiment, the additive is DMSO. In another embodiment, the
additive is sucrose. In another embodiment, the additive is any
other colligative additive or additive with anti-freeze properties
that is known in the art. Each possibility represents a separate
embodiment of the present invention.
[0115] In another embodiment, the nutrient media utilized for
growing a culture of a Listeria strain is LB. In another
embodiment, the nutrient media is TB. In another embodiment, the
nutrient media is a defined media. In another embodiment, the
nutrient media is a defined media of the present invention. In
another embodiment, the nutrient media is any other type of
nutrient media known in the art. Each possibility represents a
separate embodiment of the present invention.
[0116] In another embodiment of methods and compositions of the
present invention, the step of growing is performed with a shake
flask. In another embodiment, the flask is a baffled shake flask.
In another embodiment, the growing is performed with a batch
fermenter. In another embodiment, the growing is performed with a
stirred tank or flask. In another embodiment, the growing is
performed with an airflit fermenter. In another embodiment, the
growing is performed with a fed batch. In another embodiment, the
growing is performed with a continuous cell reactor. In another
embodiment, the growing is performed with an immobilized cell
reactor. In another embodiment, the growing is performed with any
other means of growing bacteria that is known in the art. Each
possibility represents a separate embodiment of the present
invention.
[0117] In another embodiment, a constant pH is maintained during
growth of the culture (e.g. in a batch fermenter). In another
embodiment, the pH is maintained at about 7.0. In another
embodiment, the pH is about 6. In another embodiment, the pH is
about 6.5. In another embodiment, the pH is about 7.5. In another
embodiment, the pH is about 8. In another embodiment, the pH is
6.5-7.5. In another embodiment, the pH is 6-8. In another
embodiment, the pH is 6-7. In another embodiment, the pH is 7-8.
Each possibility represents a separate embodiment of the present
invention.
[0118] In another embodiment, a constant temperature is maintained
during growth of the culture. In another embodiment, the
temperature is maintained at about 37.degree. C. In another
embodiment, the temperature is 37.degree. C. In another embodiment,
the temperature is 25.degree. C. In another embodiment, the
temperature is 27.degree. C. In another embodiment, the temperature
is 28.degree. C. In another embodiment, the temperature is
30.degree. C. In another embodiment, the temperature is 32.degree.
C. In another embodiment, the temperature is 34.degree. C. In
another embodiment, the temperature is 35.degree. C. In another
embodiment, the temperature is 36.degree. C. In another embodiment,
the temperature is 38.degree. C. In another embodiment, the
temperature is 39.degree. C. Each possibility represents a separate
embodiment of the present invention.
[0119] In another embodiment, a constant dissolved oxygen
concentration is maintained during growth of the culture. In
another embodiment, the dissolved oxygen concentration is
maintained at 20% of saturation. In another embodiment, the
concentration is 15% of saturation. In another embodiment, the
concentration is 16% of saturation. In another embodiment, the
concentration is 18% of saturation. In another embodiment, the
concentration is 22% of saturation. In another embodiment, the
concentration is 25% of saturation. In another embodiment, the
concentration is 30% of saturation. In another embodiment, the
concentration is 35% of saturation. In another embodiment, the
concentration is 40% of saturation. In another embodiment, the
concentration is 45% of saturation. In another embodiment, the
concentration is 50% of saturation. In another embodiment, the
concentration is 55% of saturation. In another embodiment, the
concentration is 60% of saturation. In another embodiment, the
concentration is 65% of saturation. In another embodiment, the
concentration is 70% of saturation. In another embodiment, the
concentration is 75% of saturation. In another embodiment, the
concentration is 80% of saturation. In another embodiment, the
concentration is 85% of saturation. In another embodiment, the
concentration is 90% of saturation. In another embodiment, the
concentration is 95% of saturation. In another embodiment, the
concentration is 100% of saturation. In another embodiment, the
concentration is near 100% of saturation. Each possibility
represents a separate embodiment of the present invention.
[0120] In another embodiment of methods and compositions of the
present invention, the culture is grown in media having a maximum
volume of 2 liters (L) per vessel. In another embodiment, the media
has a maximum volume of 200 ml per vessel. In another embodiment,
the media has a maximum volume of 300 ml per vessel. In another
embodiment, the media has a maximum volume of 500 ml per vessel. In
another embodiment, the media has a maximum volume of 750 ml per
vessel. In another embodiment, the media has a maximum volume of 1
L per vessel. In another embodiment, the media has a maximum volume
of 1.5 L per vessel. In another embodiment, the media has a maximum
volume of 2.5 L per vessel. In another embodiment, the media has a
maximum volume of 3 L per vessel.
[0121] In another embodiment, the media has a minimum volume of 2 L
per vessel. In another embodiment, the media has a minimum volume
of 500 ml per vessel. In another embodiment, the media has a
minimum volume of 750 ml per vessel. In another embodiment, the
media has a minimum volume of 1 L per vessel. In another
embodiment, the media has a minimum volume of 1.5 L per vessel. In
another embodiment, the media has a minimum volume of 2.5 L per
vessel. In another embodiment, the media has a minimum volume of 3
L per vessel. In another embodiment, the media has a minimum volume
of 4 L per vessel. In another embodiment, the media has a minimum
volume of 5 L per vessel. In another embodiment, the media has a
minimum volume of 6 L per vessel. In another embodiment, the media
has a minimum volume of 8 L per vessel. In another embodiment, the
media has a minimum volume of 10 L per vessel.
[0122] Each volume represents a separate embodiment of the present
invention.
[0123] In another embodiment of methods and compositions of the
present invention, the step of freezing or lyophilization is
performed when the culture has an OD.sub.600 of 0.7 units. In
another embodiment, the culture has an OD.sub.600 of 0.8 units. In
another embodiment, the OD.sub.600 is about 0.7 units. In another
embodiment, the OD.sub.600 is about 0.8 units. In another
embodiment, the OD.sub.600 is 0.6 units. In another embodiment, the
OD.sub.600 is 0.65 units. In another embodiment, the OD.sub.600 is
0.75 units. In another embodiment, the OD.sub.600 is 0.85 units. In
another embodiment, the OD.sub.600 is 0.9 units. In another
embodiment, the OD.sub.600 is 1 unit. In another embodiment, the
OD.sub.600 is 0.6-0.9 units. In another embodiment, the OD.sub.600
is 0.65-0.9 units. In another embodiment, the OD.sub.600 is 0.7-0.9
units. In another embodiment, the OD.sub.600 is 0.75-0.9 units. In
another embodiment, the OD.sub.600 is 0.8-0.9 units. In another
embodiment, the OD.sub.600 is 0.75-1 units. In another embodiment,
the OD.sub.600 is 0.9-1 units. In another embodiment, the
OD.sub.600 is greater than 1 unit.
[0124] In another embodiment, the OD.sub.600 is significantly
greater than 1 unit (e.g. when the culture is produced in a batch
fermenter). In another embodiment, the OD.sub.600 is 7.5-8.5 units.
In another embodiment, the OD.sub.600 is 1.2 units. In another
embodiment, the OD.sub.600 is 1.5 units. In another embodiment, the
OD.sub.600 is 2 units. In another embodiment, the OD.sub.600 is 2.5
units. In another embodiment, the OD.sub.600 is 3 units. In another
embodiment, the OD.sub.600 is 3.5 units. In another embodiment, the
OD.sub.600 is 4 units. In another embodiment, the OD.sub.600 is 4.5
units. In another embodiment, the OD.sub.600 is 5 units. In another
embodiment, the OD.sub.600 is 5.5 units. In another embodiment, the
OD.sub.600 is 6 units. In another embodiment, the OD.sub.600 is 6.5
units. In another embodiment, the OD.sub.600 is 7 units. In another
embodiment, the OD.sub.600 is 7.5 units. In another embodiment, the
OD.sub.600 is 8 units. In another embodiment, the OD.sub.600 is 8.5
units. In another embodiment, the OD.sub.600 is 9 units. In another
embodiment, the OD.sub.600 is 9.5 units. In another embodiment, the
OD.sub.600 is 10 units. In another embodiment, the OD.sub.600 is
more than 10 units.
[0125] In another embodiment, the OD.sub.600 is 1-2 units. In
another embodiment, the OD.sub.600 is 1.5-2.5 units. In another
embodiment, the OD.sub.600 is 2-3 units. In another embodiment, the
OD.sub.600 is 2.5-3.5 units. In another embodiment, the OD.sub.600
is 3-4 units. In another embodiment, the OD.sub.600 is 3.5-4.5
units. In another embodiment, the OD.sub.600 is 4-5 units. In
another embodiment, the OD.sub.600 is 4.5-5.5 units. In another
embodiment, the OD.sub.600 is 5-6 units. In another embodiment, the
OD.sub.600 is 5.5-6.5 units. In another embodiment, the OD.sub.600
is 1-3 units. In another embodiment, the OD.sub.600 is 1.5-3.5
units. In another embodiment, the OD.sub.600 is 2-4 units. In
another embodiment, the OD.sub.600 is 2.5-4.5 units. In another
embodiment, the OD.sub.600 is 3-5 units. In another embodiment, the
OD.sub.600 is 4-6 units. In another embodiment, the OD.sub.600 is
5-7 units. In another embodiment, the OD.sub.600 is 2-5 units. In
another embodiment, the OD.sub.600 is 3-6 units. In another
embodiment, the OD.sub.600 is 4-7 units. In another embodiment, the
OD.sub.600 is 5-8 units. In another embodiment, the OD.sub.600 is
1.2-7.5 units. In another embodiment, the OD.sub.600 is 1.5-7.5
units. In another embodiment, the OD.sub.600 is 2-7.5 units. In
another embodiment, the OD.sub.600 is 2.5-7.5 units. In another
embodiment, the OD.sub.600 is 3-7.5 units. In another embodiment,
the OD.sub.600 is 3.5-7.5 units. In another embodiment, the
OD.sub.600 is 4-7.5 units. In another embodiment, the OD.sub.600 is
4.5-7.5 units. In another embodiment, the OD.sub.600 is 5-7.5
units. In another embodiment, the OD.sub.600 is 5.5-7.5 units. In
another embodiment, the OD.sub.600 is 6-7.5 units. In another
embodiment, the OD.sub.600 is 6.5-7.5 units. In another embodiment,
the OD.sub.600 is 7-7.5 units. In another embodiment, the
OD.sub.600 is more than 10 units. In another embodiment, the
OD.sub.600 is 1.2-8.5 units. In another embodiment, the OD.sub.600
is 1.5-8.5 units. In another embodiment, the OD.sub.600 is 2-8.5
units. In another embodiment, the OD.sub.600 is 2.5-8.5 units. In
another embodiment, the OD.sub.600 is 3-8.5 units. In another
embodiment, the OD.sub.600 is 3.5-8.5 units. In another embodiment,
the OD.sub.600 is 4-8.5 units. In another embodiment, the
OD.sub.600 is 4.5-8.5 units. In another embodiment, the OD.sub.600
is 5-8.5 units. In another embodiment, the OD.sub.600 is 5.5-8.5
units. In another embodiment, the OD.sub.600 is 6-8.5 units. In
another embodiment, the OD.sub.600 is 6.5-8.5 units. In another
embodiment, the OD.sub.600 is 7-8.5 units. In another embodiment,
the OD.sub.600 is 7.5-8.5 units. In another embodiment, the
OD.sub.600 is 8-8.5 units. In another embodiment, the OD.sub.600 is
9.5-8.5 units. In another embodiment, the OD.sub.600 is 10
units.
[0126] In another embodiment, the step of freezing or
lyophilization is performed when the culture has a biomass of
1.times.10.sup.9 colony-forming units (CFU)/ml. In another
embodiment, the biomass is 1.5.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 1.5.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 2.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 3.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 4.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 5.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 7.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 9.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 10.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 12.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 15.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 20.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 25.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 30.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 33.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 40.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is 50.times.10.sup.9 CFR/ml. In another
embodiment, the biomass is more than 50.times.10.sup.9 CFR/ml.
[0127] Each number and range of OD.sub.600 readings and culture
biomass measurements represents a separate embodiment of the
present invention.
[0128] In another embodiment of methods and compositions of the
present invention, the Listeria culture is flash-frozen in liquid
nitrogen, followed by storage at the final freezing temperature. In
another embodiment, the culture is frozen in a more gradual manner;
e.g. by placing in a vial of the culture in the final storage
temperature. In another embodiment, the culture is frozen by any
other method known in the art for freezing a bacterial culture.
Each possibility represents a separate embodiment of the present
invention.
[0129] In another embodiment of methods and compositions of the
present invention, the storage temperature of the culture is
between .sup.-20 and .sup.-80 degrees Celsius (.degree. C.). In
another embodiment, the temperature is significantly below
.sup.-20.degree. C. In another embodiment, the temperature is not
warmer than 70.degree. C. In another embodiment, the temperature is
70.degree. C. In another embodiment, the temperature is about
70.degree. C. In another embodiment, the temperature is
.sup.-20.degree. C. In another embodiment, the temperature is about
.sup.-20.degree. C. In another embodiment, the temperature is
.sup.-30.degree. C. In another embodiment, the temperature is
.sup.-40.degree. C. In another embodiment, the temperature is
.sup.-50.degree. C. In another embodiment, the temperature is
.sup.-60.degree. C. In another embodiment, the temperature is
.sup.-80.degree. C. In another embodiment, the temperature is
.sup.-30-.sup.- 70.degree. C. In another embodiment, the
temperature is .sup.-40-.sup.- 70.degree. C. In another embodiment,
the temperature is .sup.-50-.sup.- 70.degree. C. In another
embodiment, the temperature is .sup.-60-.sup.-70.degree. C. In
another embodiment, the temperature is .sup.-30-.sup.-80.degree. C.
In another embodiment, the temperature is .sup.-40-.sup.-80.degree.
C. In another embodiment, the temperature is
.sup.-50-.sup.-80.degree. C. In another embodiment, the temperature
is .sup.-60-.sup.-80.degree. C. In another embodiment, the
temperature is .sup.-70-.sup.-80.degree. C. In another embodiment,
the temperature is colder than .sup.-70.degree. C. In another
embodiment, the temperature is colder than .sup.-80.degree. C. Each
possibility represents a separate embodiment of the present
invention.
[0130] In another embodiment of methods and compositions of the
present invention, the cryopreservation, frozen storage, or
lyophilization is for a maximum of 24 hours. In another embodiment,
the cryopreservation, frozen storage, or lyophilization is for
maximum of 2 days. In another embodiment, the cryopreservation,
frozen storage, or lyophilization is for maximum of 3 days. In
another embodiment, the cryopreservation, frozen storage, or
lyophilization is for maximum of 4 days. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for maximum
of 1 week. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for maximum of 2 weeks. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for maximum of 3 weeks. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for maximum
of 1 month. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for maximum of 2 months. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for maximum of 3 months. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for maximum
of 5 months. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for maximum of 6 months. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for maximum of 9 months. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for maximum
of 1 year.
[0131] In another embodiment, the cryopreservation, frozen storage,
or lyophilization is for a minimum of 1 week. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for minimum of 2 weeks. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for minimum
of 3 weeks. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for minimum of 1 month. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for minimum of 2 months. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for minimum
of 3 months. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for minimum of 5 months. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for minimum of 6 months. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for minimum
of 9 months. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for minimum of 1 year. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for minimum of 1.5 years. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for minimum
of 2 years. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for minimum of 3 years. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for minimum of 5 years. In another embodiment, the
cryopreservation, frozen storage, or lyophilization is for minimum
of 7 years. In another embodiment, the cryopreservation, frozen
storage, or lyophilization is for minimum of 10 years. In another
embodiment, the cryopreservation, frozen storage, or lyophilization
is for longer than 10 years.
[0132] Each length of cryopreservation, frozen storage, or
lyophilization represents a separate embodiment of the present
invention.
[0133] In another embodiment of methods and compositions of the
present invention, the Listeria bacteria exhibit exponential growth
essentially immediately after thawing following an extended period
of cryopreservation or frozen storage (Example 14). In another
embodiment, the Listeria bacteria exhibit exponential growth
essentially immediately after reconstitution following an extended
period of lyophilization. In another embodiment, "essentially
immediately" refers to within about 1 hour after inoculating fresh
media with cells from the cell bank or starter culture. In another
embodiment, the bacteria exhibit exponential growth shortly after
(e.g. in various embodiments, after 10 minutes (min), 20 min, 30
min, 40 min, 50 min, 1 hour, 75 min, 90 min, 105 min, or 2 hours)
thawing following the period of cryopreservation or storage. Each
possibility represents a separate embodiment of the present
invention.
[0134] The "extended period" of cryopreservation, frozen storage,
or lyophilization is, in another embodiment, 1 month. In another
embodiment, the period is 2 months. In another embodiment, the
period is 3 months. In another embodiment, the period is 5 months.
In another embodiment, the period is 6 months. In another
embodiment, the period is 9 months. In another embodiment, the
period is 1 year. In another embodiment, the period is 1.5 years.
In another embodiment, the period is 2 years. Each possibility
represents a separate embodiment of the present invention.
[0135] In another embodiment, "exponential growth" refers to a
doubling time that is close to the maximum observed for the
conditions (e.g. media type, temperature, etc.) in which the
culture is growing. In another embodiment, "exponential growth"
refers to a doubling time that is reasonable constant several hours
(e.g. 1 hour, 1.5 hours, 2 hours, or 2.5 hours) after dilution of
the culture; optionally following a brief recovery period. Each
possibility represents a separate embodiment of the present
invention.
[0136] In another embodiment, a Listeria vaccine strain of methods
and compositions of the present invention retains a viability of
over 90% after thawing following 14 days of cryopreservation
(Example 14). In another embodiment, the viability upon thawing is
close to 100% following the period of cryopreservation. In another
embodiment, the viability upon thawing is about 90%. In another
embodiment, the viability upon thawing is close to 90%. In another
embodiment, the viability upon thawing is at least 90%. In another
embodiment, the viability upon thawing is over 80%. Each
possibility represents a separate embodiment of the present
invention.
[0137] In another embodiment, a Listeria vaccine strain of methods
and compositions of the present invention retains a viability of
over 90% after reconstitution following lyophilization. In another
embodiment, the viability upon thawing is close to 100% following
the period of lyophilization. In another embodiment, the viability
upon thawing is about 90%. In another embodiment, the viability
upon thawing is close to 90%. In another embodiment, the viability
upon thawing is at least 90%. In another embodiment, the viability
upon thawing is over 80%. Each possibility represents a separate
embodiment of the present invention.
[0138] In another embodiment, a cell bank, frozen stock, or batch
of vaccine doses of the present invention is grown in a defined
microbiological media, comprising: (1) between about 0.3 and about
0.6 g/L of methionine; and (2) effective amounts of: (a) cysteine;
(b) a pH buffer; (c) a carbohydrate; (d) a divalent cation; (e)
ferric or ferrous ions; (f) glutamine or another nitrogen source;
(g) riboflavin; (h) thioctic acid (also known as lipoic acid); (i)
another or more components selected from leucine, isoleucine,
valine, arginine, histidine, tryptophan, and phenylalanine; (j) one
or more components selected from adenine, biotin, thiamine,
pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide;
and (k) one or more components selected from cobalt, copper, boron,
manganese, molybdenum, zinc, calcium, and citrate.
[0139] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L of cysteine;
and (2) effective amounts of: (a) methionine; (b) a pH buffer; (c)
a carbohydrate; (d) a divalent cation; (e) ferric or ferrous ions;
(f) glutamine or another nitrogen source; (g) riboflavin; (h)
thioctic acid; (i) one or more components selected from leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; (j) one or more components selected from adenine,
biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate,
and nicotinamide; and (k) one or more components selected from
cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and
citrate.
[0140] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.00123-0.00246 moles of ferric or
ferrous ions per liter; and (2) effective amounts of: (a) a pH
buffer; (b) a carbohydrate; (c) a divalent cation; (d) methionine;
(e) cysteine; (f) glutamine or another nitrogen source; (g)
riboflavin; (h) thioctic acid; (i) one or more components selected
from leucine, isoleucine, valine, arginine, histidine, tryptophan,
and phenylalanine; (j) one or more components selected from
adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid,
pantothenate, and nicotinamide; and (k) one or more components
selected from cobalt, copper, boron, manganese, molybdenum, zinc,
calcium, and citrate.
[0141] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 1.8-3.6 g/L of glutamine or another
nitrogen source; and (2) effective amounts of: (a) a pH buffer; (b)
a carbohydrate: (c) a divalent cation; (d) methionine (e) cysteine;
(f) ferric or ferrous ions (g) riboflavin (h); thioctic acid; (i)
one or more components selected from leucine, isoleucine, valine,
arginine, histidine, tryptophan, and phenylalanine; (j) one or more
components selected from adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one
or more components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, calcium, and citrate.
[0142] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 15 and about 30 mg/L of riboflavin;
and (2) effective amounts of: (a) a pH buffer; (b) a carbohydrate;
(c) a divalent cation; (d) methionine; (e) cysteine; (f) ferric or
ferrous ions; (g) glutamine or another nitrogen source; (h)
thioctic acid; (i) one or more components selected from leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; (j) one or more components selected from adenine,
biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate,
and nicotinamide; and (k) one or more components selected from
cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and
citrate.
[0143] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising (1) between about 0.3 and about 0.6 g/L of thioctic
acid; and (2) effective amounts of: (a) a pH buffer; (b) a
carbohydrate (c) a divalent cation; (d) methionine (e) cysteine;
(f) ferric or ferrous ions; (g) glutamine or another nitrogen
source; (h) riboflavin; (i) one or more components selected from
leucine, isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; (j) one or more components selected from adenine,
biotin, thiamine, pyridoxal, para-aminobenzoic acid, pantothenate,
and nicotinamide; and (k) one or more components selected from
cobalt, copper, boron, manganese, molybdenum, zinc, calcium, and
citrate.
[0144] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L each of
methionine and cysteine; (2) between about 0.00123 and 0.00246
moles of ferric or ferrous ions per liter; (3) between about 1.8
and about 3.6 g/L of glutamine or another nitrogen source; (4)
between about 0.3 and about 0.6 g/L of thioctic acid; (5) between
about 15 and about 30 mg/L of riboflavin; and (6) effective amounts
of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d)
one or more components selected from leucine, isoleucine, valine,
arginine, histidine, tryptophan, and phenylalanine; (e) one or more
components selected from adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide; and (f) one
or more components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, calcium, and citrate.
[0145] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L each of
methionine and cysteine; (2) between about 0.00123 and 0.00246
moles of ferric or ferrous ions per liter; (3) between about 1.8
and about 3.6 g/L of glutamine or another nitrogen source; (4)
between about 0.3 and about 0.6 g/L of thioctic acid; (5) between
about 15 and about 30 mg/L of riboflavin; and (6) effective amounts
of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d)
leucine; (e) isoleucine; (f) valine; (g) arginine; (h) histidine;
(i) tryptophan; (j) phenylalanine; (k) one or more components
selected from adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide; and (1) one
or more components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, calcium, and citrate.
[0146] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising (1) between about 0.3 and about 0.6 g/L each of one or
more components selected from leucine, isoleucine, valine,
arginine, histidine, tryptophan, and phenylalanine; and (2)
effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a
divalent cation; (d) methionine; (e) cysteine; (f) ferric or
ferrous ions; (g) glutamine or another nitrogen source; (h)
riboflavin; (i) thioctic acid; (j) one or more components selected
from adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid,
pantothenate, and nicotinamide; and (k) one or more components
selected from cobalt, copper, boron, manganese, molybdenum, zinc,
calcium, and citrate.
[0147] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising (1) between about 0.3 and about 0.6 g/L each of leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; and (2) effective amounts of: (a) a pH buffer; (b) a
carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine;
(f) ferric or ferrous ions; (g) glutamine or another nitrogen
source; (h) riboflavin; (i) thioctic acid; (j) one or more
components selected from adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide; and (k) one
or more components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, calcium, and citrate.
[0148] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising (1) between about 0.2 and about 0.75 of one or more
components selected from biotin and adenine; and (2) effective
amounts of: (a) a pH buffer; (b) a carbohydrate; (c) a divalent
cation; (d) methionine; (e) cysteine; (f) ferric or ferrous ions;
(g) glutamine or another nitrogen source; (h) riboflavin; (i)
thioctic acid; (j) one or more components selected from leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; (k) one or more components selected from thiamine,
pyridoxal, para-aminobenzoic acid, pantothenate, and nicotinamide;
and (l) one or more components selected from cobalt, copper, boron,
manganese, molybdenum, zinc, calcium, and citrate.
[0149] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising (1) between about 3 and about 6 mg/L each of one or more
components selected from thiamine, pyridoxal, para-aminobenzoic
acid, pantothenate, and nicotinamide; and (2) effective amounts of:
(a) a pH buffer; (b) a carbohydrate; (c) a divalent cation; (d)
methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine
or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j)
one or more components selected from leucine, isoleucine, valine,
arginine, histidine, tryptophan, and phenylalanine; (k) biotin; (l)
adenine; and (l) one or more components selected from cobalt,
copper, boron, manganese, molybdenum, zinc, calcium, and
citrate.
[0150] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.2 and about 0.75 mg/L each of one
or more components selected from biotin and adenine; (2) between
about 3 and about 6 mg/L each of one or more components selected
from thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and
nicotinamide; and (3) effective amounts of: (a) a pH buffer; (b) a
carbohydrate; (c) a divalent cation; (d) methionine; (e) cysteine;
(f) ferric or ferrous ions; (g) glutamine or another nitrogen
source; (h) riboflavin; (i) thioctic acid; (j) one or more
components selected from leucine, isoleucine, valine, arginine,
histidine, tryptophan, and phenylalanine; and (k) one or more
components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, calcium, and citrate.
[0151] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.005 and about 0.02 g/L each of one
or more components selected from cobalt, copper, boron, manganese,
molybdenum, zinc, and calcium; and (2) effective amounts of: (a) a
pH buffer; (b) a carbohydrate; (c) a divalent cation; (d)
methionine; (e) cysteine; (f) ferric or ferrous ions; (g) glutamine
or another nitrogen source; (h) riboflavin; (i) thioctic acid; (j)
one or more components selected from leucine, isoleucine, valine,
arginine, histidine, tryptophan, and phenylalanine; and (k) one or
more components selected from adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide.
[0152] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.4 and about 1 g/L of citrate; and
(2) effective amounts of: (a) a pH buffer; (b) a carbohydrate; (c)
a divalent cation; (d) methionine; (e) cysteine; (f) ferric or
ferrous ions; (g) glutamine or another nitrogen source; (h)
riboflavin; (i) thioctic acid; (j) one or more components selected
from leucine, isoleucine, valine, arginine, histidine, tryptophan,
and phenylalanine; (k) one or more components selected from cobalt,
copper, boron, manganese, molybdenum, zinc, and calcium; and (l)
one or more components selected from adenine, biotin, thiamine,
pyridoxal, para-aminobenzoic acid, pantothenate, and
nicotinamide.
[0153] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L each of
methionine and cysteine; (2) between about 0.00123 and 0.00246
moles of ferric or ferrous ions per liter; (3) between about 1.8
and about 3.6 g/L of glutamine or another nitrogen source; (4)
between about 0.3 and about 0.6 g/L of thioctic acid; (5) between
about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and
about 0.6 g/L each of one or more components selected from leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine; (7) between about 0.2 and about 0.75 mg/L each of
one or more components selected from biotin and adenine; (8)
between about 3 and about 6 mg/L each of one or more components
selected from thiamine, pyridoxal, para-aminobenzoic acid,
pantothenate, and nicotinamide; (9) between about 0.005 and about
0.02 g/L each of one or more components selected from cobalt,
copper, boron, manganese, molybdenum, zinc, and calcium; (10)
between about 0.4 and about 1 g/L of citrate; and (11) and
effective amounts of: (a) a pH buffer; (b) a carbohydrate; and (c)
a divalent cation.
[0154] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L each of
methionine and cysteine; (2) between about 0.00123 and 0.00246
moles of ferric or ferrous ions per liter; (3) between about 1.8
and about 3.6 g/L of glutamine or another nitrogen source; (4)
between about 0.3 and about 0.6 g/L of thioctic acid; (5) between
about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and
about 0.6 g/L each of leucine, isoleucine, valine, arginine,
histidine, tryptophan, and phenylalanine; (7) between about 0.2 and
about 0.75 mg/L each of one or more components selected from biotin
and adenine; (8) between about 3 and about 6 mg/L each of one or
more components selected from thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide; (9) between
about 0.005 and about 0.02 g/L each of one or more components
selected from cobalt, copper, boron, manganese, molybdenum, zinc,
and calcium; (10) between about 0.4 and about 1 g/L of citrate; and
(11) and effective amounts of: (a) a pH buffer; (b) a carbohydrate;
and (c) a divalent cation.
[0155] In another embodiment, the cell bank, frozen stock, or batch
of vaccine doses is grown in a defined microbiological media,
comprising: (1) between about 0.3 and about 0.6 g/L each of
methionine and cysteine; (2) between about 0.00123 and 0.00246
moles of ferric or ferrous ions per liter; (3) between about 1.8
and about 3.6 g/L of glutamine or another nitrogen source; (4)
between about 0.3 and about 0.6 g/L of thioctic acid; (5) between
about 15 and about 30 mg/L of riboflavin; (6) between about 0.3 and
about 0.6 g/L each of leucine, isoleucine, valine, arginine,
histidine, tryptophan, and phenylalanine; (7) between about 0.2 and
about 0.75 mg/L each of biotin and adenine; (8) between about 3 and
about 6 mg/L each of thiamine, pyridoxal, para-aminobenzoic acid,
pantothenate, and nicotinamide; (9) between about 0.005 and about
0.02 g/L each of one or more components selected from cobalt,
copper, boron, manganese, molybdenum, zinc, and calcium; (10)
between about 0.4 and about 1 g/L of citrate; and (11) and
effective amounts of: (a) a pH buffer; (b) a carbohydrate; and (c)
a divalent cation.
[0156] In another embodiment, a defined microbiological media of
the present invention further comprises an aqueous solvent. In
another embodiment, the aqueous solvent is water. In another
embodiment, the aqueous solvent is any other aqueous solvent known
in the art. Each possibility represents a separate embodiment of
the present invention.
[0157] The carbohydrate utilized in methods and compositions of the
present invention is, in another embodiment, glucose. In another
embodiment, the carbohydrate is lactose. In another embodiment, the
carbohydrate is fructose. In another embodiment, the carbohydrate
is mannose. In another embodiment, the carbohydrate is cellobiose.
In another embodiment, the carbohydrate is trehalose. In another
embodiment, the carbohydrate is maltose. In another embodiment, the
carbohydrate is glycerol. In another embodiment, the carbohydrate
is glucosamine. In another embodiment, the carbohydrate is
N-acetylglucosamine. In another embodiment, the carbohydrate is
N-acetylmuramic acid. In another embodiment, the carbohydrate is
any other carbohydrate that can be utilized by Listeria. Each
possibility represents a separate embodiment of the present
invention.
[0158] In another embodiment, the amount of a carbohydrate present
in a defined microbiological media of methods and compositions of
the present invention is between about 12-18 grams/liter (g/L). In
another embodiment, the amount is 15 g/L. In another embodiment,
the amount is 10 g/L. In another embodiment, the amount is 9 g/L.
In another embodiment, the amount is 11 g/L. In another embodiment,
the amount is 12 g/L. In another embodiment, the amount is 13 g/L.
In another embodiment, the amount is 14 g/L. In another embodiment,
the amount is 16 g/L. In another embodiment, the amount is 17 g/L.
In another embodiment, the amount is 18 g/L. In another embodiment,
the amount is 19 g/L. In another embodiment, the amount is 20 g/L.
In another embodiment, the amount is more than 20 g/L.
[0159] In another embodiment, the amount is 9-15 g/L. In another
embodiment, the amount is 10-15 g/L. In another embodiment, the
amount is 11-15 g/L. In another embodiment, the amount is 12-16
g/L. In another embodiment, the amount is 13-17 g/L. In another
embodiment, the amount is 14-18 g/L. In another embodiment, the
amount is 16-19 g/L. In another embodiment, the amount is 17-20
g/L. In another embodiment, the amount is 10-20 g/L. In another
embodiment, the amount is 12-20 g/L. In another embodiment, the
amount is 15-20 g/L.
[0160] In another embodiment, the total amount of carbohydrate in
the media is one of the above amounts. In another embodiment, the
amount of one of the carbohydrates in the media is one of the above
amounts. In another embodiment, the amount of each of the
carbohydrates in the media is one of the above amounts.
[0161] Each of the above amounts of carbohydrates represents a
separate embodiment of the present invention.
[0162] The cobalt present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a cobalt ion. In another embodiment, the
cobalt is present as a cobalt salt. In another embodiment, the salt
is cobalt chloride. In another embodiment, the salt is any other
cobalt salt known in the art. In another embodiment, the cobalt is
present as any other form of cobalt known in the art.
[0163] In another embodiment, the cobalt salt is a hydrate (e.g.
cobalt chloride hexahydrate). In another embodiment, the cobalt
salt is anhydrous. In another embodiment, the cobalt salt is any
other form of a cobalt salt known in the art. Each of the above
forms of cobalt represents a separate embodiment of the present
invention.
[0164] A hydrate of a component of a defined media of methods and
compositions of the present invention is, in another embodiment, a
monohydrate. In another embodiment, the hydrate is a dihydrate. In
another embodiment, the hydrate is a trihydrate. In another
embodiment, the hydrate is a tetrahydrate. In another embodiment,
the hydrate is a pentahydrate. In another embodiment, the hydrate
is a hexahydrate. In another embodiment, the hydrate is a
heptahydrate. In another embodiment, the hydrate is any other
hydrate known in the art. Each possibility represents a separate
embodiment of the present invention.
[0165] The copper present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a copper ion. In another embodiment, the
copper ion is a copper (I) ion. In another embodiment, the copper
ion is a copper (II) ion. In another embodiment, the copper ion is
a copper (III) ion.
[0166] In another embodiment, the copper is present as a copper
salt. In another embodiment, the salt is copper chloride. In
another embodiment, the salt is any other copper salt known in the
art. In another embodiment, the copper is present as any other form
of copper known in the art.
[0167] In another embodiment, the copper salt is a hydrate (e.g.
copper chloride dihydrate). In another embodiment, the copper salt
is anhydrous. In another embodiment, the copper salt is any other
form of a copper salt known in the art. Each of the above forms of
copper represents a separate embodiment of the present
invention.
[0168] The boron present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a borate ion. In another embodiment, the
boron is present as a borate acid (e.g. boric acid,
H.sub.3BO.sub.3). In another embodiment, the boron is present as
any other form of boron known in the art.
[0169] In another embodiment, the borate salt or borate acid is a
hydrate. In another embodiment, the borate salt or borate acid is
anhydrous. In another embodiment, the borate salt or borate acid is
any other form of a borate salt or borate acid known in the art.
Each of the above forms of boron represents a separate embodiment
of the present invention.
[0170] The manganese present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a manganese ion. In another embodiment, the
manganese is present as a manganese salt. In another embodiment,
the salt is manganese sulfate. In another embodiment, the salt is
any other manganese salt known in the art. In another embodiment,
the manganese is present as any other form of manganese known in
the art.
[0171] In another embodiment, the manganese salt is a hydrate (e.g.
manganese sulfate monohydrate). In another embodiment, the
manganese salt is anhydrous. In another embodiment, the manganese
salt is any other form of a manganese salt known in the art. Each
of the above forms of manganese represents a separate embodiment of
the present invention.
[0172] The molybdenum present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a molybdate ion. In another embodiment, the
molybdenum is present as a molybdate salt. In another embodiment,
the salt is sodium molybdate. In another embodiment, the salt is
any other molybdate salt known in the art. In another embodiment,
the molybdenum is present as any other form of molybdenum known in
the art.
[0173] In another embodiment, the molybdate salt is a hydrate (e.g.
sodium molybdate dihydrate). In another embodiment, the molybdate
salt is anhydrous. In another embodiment, the molybdate salt is any
other form of a molybdate salt known in the art. Each of the above
forms of molybdenum represents a separate embodiment of the present
invention.
[0174] The zinc present in defined microbiological media of methods
and compositions of the present invention is, in another
embodiment, present as a zinc ion. In another embodiment, the zinc
is present as a zinc salt. In another embodiment, the salt is zinc
chloride. In another embodiment, the salt is any other zinc salt
known in the art. In another embodiment, the zinc is present as any
other form of zinc known in the art.
[0175] In another embodiment, the zinc salt is a hydrate (e.g. zinc
chloride heptahydrate). In another embodiment, the zinc salt is
anhydrous. In another embodiment, the zinc salt is any other form
of a zinc salt known in the art. Each of the above forms of zinc
represents a separate embodiment of the present invention.
[0176] The iron present in defined microbiological media of methods
and compositions of the present invention is, in another
embodiment, present as a ferric ion. In another embodiment, the
iron is present as a ferrous ion. In another embodiment, the iron
is present as a ferric salt. In another embodiment, the iron is
present as a ferrous salt. In another embodiment, the salt is
ferric sulfate. In another embodiment, the salt is ferric citrate.
In another embodiment, the salt is any other ferric salt known in
the art. In another embodiment, the salt is any other ferrous salt
known in the art. In another embodiment, the iron is present as any
other form of iron known in the art.
[0177] In another embodiment, the ferric or ferrous salt is a
hydrate (e.g. ferric sulfate monohydrate). In another embodiment,
the ferric or ferrous salt is anhydrous. In another embodiment, the
ferric or ferrous salt is any other form of a ferric or ferrous
salt known in the art. Each of the above forms of iron represents a
separate embodiment of the present invention.
[0178] The calcium present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a calcium ion. In another embodiment, the
calcium is present as a calcium salt. In another embodiment, the
salt is calcium chloride. In another embodiment, the salt is any
other calcium salt known in the art. In another embodiment, the
calcium is present as any other form of calcium known in the
art.
[0179] In another embodiment, the calcium salt is a hydrate (e.g.
calcium chloride dihydrate). In another embodiment, the calcium
salt is anhydrous. In another embodiment, the calcium salt is any
other form of a calcium salt known in the art. Each of the above
forms of calcium represents a separate embodiment of the present
invention.
[0180] The citrate present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present as a citrate ion. In another embodiment, the
citrate is present as a citrate salt. In another embodiment, the
citrate is present as a citrate acid (e.g. citric acid). In another
embodiment, the citrate is present as both ferric citrate and
citric acid (Examples 15-16). In another embodiment, the citrate is
present as any other form of citrate known in the art.
[0181] In another embodiment, the citrate salt or citrate acid is a
hydrate. In another embodiment, the citrate salt or citrate acid is
anhydrous. In another embodiment, the citrate salt or citrate acid
is any other form of a citrate salt or citrate acid known in the
art. Each of the above forms of citrate represents a separate
embodiment of the present invention.
[0182] The cobalt present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.02 g/L (Examples 15-16). In
another embodiment, the amount is about 0.02 g/L. In another
embodiment, the amount is 0.003 g/L. In another embodiment, the
amount is 0.005 g/L. In another embodiment, the amount is 0.007
g/L. In another embodiment, the amount is 0.01 g/L. In another
embodiment, the amount is 0.015 g/L. In another embodiment, the
amount is 0.025 g/L. In another embodiment, the amount is 0.03 g/L.
In another embodiment, the amount is 0.003-0.006 g/L. In another
embodiment, the amount is 0.005-0.01 g/L. In another embodiment,
the amount is 0.01-0.02 g/L. In another embodiment, the amount is
0.02-0.04 g/L. In another embodiment, the amount is 0.03-0.06
g/L.
[0183] In another embodiment, the cobalt is present in an amount
that is the molar equivalent of 0.02 g/L of cobalt chloride
hexahydrate. In another embodiment, the amount of cobalt present is
the molar equivalent of about 0.02 g/L of cobalt chloride
hexahydrate. In another embodiment, the amount of cobalt present is
the molar equivalent of another of the above amounts or ranges of
cobalt chloride hexahydrate. Each of the above amounts or ranges of
cobalt represents a separate embodiment of the present
invention.
[0184] The copper present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.019 g/L (Examples 15-16). In
another embodiment, the amount is about 0.019 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0185] In another embodiment, the copper is present in an amount
that is the molar equivalent of 0.019 g/L of copper chloride
dihydrate. In another embodiment, the amount of copper present is
the molar equivalent of about 0.019 g/L of copper chloride
dihydrate. In another embodiment, the amount of copper present is
the molar equivalent of copper chloride dihydrate in any of the
amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of copper represents a separate embodiment of the
present invention.
[0186] The borate present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.016 g/L (Examples 15-16). In
another embodiment, the amount is about 0.016 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0187] In another embodiment, the borate is present in an amount
that is the molar equivalent of 0.016 g/L of boric acid. In another
embodiment, the amount of borate present is the molar equivalent of
about 0.016 g/L of boric acid. In another embodiment, the amount of
borate present is the molar equivalent of boric acid in any of the
amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of borate represents a separate embodiment of the
present invention.
[0188] The manganese present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.016 g/L (Examples 15-16). In
another embodiment, the amount is about 0.016 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0189] In another embodiment, the manganese is present in an amount
that is the molar equivalent of 0.016 g/L of manganese sulfate
monohydrate. In another embodiment, the amount of manganese present
is the molar equivalent of about 0.016 g/L of manganese sulfate
monohydrate. In another embodiment, the amount of manganese present
is the molar equivalent of manganese sulfate monohydrate in any of
the amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of manganese represents a separate embodiment of
the present invention.
[0190] The molybdenum present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.02 g/L (Examples 15-16). In
another embodiment, the amount is about 0.02 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0191] In another embodiment, the molybdenum is present in an
amount that is the molar equivalent of 0.2 g/L of sodium molybdate
dihydrate. In another embodiment, the amount of molybdenum present
is the molar equivalent of about 0.02 g/L of sodium molybdate
dihydrate. In another embodiment, the amount of molybdenum present
is the molar equivalent of sodium molybdate dihydrate in any of the
amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of molybdenum represents a separate embodiment of
the present invention.
[0192] The zinc present in defined microbiological media of methods
and compositions of the present invention is, in another
embodiment, present in an amount of 0.02 g/L (Examples 15-16). In
another embodiment, the amount is about 0.02 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0193] In another embodiment, the zinc is present in an amount that
is the molar equivalent of 0.02 g/L of zinc chloride heptahydrate.
In another embodiment, the amount of zinc present is the molar
equivalent of about 0.02 g/L of zinc chloride heptahydrate. In
another embodiment, the amount of zinc present is the molar
equivalent of zinc chloride heptahydrate in any of the amounts or
ranges listed above for cobalt. Each of the above amounts or ranges
of zinc represents a separate embodiment of the present
invention.
[0194] In another embodiment, ferric sulfate or a related compound
is present in defined microbiological media of methods and
compositions of the present invention. In another embodiment, the
ferric sulfate or related compound is present in an amount of 0.01
g/L (Examples 15-16). In another embodiment, the amount is about
0.01 g/L. In other embodiments, the amount is any of the amounts or
ranges listed above for cobalt.
[0195] In another embodiment, the iron is present in an amount that
is the molar equivalent of 0.01 g/L of ferric sulfate. In another
embodiment, the amount of iron present is the molar equivalent of
about 0.01 g/L of ferric sulfate. In another embodiment, the amount
of iron present is the molar equivalent of ferric sulfate in any of
the amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of iron represents a separate embodiment of the
present invention.
[0196] The calcium present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.01 g/L (Examples 15-16). In
another embodiment, the amount is about 0.01 g/L. In other
embodiments, the amount is any of the amounts or ranges listed
above for cobalt.
[0197] In another embodiment, the calcium is present in an amount
that is the molar equivalent of 0.01 g/L of calcium chloride
dihydrate. In another embodiment, the amount of calcium present is
the molar equivalent of about 0.01 g/L of calcium chloride
dihydrate. In another embodiment, the amount of calcium present is
the molar equivalent of calcium chloride dihydrate in any of the
amounts or ranges listed above for cobalt. Each of the above
amounts or ranges of calcium represents a separate embodiment of
the present invention.
[0198] The citrate present in defined microbiological media of
methods and compositions of the present invention is, in another
embodiment, present in an amount of 0.9 g/L (Examples 15-16). In
another embodiment, the amount is 0.6 g/L in the form of citric
acid (Examples 15-16). In another embodiment, the amount is 0.4 g/L
in the form of ferric citrate (Examples 15-16). In another
embodiment, the amount is 0.6 g/L in the form of citric acid and
0.4 g/L in the form of ferric citrate (Examples 15-16). In another
embodiment, the amount is about 0.6 g/L. In another embodiment, the
amount is 0.1 g/L. In another embodiment, the amount is 0.2 g/L. In
another embodiment, the amount is 0.3 g/L. In another embodiment,
the amount is 0.4 g/L. In another embodiment, the amount is 0.5
g/L. In another embodiment, the amount is 0.7 g/L. In another
embodiment, the amount is 0.8 g/L. In another embodiment, the
amount is 1 g/L. In another embodiment, the amount is more than 1
g/L.
[0199] In another embodiment, the citrate is present in an amount
that is the molar equivalent of 0.6 g/L of citric acid. In another
embodiment, the amount of citrate present is the molar equivalent
of about 0.6 g/L of citric acid. In another embodiment, the amount
of citrate present is the molar equivalent of about 0.4 g/L of
ferric citrate. In another embodiment, the amount of citrate
present is the molar equivalent of 0.4 g/L of ferric citrate. In
another embodiment, the amount of citrate present is the molar
equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric citrate.
In another embodiment, the amount of citrate present is the about
molar equivalent of 0.6 g/L of citric acid and 0.4 g/L of ferric
citrate. In another embodiment, the amount of citrate present is
the molar equivalent of citric acid in any of the amounts or ranges
listed above for citrate. Each of the above amounts or ranges of
citrate represents a separate embodiment of the present
invention.
[0200] One or more of the adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide present in
defined microbiological media of methods and compositions of the
present invention are, in another embodiment, present as the free
compound. In another embodiment, one of the above compounds is
present as a salt thereof. In another embodiment, one of the above
compounds is present as a derivative thereof. In another
embodiment, one of the above compounds is present as a hydrate
thereof. In other embodiments, the salt, derivative, or hydrate can
be any salt, derivative, or hydrate known in the art. Each of the
above forms of adenine, biotin, thiamine, pyridoxal,
para-aminobenzoic acid, pantothenate, and nicotinamide represents a
separate embodiment of the present invention.
[0201] The thiamine (vitamin B1) present in defined microbiological
media of methods and compositions of the present invention is, in
another embodiment, present in the form of thiamine HCl. In another
embodiment, the thiamine is present as any other salt, derivative,
or hydrate of thiamine known in the art. In another embodiment,
another form of vitamin B1 is substituted for thiamine. Each
possibility represents a separate embodiment of the present
invention.
[0202] In another embodiment, the thiamine is present in an amount
of 4 mg/L (Examples 15-16). In another embodiment, the amount is
about 0.5 mg/L. In another embodiment, the amount is 0.7 mg/L. In
another embodiment, the amount is 1 mg/L. In another embodiment,
the amount is 1.5 mg/L. In another embodiment, the amount is 2
mg/L. In another embodiment, the amount is 3 mg/L. In another
embodiment, the amount is 5 mg/L. In another embodiment, the amount
is 6 mg/L. In another embodiment, the amount is 8 mg/L. In another
embodiment, the amount is more than 8 mg/L. In another embodiment,
the thiamine is present in an amount that is the molar equivalent
of 4 mg/L of thiamine HCl. In another embodiment, the thiamine is
present in an amount that is the molar equivalent of thiamine HCl
in one of the above amounts. Each possibility represents a separate
embodiment of the present invention.
[0203] The pyridoxal (vitamin B6) present in defined
microbiological media of methods and compositions of the present
invention is, in another embodiment, present in the form of
pyridoxal HCl. In another embodiment, the pyridoxal is present as
any other salt, derivative, or hydrate of pyridoxal known in the
art. In another embodiment, another form of vitamin B6 is
substituted for pyridoxal. Each possibility represents a separate
embodiment of the present invention.
[0204] In another embodiment, the pyridoxal is present in an amount
of 4 mg/L (Examples 15-16). In another embodiment, the amount is
any of the amounts or ranges listed above for thiamine. In another
embodiment, the amount of pyridoxal present is the molar equivalent
of about 4 mg/L of pyridoxal HCl. In another embodiment, the amount
of pyridoxal present is the molar equivalent of pyridoxal HCl in
any of the amounts or ranges listed above for thiamine. Each
possibility represents a separate embodiment of the present
invention.
[0205] The adenine (vitamin B4) present in defined microbiological
media of methods and compositions of the present invention is, in
another embodiment, present in the form of free adenine. In another
embodiment, the adenine is present as any other salt, derivative,
or hydrate of adenine known in the art. In another embodiment,
another form of vitamin B4 is substituted for adenine. Each
possibility represents a separate embodiment of the present
invention.
[0206] In another embodiment, the adenine is present in an amount
of 0.25 mg/L (Examples 15-16). In another embodiment, the amount is
any of the amounts or ranges listed above for cobalt. In another
embodiment, the amount of adenine present is the molar equivalent
of about 0.25 mg/L of free adenine. In another embodiment, the
amount of adenine present is the molar equivalent of free adenine
in any of the amounts or ranges listed above for cobalt. Each
possibility represents a separate embodiment of the present
invention.
[0207] The biotin (vitamin B7) present in defined microbiological
media of methods and compositions of the present invention is, in
another embodiment, present in the form of free biotin. In another
embodiment, the biotin is present as any other salt, derivative, or
hydrate of biotin known in the art. In another embodiment, another
form of vitamin B7 is substituted for biotin. Each possibility
represents a separate embodiment of the present invention.
[0208] In another embodiment, the biotin is present in an amount of
2 mg/L (Examples 15-16). In another embodiment, the amount is any
of the amounts or ranges listed above for thiamine. In another
embodiment, the amount of biotin present is the molar equivalent of
about 2 mg/L of free biotin. In another embodiment, the amount of
biotin present is the molar equivalent of free biotin in any of the
amounts or ranges listed above for thiamine. Each possibility
represents a separate embodiment of the present invention.
[0209] The para-aminobenzoic acid (vitamin B-x) present in defined
microbiological media of methods and compositions of the present
invention is, in another embodiment, present in the form of free
para-aminobenzoic acid. In another embodiment, the
para-aminobenzoic acid is present as any other salt, derivative, or
hydrate of para-aminobenzoic acid known in the art. In another
embodiment, another form of vitamin B-x is substituted for
para-aminobenzoic acid. Each possibility represents a separate
embodiment of the present invention.
[0210] In another embodiment, the para-aminobenzoic acid is present
in an amount of 4 mg/L (Examples 15-16). In another embodiment, the
amount is any of the amounts or ranges listed above for thiamine.
In another embodiment, the amount of para-aminobenzoic acid present
is the molar equivalent of about 4 mg/L of free para-aminobenzoic
acid. In another embodiment, the amount of para-aminobenzoic acid
present is the molar equivalent of free para-aminobenzoic acid in
any of the amounts or ranges listed above for thiamine. Each
possibility represents a separate embodiment of the present
invention.
[0211] The pantothenate (vitamin B5) present in defined
microbiological media of methods and compositions of the present
invention is, in another embodiment, present in the form of calcium
pantothenate. In another embodiment, the pantothenate is present as
any other salt, derivative, or hydrate of pantothenate known in the
art. In another embodiment, another form of vitamin B5 is
substituted for pantothenate. Each possibility represents a
separate embodiment of the present invention.
[0212] In another embodiment, the pantothenate is present in an
amount of 4 mg/L (Examples 15-16). In another embodiment, the
amount is any of the amounts or ranges listed above for thiamine.
In another embodiment, the amount of pantothenate present is the
molar equivalent of about 4 mg/L of calcium pantothenate. In
another embodiment, the amount of pantothenate present is the molar
equivalent of calcium pantothenate in any of the amounts or ranges
listed above for thiamine. Each possibility represents a separate
embodiment of the present invention.
[0213] The nicotinamide (vitamin B3) present in defined
microbiological media of methods and compositions of the present
invention is, in another embodiment, present in the form of free
nicotinamide. In another embodiment, the nicotinamide is present as
any other salt, derivative, or hydrate of nicotinamide known in the
art. In another embodiment, another form of vitamin B3 is
substituted for nicotinamide. Each possibility represents a
separate embodiment of the present invention.
[0214] In another embodiment, the nicotinamide is present in an
amount of 4 mg/L (Examples 15-16). In another embodiment, the
amount is any of the amounts or ranges listed above for thiamine.
In another embodiment, the amount of nicotinamide present is the
molar equivalent of about 4 mg/L of free nicotinamide. In another
embodiment, the amount of nicotinamide present is the molar
equivalent of free nicotinamide in any of the amounts or ranges
listed above for thiamine. Each possibility represents a separate
embodiment of the present invention.
[0215] One or more of the leucine, isoleucine, valine, arginine,
histidine, tryptophan, and phenylalanine present in defined
microbiological media of methods and compositions of the present
invention are, in another embodiment, present as free amino acids.
In another embodiment, one of the above compounds is present as a
salt thereof. In another embodiment, one of the above compounds is
present as a derivative thereof. In another embodiment, one of the
above compounds is present as a hydrate thereof. In other
embodiments, the salt, derivative, or hydrate can be any salt,
derivative, or hydrate known in the art. Each of the above forms of
adenine, biotin, thiamine, pyridoxal, para-aminobenzoic acid,
pantothenate, and nicotinamide represents a separate embodiment of
the present invention.
[0216] In another embodiment, one or more of the leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine is present in an amount of 0.4 g/L (Examples 15-16).
In another embodiment, the amount is about 0.05 g/L. In another
embodiment, the amount is 0.07 g/L. In another embodiment, the
amount is 0.1 g/L. In another embodiment, the amount is 0.15 g/L.
In another embodiment, the amount is 0.2 g/L. In another
embodiment, the amount is 0.3 g/L. In another embodiment, the
amount is 0.5 g/L. In another embodiment, the amount is 0.6 g/L. In
another embodiment, the amount is 0.8 g/L. In another embodiment,
the amount is more than 0.8 g/L. In another embodiment, one or more
of these AA is present in an amount that is the molar equivalent of
0.4 g/L of the free AA. In another embodiment, the amount is the
molar equivalent of thiamine the free AA in one of the above
amounts. Each possibility represents a separate embodiment of the
present invention.
[0217] In another embodiment, a defined media of methods and
compositions of the present invention contains two of the amino
acids (AA) listed in the second section of Table 3B, e.g. leucine,
isoleucine, valine, arginine, histidine, tryptophan, and
phenylalanine. In another embodiment, the defined media contains 3
of these AA. In another embodiment, the media contains 4 of these
AA. In another embodiment, the media contains 3 of these AA. In
another embodiment, the media contains 5 of these AA. In another
embodiment, the media contains 6 of these AA. In another
embodiment, the media contains all of these AA. In another
embodiment, the media contains at least 2 of these AA. In another
embodiment, the media contains at least 3 of these AA. In another
embodiment, the media contains at least 4 of these AA. In another
embodiment, the media contains at least 5 of these AA. In another
embodiment, the media contains at least 6 of these AA. Each
possibility represents a separate embodiment of the present
invention.
[0218] In another embodiment, a defined media of methods and
compositions of the present invention contains 2 of the vitamins
listed in the third section of Table 3B, e.g. adenine, biotin,
thiamine, pyridoxal, para-aminobenzoic acid, pantothenate, and
nicotinamide. In another embodiment, the defined media contains 3
of these vitamins. In another embodiment, the media contains 4 of
these vitamins. In another embodiment, the media contains 3 of
these vitamins. In another embodiment, the media contains 5 of
these vitamins. In another embodiment, the media contains 6 of
these vitamins. In another embodiment, the media contains all of
these vitamins. In another embodiment, the media contains at least
2 of these vitamins. In another embodiment, the media contains at
least 3 of these vitamins. In another embodiment, the media
contains at least 4 of these vitamins. In another embodiment, the
media contains at least 5 of these vitamins. In another embodiment,
the media contains at least 6 of these vitamins. Each possibility
represents a separate embodiment of the present invention.
[0219] In another embodiment, a defined media of methods and
compositions of the present invention contains 2 of the trace
elements listed in the fourth section of Table 3B, e.g. cobalt,
copper, boron, manganese, molybdenum, zinc, iron, calcium, and
citrate. In another embodiment, the defined media contains 3 of
these trace elements. In another embodiment, the media contains 4
of these trace elements. In another embodiment, the media contains
3 of these trace elements. In another embodiment, the media
contains 5 of these trace elements. In another embodiment, the
media contains 6 of these trace elements. In another embodiment,
the media contains 7 of these trace elements. In another
embodiment, the media contains 7 of these trace elements. In
another embodiment, the media contains all of these trace elements.
In another embodiment, the media contains at least 2 of these trace
elements. In another embodiment, the media contains at least 3 of
these trace elements. In another embodiment, the media contains at
least 4 of these trace elements. In another embodiment, the media
contains at least 5 of these trace elements. In another embodiment,
the media contains at least 6 of these trace elements. In another
embodiment, the media contains at least 7 of these trace elements.
In another embodiment, the media contains at least 8 of these trace
elements. Each possibility represents a separate embodiment of the
present invention.
[0220] In another embodiment, a defined media of methods and
compositions of the present invention contains more than 1
component from 2 of the above classes of components; e.g more than
one of the AA listed in the second section of Table 3B, and more
than one of the vitamins listed in the third section. In another
embodiment, the media contains more than 2 components from 2 of the
above classes of components; e.g more than 2 of the AA listed in
the second section of Table 3B, and more than 2 of the trace
elements listed in the fourth section. In another embodiment, the
media contains more than 3 components from 2 of the above classes.
In another embodiment, the media contains more than 4 components
from 2 of the above classes. In another embodiment, the media
contains more than 5 components from 2 of the above classes. In
another embodiment, the media contains more than 6 components from
2 of the above classes. In another embodiment, the media contains
all of the components from 2 of the above classes.
[0221] In another embodiment, a defined media of methods and
compositions of the present invention contains more than 1
component from all of the above classes of components (e.g. more
than 1 component each from AA, vitamins and trace elements). In
another embodiment, the media contains more than 2 components from
all of the above classes of components. In another embodiment, the
media contains more than 3 components from all of the above
classes. In another embodiment, the media contains more than 4
components from all of the above classes. In another embodiment,
the media contains more than all components from 2 of the above
classes. In another embodiment, the media contains more than 6
components from all of the above classes. In another embodiment,
the media contains all of the components from all of the above
classes.
[0222] In another embodiment, the media contains any other
combination of numbers of components from each of the above
classes; e.g. 2 AA, 2 vitamins, and 3 trace elements; 3 AA, 3
vitamins, and 2 trace elements; 2 AA, 3 vitamins, and all of the
trace elements, etc.
[0223] Each of the above combinations of numbers of components from
each of the above classes represents a separate embodiment of the
present invention.
[0224] In another embodiment, a defined media of methods and
compositions of the present invention consists of one of the above
recipes, mixtures of components, lists of components in specified
amounts, or combinations of numbers of components from each of the
above classes. Each possibility represents a separate embodiment of
the present invention.
[0225] The divalent cation present in defined microbiological media
of methods and compositions of the present invention is, in another
embodiment, Mg. In another embodiment, the divalent cation is Ca.
In another embodiment, the divalent cation is any other divalent
cation known in the art. Mg can, in other embodiments, be present
in any form of Mg known in the art, e.g. MgSO.sub.4 (Examples
15-16). In another embodiment, the divalent cation is present in an
amount that is the molar equivalent of about 0.41 g/mL. In other
embodiments, the divalent cation is present in another effective
amount, as known to those skilled in the art.
[0226] In another embodiment, a nitrogen source other than
glutamine is utilized in defined media of the present invention. In
another embodiment, the nitrogen source is another AA. In another
embodiment, the nitrogen source is another source of peptides or
proteins (e.g. casitone or casamino acids). In another embodiment,
the nitrogen source is ammonium chloride. In another embodiment,
the nitrogen source is ammonium nitrate. In another embodiment, the
nitrogen source is ammonium sulfate. In another embodiment, the
nitrogen source is another ammonium salt. In another embodiment,
the nitrogen source is any other nitrogen source known in the art.
Each possibility represents a separate embodiment of the present
invention.
[0227] In another embodiment, a defined microbiological media of
methods and compositions of the present invention does not contain
a component derived from an animal source. In another embodiment,
the defined microbiological media does not contain an
animal-derived component of incompletely defined composition (e.g.
yeast extract, bacto-tryptone, etc.). Each possibility represents a
separate embodiment of the present invention.
[0228] In another embodiment, "defined microbiological media"
refers to a media whose components are known. In another
embodiment, the term refers to a media that does not contain a
component derived from an animal source. In another embodiment, the
term refers to a media whose components have been chemically
characterized. Each possibility represents a separate embodiment of
the present invention.
[0229] In another embodiment, a defined media of methods and
compositions of the present invention supports growth of the
Listeria strain to about 1.1.times.10.sup.10 CFU/mL (e.g. when
grown in flasks; Examples 13-16). In another embodiment, the
defined media supports growth to about 1.1.times.10.sup.10 CFU/mL
(e.g. when grown in fermenters; Examples 13-16). In another
embodiment, the defined media supports growth to about
5.times.10.sup.9 CFU/mL (e.g. when grown in fermenters; Examples
13-16). In another embodiment, the defined media supports growth of
viable bacteria (e.g. bacteria that can be cryopreserved without
significant loss of viability) to about 3.times.10.sup.10 CFU/mL
(e.g. when grown in fermenters; Examples 13-16). In another
embodiment, the defined media supports growth to an OD.sub.600 of
about 4.5 (Examples 13-16). In other embodiments, the defined media
supports growth to another OD.sub.600 value enumerated herein. In
other embodiments, the defined media supports growth to another
CFU/mL value enumerated herein. In another embodiment, the defined
media supports growth to a density approximately equivalent to that
obtained with TB. In another embodiment, the defined media supports
growth to a density approximately equivalent to that obtained with
LB. Each possibility represents a separate embodiment of the
present invention.
[0230] In another embodiment, a defined media of methods and
compositions of the present invention supports a growth rate of the
Listeria strain of about 0.25 h.sup.-1 (Examples). In another
embodiment, the growth rate is about 0.15 h.sup.-1. In another
embodiment, the growth rate is about 0.2 h.sup.-1. In another
embodiment, the growth rate is about 0.3 h.sup.-1. In another
embodiment, the growth rate is about 0.4 h.sup.-1. In another
embodiment, the growth rate is about 0.5 h.sup.-1. In another
embodiment, the growth rate is about 0.6 h.sup.-1. In another
embodiment, the defined media supports a growth rate approximately
equivalent to that obtained with TB. In another embodiment, the
defined media supports a growth rate approximately equivalent to
that obtained with LB. Each possibility represents a separate
embodiment of the present invention.
[0231] As provided herein, vaccines of the present invention were
completely well tolerated in 5/6 patients, even though the patients
were very sick with metastatic cancer. It should be noted that
halting of therapy in the case of the other patient, Patient 5, was
done purely as a precaution. At no point was the patient's life
considered to be even remotely in danger. The safety results in
such patients, at least some of which were likely to be
immunosuppressed, shows that the Listeria vaccines can be safely
administered to a wide variety of patients.
[0232] In another embodiment, a peptide of the present invention is
a fusion peptide. In another embodiment, "fusion peptide" refers to
a peptide or polypeptide comprising 2 or more proteins linked
together by peptide bonds or other chemical bonds. In another
embodiment, the proteins are linked together directly by a peptide
or other chemical bond. In another embodiment, the proteins are
linked together with 1 or more AA (e.g. a "spacer") between the 2
or more proteins. Each possibility represents a separate embodiment
of the present invention.
[0233] In another embodiment, a vaccine of the present invention
further comprises an adjuvant. The adjuvant utilized in methods and
compositions of the present invention is, in another embodiment, a
granulocyte/macrophage colony-stimulating factor (GM-CSF) protein.
In another embodiment, the adjuvant comprises a GM-CSF protein. In
another embodiment, the adjuvant is a nucleotide molecule encoding
GM-CSF. In another embodiment, the adjuvant comprises a nucleotide
molecule encoding GM-CSF. In another embodiment, the adjuvant is
saponin QS21. In another embodiment, the adjuvant comprises saponin
QS21. In another embodiment, the adjuvant is monophosphoryl lipid
A. In another embodiment, the adjuvant comprises monophosphoryl
lipid A. In another embodiment, the adjuvant is SBAS2. In another
embodiment, the adjuvant comprises SBAS2. In another embodiment,
the adjuvant is an unmethylated CpG-containing oligonucleotide. In
another embodiment, the adjuvant comprises an unmethylated
CpG-containing oligonucleotide. In another embodiment, the adjuvant
is an immune-stimulating cytokine. In another embodiment, the
adjuvant comprises an immune-stimulating cytokine. In another
embodiment, the adjuvant is a nucleotide molecule encoding an
immune-stimulating cytokine. In another embodiment, the adjuvant
comprises a nucleotide molecule encoding an immune-stimulating
cytokine. In another embodiment, the adjuvant is or comprises a
quill glycoside. In another embodiment, the adjuvant is or
comprises a bacterial mitogen. In another embodiment, the adjuvant
is or comprises a bacterial toxin. In another embodiment, the
adjuvant is or comprises any other adjuvant known in the art. Each
possibility represents a separate embodiment of the present
invention.
[0234] In another embodiment, a nucleotide of the present invention
is operably linked to a promoter/regulatory sequence that drives
expression of the encoded peptide in the Listeria strain.
Promoter/regulatory sequences useful for driving constitutive
expression of a gene are well known in the art and include, but are
not limited to, for example, the P.sub.hlyA, P.sub.ActA, and p60
promoters of Listeria, the Streptococcus bac promoter, the
Streptomyces griseus sgiA promoter, and the B. thuringiensis phaZ
promoter. In another embodiment, inducible and tissue specific
expression of the nucleic acid encoding a peptide of the present
invention is accomplished by placing the nucleic acid encoding the
peptide under the control of an inducible or tissue specific
promoter/regulatory sequence. Examples of tissue specific or
inducible promoter/regulatory sequences which are useful for his
purpose include, but are not limited to the MMTV LTR inducible
promoter, and the SV40 late enhancer/promoter. In another
embodiment, a promoter that is induced in response to inducing
agents such as metals, glucocorticoids, and the like, is utilized.
Thus, it will be appreciated that the invention includes the use of
any promoter/regulatory sequence, which is either known or unknown,
and which is capable of driving expression of the desired protein
operably linked thereto.
[0235] In another embodiment of methods and compositions of the
present invention, a PEST-like AA sequence is fused to the E7 or E6
antigen. As provided herein, recombinant Listeria strains
expressing PEST-like sequence-antigen fusions induce anti-tumor
immunity (Example 3) and generate antigen-specific,
tumor-infiltrating T cells (Example 4). Further, enhanced cell
mediated immunity was demonstrated for fusion proteins comprising
an antigen and LLO containing the PEST-like AA sequence
TABLE-US-00004 (SEQ ID NO: 1) KENSISSMAPPASPPASPKTPIEKKHADEIDK.
[0236] Thus, fusion of an antigen to other LM PEST-like sequences
and PEST-like sequences derived from other prokaryotic organisms
will also enhance immunogenicity of the antigen. The PEST-like AA
sequence has, in another embodiment, a sequence selected from SEQ
ID NO: 2-7. In another embodiment, the PEST-like sequence is
KTEEQPSEVNTGPR (SEQ ID NO: 2), KASVTDTSEGDLDSSMQSADESTPQPLK (SEQ ID
NO: 3), KNEEVNASDFPPPPTDEELR (SEQ ID NO: 4), or
RGGIPTSEEFSSLNSGDFTDDENSETTEEEIDR (SEQ ID NO: 5). In another
embodiment, the PEST-like sequence is from Streptolysin O protein
of Streptococcus sp. In another embodiment, the PEST-like sequence
is from Streptococcus pyogenes Streptolysin O, e.g.
KQNTASTETTTTNEQPK (SEQ ID NO: 6) at AA 35-51. In another
embodiment, the PEST-like sequence is from Streptococcus
equisimilis Streptolysin O, e.g. KQNTANTETTTTNEQPK (SEQ ID NO: 7)
at AA 38-54. In another embodiment, the PEST-like sequence is
another PEST-like AA sequence derived from a prokaryotic organism.
In another embodiment, the PEST-like sequence is any other
PEST-like sequence known in the art. Each possibility represents a
separate embodiment of the present invention.
[0237] PEST-like sequences of other prokaryotic organism can be
identified in accordance with methods such as described by, for
example Rechsteiner and Rogers (1996, Trends Biochem. Sci.
21:267-271) for LM. Alternatively, PEST-like AA sequences from
other prokaryotic organisms can also be identified based by this
method. Other prokaryotic organisms wherein PEST-like AA sequences
would be expected to include, but are not limited to, other
Listeria species. In another embodiment, the PEST-like sequence is
embedded within the antigenic protein. Thus, in another embodiment,
"fusion" refers to an antigenic protein comprising both the antigen
and the PEST-like amino acid sequence either linked at one end of
the antigen or embedded within the antigen.
[0238] In another embodiment, the PEST-like sequence is identified
using any other method or algorithm known in the art, e.g the
CaSPredictor (Garay-Malpartida H M, Occhiucci J M, Alves J,
Belizario J E. Bioinformatics. 2005 June; 21 Suppl 1:i169-76). In
another embodiment, the following method is used:
[0239] A PEST index is calculated for each 30-35 AA stretch by
assigning a value of 1 to the amino acids Ser, Thr, Pro, Glu, Asp,
Asn, or Gln. The coefficient value (CV) for each of the PEST
residue is 1 and for each of the other AA (non-PEST) is 0.
[0240] Each method for identifying a PEST-like sequence represents
a separate embodiment of the present invention.
[0241] In another embodiment, the LLO protein, or fragment thereof
of the present invention need not be that which is set forth
exactly in the sequences set forth herein, but rather other
alterations, modifications, or changes can be made that retain the
functional characteristics of an LLO protein fused to an antigen as
set forth elsewhere herein. In another embodiment, the present
invention utilizes an analog of an LLO protein, or fragment
thereof. Analogs differ, in another embodiment, from naturally
occurring proteins or peptides by conservative AA sequence
differences or by modifications which do not affect sequence, or by
both.
[0242] In another embodiment, either a whole E7 protein or a
fragment thereof is fused to a LLO protein, to generate a
recombinant peptide of methods of the present invention. The E7
protein that is utilized (either whole or as the source of the
fragments) has, in another embodiment, the sequence
TABLE-US-00005 (SEQ ID No: 20)
MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRA
HYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP.
In another embodiment, the E7 protein is a homologue of SEQ ID No:
20. In another embodiment, the E7 protein is a variant of SEQ ID
No: 20. In another embodiment, the E7 protein is an isomer of SEQ
ID No: 20. In another embodiment, the E7 protein is a fragment of
SEQ ID No: 20. In another embodiment, the E7 protein is a fragment
of a homologue of SEQ ID No: 20. In another embodiment, the E7
protein is a fragment of a variant of SEQ ID No: 20. In another
embodiment, the E7 protein is a fragment of an isomer of SEQ ID No:
20. Each possibility represents a separate embodiment of the
present invention.
[0243] In another embodiment, the sequence of the E7 protein
is:
TABLE-US-00006 (SEQ ID No: 21)
MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLP
ARRAEPQRHTMLCMCCKCEARIELVVESSADDLRAFQQLFLNTLSFVCPW CASQQ.
In another embodiment, the E6 protein is a homologue of SEQ ID No:
21. In another embodiment, the E6 protein is a variant of SEQ ID
No: 21. In another embodiment, the E6 protein is an isomer of SEQ
ID No: 21. In another embodiment, the E6 protein is a fragment of
SEQ ID No: 21. In another embodiment, the E6 protein is a fragment
of a homologue of SEQ ID No: 21. In another embodiment, the E6
protein is a fragment of a variant of SEQ ID No: 21. In another
embodiment, the E6 protein is a fragment of an isomer of SEQ ID No:
21. Each possibility represents a separate embodiment of the
present invention.
[0244] In another embodiment, the E7 protein has a sequence set
forth in one of the following GenBank entries: M24215,
NC.sub.--004500, V01116, X62843, or M14119. In another embodiment,
the E7 protein is a homologue of a sequence from one of the above
GenBank entries. In another embodiment, the E7 protein is a variant
of a sequence from one of the above GenBank entries. In another
embodiment, the E7 protein is an isomer of a sequence from one of
the above GenBank entries. In another embodiment, the E7 protein is
a fragment of a sequence from one of the above GenBank entries. In
another embodiment, the E7 protein is a fragment of a homologue of
a sequence from one of the above GenBank entries. In another
embodiment, the E7 protein is a fragment of a variant of a sequence
from one of the above GenBank entries. In another embodiment, the
E7 protein is a fragment of an isomer of a sequence from one of the
above GenBank entries. Each possibility represents a separate
embodiment of the present invention.
[0245] In another embodiment, either a whole E6 protein or a
fragment thereof is fused to a LLO protein, to generate a
recombinant peptide of methods of the present invention. The E6
protein that is utilized (either whole or as the source of the
fragments) has, in another embodiment, the sequence
TABLE-US-00007 (SEQ ID No: 22)
MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVY
DFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYN
KPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSS RTRRETQL.
In another embodiment, the E6 protein is a homologue of SEQ ID No:
22. In another embodiment, the E6 protein is a variant of SEQ ID
No: 22. In another embodiment, the E6 protein is an isomer of SEQ
ID No: 22. In another embodiment, the E6 protein is a fragment of
SEQ ID No: 22. In another embodiment, the E6 protein is a fragment
of a homologue of SEQ ID No: 22. In another embodiment, the E6
protein is a fragment of a variant of SEQ ID No: 22. In another
embodiment, the E6 protein is a fragment of an isomer of SEQ ID No:
22. Each possibility represents a separate embodiment of the
present invention.
[0246] In another embodiment, the sequence of the E6 protein
is:
TABLE-US-00008 (SEQ ID No: 23)
MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFK
DLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYN
LLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERL QRRRETQV.
In another embodiment, In another embodiment, the E6 protein is a
homologue of SEQ ID No: 23. In another embodiment, the E6 protein
is a variant of SEQ ID No: 23. In another embodiment, the E6
protein is an isomer of SEQ ID No: 23. In another embodiment, the
E6 protein is a fragment of SEQ ID No: 23. In another embodiment,
the E6 protein is a fragment of a homologue of SEQ ID No: 23. In
another embodiment, the E6 protein is a fragment of a variant of
SEQ ID No: 23. In another embodiment, the E6 protein is a fragment
of an isomer of SEQ ID No: 23. Each possibility represents a
separate embodiment of the present invention.
[0247] In another embodiment, the E6 protein has a sequence set
forth in one of the following GenBank entries: M24215, M14119,
NC.sub.--004500, V01116, X62843, or M14119. In another embodiment,
the E6 protein is a homologue of a sequence from one of the above
GenBank entries. In another embodiment, the E6 protein is a variant
of a sequence from one of the above GenBank entries. In another
embodiment, the E6 protein is an isomer of a sequence from one of
the above GenBank entries. In another embodiment, the E6 protein is
a fragment of a sequence from one of the above GenBank entries. In
another embodiment, the E6 protein is a fragment of a homologue of
a sequence from one of the above GenBank entries. In another
embodiment, the E6 protein is a fragment of a variant of a sequence
from one of the above GenBank entries. In another embodiment, the
E6 protein is a fragment of an isomer of a sequence from one of the
above GenBank entries. Each possibility represents a separate
embodiment of the present invention.
[0248] In another embodiment, "homology" refers to identity to an
LLO sequence (e.g. to one of SEQ ID No: 15-17) of greater than 70%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 72%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 75%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 78%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 80%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 82%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 83%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 85%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 87%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 88%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 90%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 92%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 93%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 95%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 96%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 97%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of greater than 98%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 15-17 of greater than 99%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 15-17 of 100%. Each
possibility represents a separate embodiment of the present
invention.
[0249] In another embodiment, "homology" refers to identity to an
E7 sequence (e.g. to one of SEQ ID No: 20-21) of greater than 70%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 72%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 75%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 78%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 80%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 82%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 83%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 85%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 87%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 88%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 90%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 92%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 93%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 95%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 96%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 97%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of greater than 98%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 20-21 of greater than 99%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 20-21 of 100%. Each
possibility represents a separate embodiment of the present
invention.
[0250] In another embodiment, "homology" refers to identity to an
E6 sequence (e.g. to one of SEQ ID No: 22-23) of greater than 70%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 72%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 75%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 78%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 80%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 82%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 83%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 85%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 87%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 88%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 90%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 92%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 93%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 95%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 96%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 97%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of greater than 98%.
In another embodiment, "homology" refers to identity to one of SEQ
ID No: 22-23 of greater than 99%. In another embodiment, "homology"
refers to identity to one of SEQ ID No: 22-23 of 100%. Each
possibility represents a separate embodiment of the present
invention.
[0251] Protein and/or peptide homology for any AA sequence listed
herein is determined, in one embodiment, by methods well described
in the art, including immunoblot analysis, or via computer
algorithm analysis of AA sequences, utilizing any of a number of
software packages available, via established methods. Some of these
packages include the FASTA, BLAST, MPsrch or Scanps packages, and
employ, in other embodiments, the use of the Smith and Waterman
algorithms, and/or global/local or BLOCKS alignments for analysis,
for example. Each method of determining homology represents a
separate embodiment of the present invention.
[0252] In another embodiment, the LLO protein is attached to the E7
or E6 antigen by chemical conjugation. In another embodiment,
glutaraldehyde is used for the conjugation. In another embodiment,
the conjugation is performed using any suitable method known in the
art. Each possibility represents another embodiment of the present
invention.
[0253] In another embodiment, the present invention provides a kit
comprising vaccine of the present invention, an applicator, and
instructional material that describes use of the methods of the
invention. Although model kits are described below, the contents of
other useful kits will be apparent to the skilled artisan in light
of the present disclosure. Each of these kits represents a separate
embodiment of the present invention.
EXPERIMENTAL DETAILS SECTION
Example 1
LLO-Antigen Fusions Induce Anti-Tumor Immunity
Materials and Experimental Methods (Examples 1-2)
Cell Lines
[0254] The C57BL/6 syngeneic TC-1 tumor was immortalized with
HPV-16 E6 and E7 and transformed with the c-Ha-ras oncogene. TC-1,
provided by T. C. Wu (Johns Hopkins University School of Medicine,
Baltimore, Md.) is a highly tumorigenic lung epithelial cell
expressing low levels of with HPV-16 E6 and E7 and transformed with
the c-Ha-ras oncogene. TC-1 was grown in RPMI 1640, 10% FCS, 2 mM
L-glutamine, 100 U/ml penicillin, 100 .mu.g/ml streptomycin, 100
.mu.M nonessential amino acids, 1 mM sodium pyruvate, 50 micromolar
(mcM) 2-ME, 400 microgram (mcg)/ml G418, and 10% National
Collection Type Culture-109 medium at 37.degree. with 10% CO.sub.2.
C3 is a mouse embryo cell from C57BL/6 mice immortalized with the
complete genome of HPV 16 and transformed with pEJ-ras. EL-4/E7 is
the thymoma EL-4 retrovirally transduced with E7.
L. monocytogenes Strains and Propagation
[0255] Listeria strains used were Lm-LLO-E7 (hly-E7 fusion gene in
an episomal expression system; FIG. 1A), Lm-E7 (single-copy E7 gene
cassette integrated into Listeria genome), Lm-LLO-NP ("DP-L2028";
hly-NP fusion gene in an episomal expression system), and Lm-Gag
("ZY-18"; single-copy HIV-1 Gag gene cassette integrated into the
chromosome). E7 was amplified by PCR using the primers
5'-GGCTCGAGCATGGAGATACACC-3' (SEQ ID No: 8; XhoI site is
underlined) and 5'-GGGGACTAGTTTATGGTTTCTGAGAACA-3' (SEQ ID No: 9;
SpeI site is underlined) and ligated into pCR2.1 (Invitrogen, San
Diego, Calif.). E7 was excised from pCR2.1 by XhoI/SpeI digestion
and ligated into pGG-55. The hly-E7 fusion gene and the
pluripotential transcription factor prfA were cloned into pAM401, a
multicopy shuttle plasmid (Wirth R et al, J Bacteriol, 165: 831,
1986), generating pGG-55. The hly promoter drives the expression of
the first 441 AA of the hly gene product, (lacking the hemolytic
C-terminus, referred to below as "ALLO," and having the sequence
set forth in SEQ ID No: 15), which is joined by the XhoI site to
the E7 gene, yielding a hly-E7 fusion gene that is transcribed and
secreted as LLO-E7. Transformation of a prfA negative strain of
Listeria, XFL-7 (provided by Dr. Hao Shen, University of
Pennsylvania), with pGG-55 selected for the retention of the
plasmid in vivo (FIGS. 1A-B). The hly promoter and gene fragment
were generated using primers 5'-GGGGGCTAGCCCTCCTTTGATTAGTATATTC-3'
(SEQ ID No: 10; NheI site is underlined) and
5'-CTCCCTCGAGATCATAATTTACTTCATC-3' (SEQ ID No: 11; `Choi site is
underlined). The prfA gene was PCR amplified using primers
5`-GACTACAAGGACGATGACCGACAAGTGATAACCCGGGATCTAAATAAATCCGTT T-3' (SEQ
ID No: 12; XbaI site is underlined) and
5'-CCCGTCGACCAGCTCTTCTTGGTGAAG-3' (SEQ ID No: 13; SalI site is
underlined). Lm-E7 was generated by introducing an expression
cassette containing the hly promoter and signal sequence driving
the expression and secretion of E7 into the orfZ domain of the LM
genome. E7 was amplified by PCR using the primers
5'-GCGGATCCCATGGAGATACACCTAC-3' (SEQ ID No: 18; BamHI site is
underlined) and 5'-GCTCTAGATTATGGTTTCTGAG-3' (SEQ ID No: 19; XbaI
site is underlined). E7 was then ligated into the pZY-21 shuttle
vector. LM strain 10403S was transformed with the resulting
plasmid, pZY-21-E7, which includes an expression cassette inserted
in the middle of a 1.6-kb sequence that corresponds to the orfX, Y,
Z domain of the LM genome. The homology domain allows for insertion
of the E7 gene cassette into the orfZ domain by homologous
recombination. Clones were screened for integration of the E7 gene
cassette into the orfZ domain. Bacteria were grown in brain heart
infusion medium with (Lm-LLO-E7 and Lm-LLO-NP) or without (Lm-E7
and ZY-18) chloramphenicol (20 .mu.g/ml). Bacteria were frozen in
aliquots at -80.degree. C. Expression was verified by Western
blotting (FIG. 2).
Measurement of Tumor Growth
[0256] Tumors were measured every other day with calipers spanning
the shortest and longest surface diameters. The mean of these two
measurements was plotted as the mean tumor diameter in millimeters
against various time points. Mice were sacrificed when the tumor
diameter reached 20 mm Tumor measurements for each time point are
shown only for surviving mice.
Effects of Listeria Recombinants on Established Tumor Growth
[0257] Six- to 8-wk-old C57BL/6 mice (Charles River) received
2.times.10.sup.5 TC-1 cells s.c. on the left flank. One week
following tumor inoculation, the tumors had reached a palpable size
of 4-5 mm in diameter. Groups of eight mice were then treated with
0.1 LD.sub.50 i.p. Lm-LLO-E7 (10.sup.7 CFU), Lm-E7 (10.sup.6 CFU),
Lm-LLO-NP (10.sup.7 CFU), or Lm-Gag (5.times.10.sup.5 CFU) on days
7 and 14.
.sup.51Cr Release Assay
[0258] C57BL/6 mice, 6-8 wk old, were immunized i.p. with
0.1LD.sub.50 Lm-LLO-E7, Lm-E7, Lm-LLO-NP, or Lm-Gag. Ten days
post-immunization, spleens were harvested. Splenocytes were
established in culture with irradiated TC-1 cells (100:1,
splenocytes:TC-1) as feeder cells; stimulated in vitro for 5 days,
then used in a standard .sup.51Cr release assay, using the
following targets: EL-4, EL-4/E7, or EL-4 pulsed with E7 H-2b
peptide (RAHYNIVTF). E:T cell ratios, performed in triplicate, were
80:1, 40:1, 20:1, 10:1, 5:1, and 2.5:1. Following a 4-h incubation
at 37.degree. C., cells were pelleted, and 50 .mu.l supernatant was
removed from each well. Samples were assayed with a Wallac 1450
scintillation counter (Gaithersburg, Md.). The percent specific
lysis was determined as [(experimental counts per minute
(cpm)-spontaneous cpm)/(total cpm-spontaneous cpm)].times.100.
TC-1-Specific Proliferation
[0259] C57BL/6 mice were immunized with 0.1 LD.sub.50 and boosted
by i.p. injection 20 days later with 1 LD.sub.50 Lm-LLO-E7, Lm-E7,
Lm-LLO-NP, or Lm-Gag. Six days after boosting, spleens were
harvested from immunized and naive mice. Splenocytes were
established in culture at 5.times.10.sup.5/well in flat-bottom
96-well plates with 2.5.times.10.sup.4, 1.25.times.10.sup.4,
6.times.10.sup.3, or 3.times.10.sup.3 irradiated TC-1 cells/well as
a source of E7 Ag, or without TC-1 cells or with 10 .mu.g/ml Con A.
Cells were pulsed 45 h later with 0.5 .mu.Ci
[.sup.3H]thymidine/well. Plates were harvested 18 h later using a
Tomtec harvester 96 (Orange, Conn.), and proliferation was assessed
with a Wallac 1450 scintillation counter. The change in cpm was
calculated as experimental cpm-no Ag cpm.
Flow Cytometric Analysis
[0260] C57BL/6 mice were immunized intravenously (i.v.) with 0.1
LD.sub.50 Lm-LLO-E7 or Lm-E7 and boosted 30 days later. Three-color
flow cytometry for CD8 (53-6.7, PE conjugated), CD62 ligand (CD62L;
MEL-14, APC conjugated), and E7 H-2Db tetramer was performed using
a FACSCalibur.RTM. flow cytometer with CellQuest.RTM. software
(Becton Dickinson, Mountain View, Calif.). Splenocytes harvested 5
days after the boost were stained at room temperature (rt) with
H-2Db tetramers loaded with the E7 peptide (RAHYNIVTF) or a control
(HIV-Gag) peptide. Tetramers were used at a 1/200 dilution and were
provided by Dr. Larry R. Pease (Mayo Clinic, Rochester, Minn.) and
by the NIAID Tetramer Core Facility and the NIH AIDS Research and
Reference Reagent Program. Tetramer.sup.+, CD8.sup.+, CD62L.sup.low
cells were analyzed.
B16F0-Ova Experiment
[0261] 24 C57BL/6 mice were inoculated with 5.times.10.sup.5
B16F0-Ova cells. On days 3, 10 and 17, groups of 8 mice were
immunized with 0.1 LD.sub.50 Lm-OVA (10.sup.6 cfu), Lm-LLO-OVA
(10.sup.8 cfu) and eight animals were left untreated.
Statistics
[0262] For comparisons of tumor diameters, mean and SD of tumor
size for each group were determined, and statistical significance
was determined by Student's t test. p<0.05 was considered
significant.
Results
[0263] Lm-E7 and Lm-LLO-E7 were compared for their abilities to
impact on TC-1 growth. Subcutaneous tumors were established on the
left flank of C57BL/6 mice. Seven days later tumors had reached a
palpable size (4-5 mm) Mice were vaccinated on days 7 and 14 with
0.1 LD.sub.50 Lm-E7, Lm-LLO-E7, or, as controls, Lm-Gag and
Lm-LLO-NP. Lm-LLO-E7 induced complete regression of 75% of
established TC-1 tumors, while tumor growth was controlled in the
other 2 mice in the group (FIG. 3). By contrast, immunization with
Lm-E7 and Lm-Gag did not induce tumor regression. This experiment
was repeated multiple times, always with very similar results. In
addition, similar results were achieved for Lm-LLO-E7 under
different immunization protocols. In another experiment, a single
immunization was able to cure mice of established 5 mm TC-1
tumors.
[0264] In other experiments, similar results were obtained with 2
other E7-expressing tumor cell lines: C3 and EL-4/E7. To confirm
the efficacy of vaccination with Lm-LLO-E7, animals that had
eliminated their tumors were re-challenged with TC-1 or EL-4/E7
tumor cells on day 60 or day 40, respectively Animals immunized
with Lm-LLO-E7 remained tumor free until termination of the
experiment (day 124 in the case of TC-1 and day 54 for
EL-4/E7).
[0265] Thus, expression of an antigen as a fusion protein with ALLO
enhances the immunogenicity of the antigen.
Example 2
Lm-LLO-E7 Treatment Elicits TC-1 Specific Splenocyte
Proliferation
[0266] To measure induction of T cells by Lm-E7 with Lm-LLO-E7,
TC-1-specific proliferative responses, a measure of
antigen-specific immunocompetence, were measured in immunized mice.
Splenocytes from Lm-LLO-E7-immunized mice proliferated when exposed
to irradiated TC-1 cells as a source of E7, at splenocyte: TC-1
ratios of 20:1, 40:1, 80:1, and 160:1 (FIG. 4). Conversely,
splenocytes from Lm-E7 and rLm control-immunized mice exhibited
only background levels of proliferation.
Example 3
Fusion of E7 to LLO Enhances E7-Specific Immunity and Generates
Tumor-Infiltrating E7-Specific CD8.sup.+ Cells
Materials and Experimental Methods
[0267] 500 mcl (microliter) of MATRIGEL.RTM., comprising 100 mcl of
2.times.10.sup.5 TC-1 tumor cells in phosphate buffered saline
(PBS) plus 400 mcl of MATRIGEL.RTM. (BD Biosciences, Franklin
Lakes, N.J.) were implanted subcutaneously on the left flank of 12
C57BL/6 mice (n=3). Mice were immunized intraperitoneally on day 7,
14 and 21, and spleens and tumors were harvested on day 28. Tumor
MATRIGELs were removed from the mice and incubated at 4.degree. C.
overnight in tubes containing 2 milliliters (ml) of RP 10 medium on
ice. Tumors were minced with forceps, cut into 2 mm blocks, and
incubated at 37.degree. C. for 1 hour with 3 ml of enzyme mixture
(0.2 mg/ml collagenase-P, 1 mg/ml DNAse-1 in PBS). The tissue
suspension was filtered through nylon mesh and washed with 5% fetal
bovine serum+0.05% of NaN.sub.3 in PBS for tetramer and IFN-gamma
staining
[0268] Splenocytes and tumor cells were incubated with 1 micromole
(mcm) E7 peptide for 5 hours in the presence of brefeldin A at
10.sup.7 cells/ml. Cells were washed twice and incubated in 50 mcl
of anti-mouse Fc receptor supernatant (2.4 G2) for 1 hour or
overnight at 4.degree. C. Cells were stained for surface molecules
CD8 and CD62L, permeabilized, fixed using the permeabilization kit
Golgi-Stop.RTM. or Golgi-Plug.RTM. (Pharmingen, San Diego, Calif.),
and stained for IFN-gamma. 500,000 events were acquired using
two-laser flow cytometer FACSCalibur and analyzed using Cellquest
Software (Becton Dickinson, Franklin Lakes, N.J.). Percentages of
IFN-gamma secreting cells within the activated (CD62L.sup.low)
CD8.sup.+ T cells were calculated.
[0269] For tetramer staining, H-2D.sup.b tetramer was loaded with
phycoerythrin (PE)-conjugated E7 peptide (RAHYNIVTF, SEQ ID NO:
14), stained at rt for 1 hour, and stained with
anti-allophycocyanin (APC) conjugated MEL-14 (CD62L) and
FITC-conjugated CD8.beta. at 4.degree. C. for 30 min Cells were
analyzed comparing tetramer.sup.+CD8.sup.+ CD62L.sup.1' cells in
the spleen and in the tumor.
Results
[0270] In another experiment, tumor-bearing mice were administered
Lm-LLO-E7, or Lm-E7epi, and levels of E7-specific lymphocytes
within the tumor were measured. Mice were treated on days 7 and 14
with 0.1 LD.sub.50 of the 4 vaccines. Tumors were harvested on day
21 and stained with antibodies to CD62L, CD8, and with the E7/Db
tetramer. An increased percentage of tetramer-positive lymphocytes
within the tumor were seen in mice vaccinated with Lm-LLO-E7 and
Lm-PEST-E7 (FIG. 5A). This result was reproducible over three
experiments (FIG. 8B).
[0271] Thus, Lm-LLO-E7, are each efficacious at induction of
tumor-infiltrating CD8.sup.+ T cells and tumor regression.
Example 4
E6/E7 Transgenic Mouse Phenotype: A Model for Spontaneous Tumor
Growth and Tolerance to a Tumor Antigen
Materials and Experimental Methods
[0272] Several C57BL/6 mouse zygotes were injected with plasmids
containing the HPV-16 E6/E7 gene under the control of the
thyroglobulin promoter (provided by M Parmentier, Brussels). Tail
clippings of several litters were screened via PCR for the E6/E7
gene. The E7 gene and the thyroglobulin promoter were integrated
into the majority of the progeny. Positive mosaic E7 transgenic
mice were then selected for F0.times.wild type breeding. Subsequent
F1 generations were screened, via PCR, for the presence of the E7
gene. E7 positive pups generated from F0.times.wt breeding pairs
were selected for F1.times.F1 breeding. The zygosity of F1 breeding
pair derived generations was determined by Taqman real-time PCR and
the .DELTA..DELTA.Ct method (Charles River, 2001). Homozygous E7
transgenic mice were selected for F2.times.F2 breeding. The
subsequent F3 generation was screened via Taqman real-time PCR and
backcrossing to confirm fidelity of homozygosity. The levels of
gene copy number and transgene expression of the E7 gene was
assessed for every homozygous line using Taqman real-time PCR.
After 6 back-crossings, these lines were used as the parents of the
colony. Transgene expression was further confirmed by appearance of
thyroid hyperplasia, as described in the Results section.
Results
[0273] E6/E7 transgenic mice were generated, and their phenotype
assessed. The mice began to develop thyroid hyperplasia at 8 weeks
and palpable goiters at 6 months. By 6 to 8 months, most mice
exhibited thyroid cancer. Transgenic mice sacrificed at 3 months of
age exhibited de-differentiation of the normal thyroid
architecture, indicative of an early stage of cancer. The enlarged,
de-differentiated cells were filled with colloid, where thyroid
hormones accumulate (FIG. 6).
Example 5
E7 is Expressed in Medullary Thymic Epithelial Cells of E6/E7
Transgenic Mice
[0274] To determine whether or not E7 was expressed in the thymus,
liver, spleen, thymus and thyroid were examined for the expression
of the transgene in 6 to 8 week old mice. Abundant E7 message was
found in the thyroid but not in other tissues (FIG. 7A). The
absence of E7 message in whole thymus preparations was not
indicative of lack of expression in the thymus, since the level of
message of a peripherally expressed, organ-specific antigen,
including thyroglobulin, has been shown to be too low to detect in
whole thymocyte preparations (Derbinski, J., A. Schulte, B.
Kyewski, and L. Klein. 2001. Promiscuous gene expression in
medullary thymic epithelial cells mirrors the peripheral self. Nat
Immunol 2:1032).
[0275] Tolerance to peripheral antigens in the thymus, including
thyroglobulin, is mediated by the transient expression of these
genes by the autoimmune regulator (AIRE) in thymic medullary
epithelial cells (mTECs), with peak expression occurring prior to
birth. AIRE is a transcription factor that maintains tolerance to
self. To determine whether E7 expression in the transgenic mice
followed the same pattern, mTECs from E6/E7 thymi of young mice
(3-5 weeks) were examined for E7 expression.
[0276] The mTECs expressed E7 message, and also expressed Cathepsin
S, which is known to be expressed in mTECs (FIG. 7B). Thus, E7 is
expressed in the thymus of the transgenic mice, showing that these
mice exhibit tolerance to the E7 antigen.
Example 6
Peptide-Based Vaccines do not Protect Against Tumor Challenge in
E6/E7 Transgenic Mice
[0277] As a measure of the impact of the self-expression of E7 on
vaccine efficacy, E6/E7 transgenic mice were tested in a tumor
protection experiment using an E7 peptide (RAHYNIVTF)-based
vaccine, along with the immunostimulatory CpG sequence 1826 (Krieg
A M, Yi A K, Matson S, Waldschmidt T J, Bishop G A, Teasdale R,
Koretzky G A, Klinman D M. Nature 374:546). While the peptide-based
vaccine protected all the wild type mice from tumor challenge, it
had no impact on tumor challenge in the transgenic mouse (FIG. 8).
Thus, the E6/E7 mice exhibit reduced ability to reject tumor
challenge, providing further evidence that they are tolerant to
E7.
Example 7
LLO Fusions Overcome Immune Tolerance of E6/E7 Transgenic Mice to
E7-Expressing Tumors
[0278] To test the ability of vaccines of the present invention to
overcome the immune tolerance of E6/E7 transgenic mice to
E7-expressing tumors, 10.sup.5 TC-1 cells were implanted
subcutaneously (s.c.) and allowed to form solid tumors in 6-8 week
old wild-type and transgenic mice 7 and 14 days later, mice were
left unimmunized or were immunized i.p. with LM-NP (control),
1.times.10.sup.8 cfu LM-LLO-E7 (FIG. 9A) or 2.5.times.10.sup.8 cfu
LM-ActA-E7 (FIG. 9B). The naive mice had a large tumor burden, as
anticipated, and were sacrificed by day 28 or 35 due to tumors of
over 2 cm. By contrast, by day 35, administration of either
LM-LLO-E7 resulted in complete tumor regression in 7/8 or 6/8,
respectively, of the wild-type mice and 3/8 of the transgenic mice.
In the transgenic mice that did not exhibit complete tumor
regression, a marked slowing of tumor growth was observed in the
LM-LLO-E7-vaccinated mice.
[0279] The effectiveness of vaccines of the present invention in
inducing complete tumor regression and/or slowing of tumor growth
in transgenic mice was in marked contrast to the inefficacy of the
peptide-based vaccine. Thus, vaccines of the present invention were
able to overcome immune tolerance of E6/E7 transgenic mice to
E7-expressing tumors.
Example 8
LLO Fusions Reduce Autochthonous (Spontaneous) Tumors in E6/E7
Transgenic Mice
[0280] To determine the impact of the Lm-LLO-E7 vaccines on
autochthonous tumors in the E6/E7 transgenic mouse, 6 to 8 week old
mice were immunized with 1.times.10.sup.8 Lm-LLO-E7 once per month
for 8 months. Mice were sacrificed 20 days after the last
immunization and their thyroids removed and weighed. This
experiment was performed twice (Table 1).
TABLE-US-00009 TABLE 1 Thyroid weight (mg) in unvaccinated and
vaccinated transgenic mice at 8 months of age (mg)*. Untreated
.+-.S.D. Lm-LLO-NP .+-.S.D. Lm-LLO-E7 .+-.S.D. Expt. 1 123 385 130
225 54 408 Expt. 2 94 503 86 239 68 588 *Statistical analyses
performed using Student's t test showed that the difference in
thyroid weight between Lm-LLO-NP treated mice and untreated mice
was not significant but that the difference between Lm-LLO-E7
treated mice was highly significant (p < 0.001)
[0281] The difference in thyroid weight between Lm-LLO-E7 treated
mice and untreated mice was significant (p<0.001 and p<0.05,
respectively) for both experiments, while the difference between
Lm-LLO-NP treated mice (irrelevant antigen control) and untreated
mice was not significant (Student's t test), showing that Lm-LLO-E7
controlled spontaneous tumor growth. Thus, vaccines of the present
invention prevent formation of new E7-expressing tumors.
[0282] To summarize the findings in the above Examples, LLO-antigen
fusions (a) induce tumor-specific immune response that include
tumor-infiltrating antigen-specific T cells; and are capable of
inducing tumor regression and controlling tumor growth of both
normal and particularly aggressive tumors; (b) overcome tolerance
to self antigens; and (c) prevent spontaneous tumor growth. These
findings are generalizable to a large number of antigens, PEST-like
sequences, and tumor types, as evidenced by their successful
implementation with a variety of different antigens, PEST-like
sequences, and tumor types.
Example 9
Lm-LLO-E7 Vaccines are Safe and Improve Clinical Indicators in
Cervical Cancer Patients
Materials and Experimental Methods
[0283] Inclusion Criteria.
[0284] All patients in the trial were diagnosed with "advanced,
progressive or recurrent cervical cancer," and an assessment at the
time of entry indicated that all were staged as having IVB disease.
All patients manifested a positive immune response to an anergy
panel containing 3 memory antigens selected from candidin, mumps,
tetanus, or Tuberculin Purified Protein Derivative (PPD); were not
pregnant or HIV positive, had taken no investigational drugs within
4 weeks, and were not receiving steroids.
[0285] Protocol:
[0286] Patients were administered 2 vaccinations at a 3-week
interval as a 30-minute intravenous (IV) infusion in 250 ml of
normal saline to inpatients. After 5 days, patients received a
single course of IV ampicillin and were released with an additional
10 days of oral ampicillin Karnofsky Performance Index, which is a
measurement of overall vitality and quality of life such as
appetite, ability to complete daily tasks, restful sleep, etc, was
used to determine overall well-being. In addition, the following
indicators of safety and general well being were determined:
alkaline phosphatase; bilirubin, both direct and total; gamma
glutamyl transpeptidase (ggt); cholesterol; systole, diastole, and
heart rate; Eastern Collaborative Oncology Group's (ECOG)'s
criteria for assessing disease progression--a Karnofsky
like--quality of life indicator; hematocrit; hemoglobin; platelet
levels; lymphocytes levels; AST (aspartate aminotransferase); ALT
(alanine aminotransferase); and LDH (lactate dehydrogenase).
Patients were followed at 3 weeks and 3 months subsequent to the
second dosing, at which time Response Evaluation Criteria in Solid
Tumors (RECIST) scores of the patients were determined, scans were
performed to determine tumor size, and blood samples were collected
for immunological analysis at the end of the trial, which includes
the evaluation of IFN-.gamma., IL-4, CD4.sup.+ and CD8.sup.+ cell
populations.
[0287] Listeria Strains:
[0288] The creation of LM-LLO-E7 is described in Example 1.
Bacteria were passaged twice through mice prior to preparation of
the working cell bank, as described in Example 12. The cell bank
exhibited viability upon thawing of greater than 90%.
Results
[0289] Prior to the clinical trial, a preclinical experiment was
performed to determine the anti-tumor efficacy of intravenous
(i.v.) vs. i.p. administration of LM-LLO-E7. A tumor containing
1.times.10.sup.4 TC-1 cells was established sub-cutaneously. On
days 7 and 14, mice were immunized with either 10.sup.8 LM-LLO-E7
i.p. or LM-LLO-E7 i.v. at doses of 10.sup.8, 10.sup.7, 10.sup.6, or
10.sup.5. At day 35, 5/8 of the mice that received 10.sup.8
LM-LLO-E7 by either route or 10.sup.7 LM-LLO-E7 i.v, and 4/8 of the
mice that received 10.sup.6 LM-LLO-E7 i.v, were cured. By contrast,
doses of less than 10.sup.7 or in some cases even 10.sup.8
LM-LLO-E7 administered i.p. were ineffective at controlling tumor
growth. Thus, i.v. administration of LM-LLO-E7 is more effective
than i.p. administration.
Clinical Trial
[0290] A phase I/II clinical trial was conducted to assess safety
and efficacy of LM-LLO-E7 vaccines in patients with advanced,
progressive, or recurrent cervical cancer. 5 patients each were
assigned to cohorts 1-2, which received 1.times.10.sup.9 or
3.3.times.10.sup.9 CFU, respectfully. An additional 5 patients each
will be assigned to cohorts 3-4, which will receive
1.times.10.sup.10 or 3.31.times.10.sup.10 CFU, respectfully.
Safety Data
First Cohort
[0291] All patients in the first cohort reported onset of
mild-to-moderate fever and chills within 1-2 hours after onset of
the infusion. Some patients exhibited vomiting, with or without
nausea. With 1 exception (described below), a single dose of a
non-steroidal agent such as paracetamol was sufficient to resolve
these symptoms. Modest, transient cardiovascular effects were
observed, consistent with, and sharing the time course of, the
fever. No other adverse effects were reported.
[0292] At this late stage of cervical cancer, 1 year survival is
typically 10-15% of patients and no tumor therapy has ever been
effective. Indeed, Patient 2 was a young patient with very
aggressive disease who passed away shortly after completing the
trial.
[0293] Quantitative blood cultures were assessed on days 2, 3, and
5 post-administration. Of the 5 evaluable patients in this cohort,
4 exhibited no serum Listeria at any time and 1 had a very small
amount (35 cfu) of circulating Listeria on day 2, with no
detectable Listeria on day 3 or 5.
[0294] Patient 5 responded to initial vaccination with mild fever
over the 48 hours subsequent to administration, and was treated
with anti-inflammatory agents. On 1 occasion, the fever rose to
moderate severity (at no time above 38.4.degree. C.), after which
she was given a course of ampicillin, which resolved the fever.
During the antibiotic administration she experienced mild
urticaria, which ended after antibiotic administration. Blood
cultures were all sterile, cardiovascular data were within the
range observed for other patients, and serum chemistry values were
normal, showing that this patient had no listerial disease.
Further, the anergy panel indicated a robust response to 1/3 memory
antigens, indicating the presence of functional immunity (similar
to the other patients). Patient 5 subsequently evidenced a response
similar to all other patients upon receiving the boost.
Second Cohort and Overall Safety Observations
[0295] In both cohorts, minor and transient changes in liver
function tests were observed following infusion. These changes were
determined by the attending physician monitoring the trial to have
no clinical significance, and were expected for a short-lived
infection of bacteria that are rapidly removed from the systemic
circulation to the liver and spleen. In general, all the safety
indicators described in the Methods section above displayed little
or no net change, indicative of an excellent safety profile. The
side effect profile in this cohort was virtually identical to that
seen in the in the initial cohort and appeared to be a dose
independent series of symptoms related to the consequences of
cytokines and similar agents that occur consequent to the induction
of an iatrogenic infection. No serum Listeria was observed at any
time and no dose limiting toxicity was observed in either
cohort.
Efficacy--First Cohort
[0296] The following indications of efficacy were observed in the 3
patients in the first cohort that finished the trial: (Table
2).
[0297] Patient 1 entered the trial with 2 tumors of 20 mm each,
which shrunk to 18 and 14 mm over the course of the trial,
indicating therapeutic efficacy of the vaccine. In addition,
patient 1 entered the trial with a Karnofsky Performance Index of
70, which rose to 90 after dosing. In the Safety Review Panel
meeting, Sini{hacek over (s)}a Radulovic, the chairman of the
Department of Oncology, Institute for Oncology and Radiology,
Belgrade, Serbia presented the results to a representative of the
entity conducting the trials; Michael Kurman, an independent
oncologist who works as a consultant for the entity; Kevin Ault, an
academic gynecologic oncologist at Emory University who conducted
the phase III Gardasil trials for Merck and the Cervarix trials for
Glaxo SmithKline; and Tate Thigpen, a founder of the Gynecologic
Oncology Group at NCI and professor of gynecologic oncology at the
University of Mississippi. In the opinion of Dr. Radulovic, patient
1 exhibited a clinical benefit from treatment with the vaccine.
[0298] Before passing away, Patient 2 exhibited a mixed response,
with 1/2 tumors shrinking.
[0299] Patient 3 enrolled with paraneoplastic disease, (an
epiphenomenon of cancer wherein the overall debilitated state of
the patient has other sequelae that are secondary to the cancer),
including an elevation of platelet count to 936.times.10.sup.9/ml.
The count decreased to 465.times.10.sup.9/ml, approximately a
normal level, following the first dose.
[0300] Patient 4 entered the trial with 2 tumors of 20 mm each,
which shrunk to 18 and 14 mm over the course of the trial,
indicating therapeutic efficacy of the vaccine. Patient 4 exhibited
a weight gain of 1.6 Kg and an increased hemoglobin count of
approximately 10% between the first and second doses.
Efficacy--Second Cohort and General Observations
[0301] In the lowest dose cohort, 2 patients demonstrated the
shrinkage of tumors. The timing of this effect was consistent with
that observed in immunological responses, in that it followed
chronologically development of the immune response. One of the 2
patients in the second cohort evaluated so far for tumor burden
exhibited a dramatic tumor load reduction at a post-vaccination
time point. At the start of the trial, this patient had 3 tumors of
13, 13, and 14 mm After the 2 doses of the vaccine, 2 of the tumor
had shrunk to 9.4 and 12 mm, and the third was no longer
detectable.
[0302] Tumors loads for the 2 cohorts are depicted in FIG. 10B. In
summary, even relatively low doses of LM-LLO-E7, administered in a
therapeutic regimen containing a priming injection and a single
boost, achieved 3 objective responses out of 6 patients for whom
data has been collected.
Discussion
[0303] At this late stage of cervical cancer, 1 year survival is
typically 10-15% of patients and no tumor therapy has ever been
effective. No treatment has shown to be effective in reversing
stage IVB cervical cancer. Despite the difficulty of treating
cervical cancer at this stage, an anti-tumor effect was observed in
2/6 patients. In addition, other indications of efficacy were
observed in patients that finished the trial, as described
hereinabove.
[0304] Thus, LM-LLO-E7 is safe in human subjects and improves
clinical indicators of cervical cancer patients, even when
administered at relatively low doses. Additional positive results
are likely to be observed when the dose and number of booster
vaccinations is increased; and/or when antibiotics are administered
in smaller doses or at a later time point after infusion.
Pre-clinical studies have shown that a dose increase of a single
order of magnitude can cause dramatic changes in response rate
(e.g. a change from 0% response rate to 50-100% complete remission
rate. Additional booster doses are also very likely to further
enhance the immune responses obtained. Moreover, the positive
effects of the therapeutic immune response observed are likely to
continue with the passage of additional time, as the immune system
continues to attack the cancer.
Example 10
Safety and Efficacy of Lm-LLO-E7 for the Treatment of Cervical
Intraepithelial Neoplasia
[0305] Advaxis has treated 45 patients with grade 2 or 3 Cervical
Intraepithelial Neoplasia (cervical dysplasia) thus far in a trial
designed to treat 120 patents. Three treatment groups of 40
patients each are comprised of 10 patients who get placebo on a
randomized basis and 30 patients who get active drug at 5.10.sup.7,
3.3.times.10.sup.8 or 1.times.10.sup.9 cfu. A safety run in of 3
patients is conducted for each dosage group and these patients
receive the active drug. The remaining 37 patients are randomized
to either placebo or active drug at a ratio of 3 active patients
for each placebo patient. The trial involves the administration of
Advaxis agent ADXS 11-001 directed against HPV 16-E7 3 times at 28
day intervals followed by a surgical LEEP procedure 6 months after
the initial dose. Pretreatment biopsy samples are compared with
post treatment LEEP surgery specimens for an assessment of
histologic response.
[0306] The objective of this study was to see whether a vaccine
regimen can replace surgery. Aside from the pain, bleeding, and
other aspects of surgery, the removal of a portion of the cervix
often leads to an inability to come to a full term pregnancy
("incompetent cervix"). A pharmaceutical treatment would thus be
preferential to surgery. Especially one that induces immunologic
memory against the etiologic agent that causes cervix cancer, HPV,
in a manner that protects against recurrence.
[0307] At the present time the random code has not been broken,
however of the 18 treated patients 3-4 patients have receive
placebo and 14-15 patients have received active drug. The average
spontaneous remission rate in this population is approximately 25%,
and 4-5 patients spontaneously remit assuming the experimental
agent was ineffective, but in the 18 patients treated to date,
irrespective of treatment, 14 have remitted. Thus, a therapeutic
effect of the agent on the precancerous condition of CIN is being
observed.
Example 11
Safety and Efficacy of Lm-LLO-E7 for the Treatment of Cervical
Intraepithelial Neoplasia Stages II and III
Materials and Experimental Methods
Inclusion Criteria
[0308] Age 18 or older and capable of providing informed consent
according to federal, state and institutional guidelines.
[0309] Patients must have either Stage II or Stage III Cervical
Intraepithelial Neoplasia for which surgical intervention is
indicated, and for whom the disease is sufficiently indolent to
allow for a 6-month treatment and observation period to occur prior
to surgery.
[0310] HPV-16 E7 positive.
[0311] Cytological evidence consistent with a diagnosis of CIN
II/III.
[0312] All patients eligible for this study must be discussed with
the principal investigators and be approved by the principal
investigators before study entry.
[0313] Patients must respond positively to at least 1 of the test
agents used in the anergy panel described for the previous Example.
A positive reaction defined by the formation of a local tissue
response of at least 5 mm in sum of the orthogonal measures in
reaction to the administration of a delayed hypersensitivity
stimulus is required.
Exclusion Criteria
[0314] Patients who have had chemotherapy, radiotherapy, or
steroids within 4 weeks prior to the initial study dose or those
who have not recovered from adverse events due to agents
administered more than 4 weeks earlier.
[0315] Patients who have received any other investigational agents
for 28 days prior to dosing.
[0316] A history of Listeriosis.
[0317] A history of prior cancer or concomitant cancer.
[0318] Patients who are immunocompromised as demonstrated by a
negative result from an anergy panel screening.
[0319] Uncontrolled intercurrent illness including, but not limited
to ongoing or active infection, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance
with study requirements.
[0320] Hepatitis, cirrhosis, or any other impaired hepatic function
as determined by serum enzymes.
[0321] Pregnant women and women actively trying to become
pregnant.
[0322] Known HIV-positive patients.
[0323] Penicillin allergy.
Primary Safety Endpoints:
[0324] Incidence and severity of observations of the administration
site including swelling, irritation, immune reaction or other
abnormalities. [0325] Incidence and severity of adverse events
assessed throughout the duration of the study. [0326] Changes in
clinical hematology and serum chemistry test results at each time
point from dosing through week 16. [0327] Rate of clearance of
LM-LLO-E7 from the blood, as determined by quantitative blood
cultures during the inpatient portion of the study following the
initial administration.
Primary Efficacy Endpoints:
[0327] [0328] Regression of CIN to normal upon colposcopic
examination [0329] Regression of CIN toward normal sufficient to
cancel or delay surgery [0330] Improved cytology subsequent to
surgery
[0331] Primary Immunogenicity Endpoints: [0332] HLA typing of
patients for Class I and II, [0333] Quantification of a serum
cytokine profile subsequent to dosing that corresponds with
observed side effects, [0334] Quantification of macrophage
activation parameters that assess macrophage activation subsequent
to dosing, [0335] Identification of tumor-associated antigen
(TAA)-specific activated T cells and quantification of T cell
responses subsequent to dosing, [0336] Quantification of T cell
subsets migrating to TAA DTH.
Immunogenicity Criteria:
Serum Cytokines
[0337] IFN-.gamma., TNF-.alpha., IL-2 & IL-12 are assessed in
serum of patients, collected at the following times: [0338]
Screening, Day 1. [0339] Day 1, pre-dose, Day 1, 3 h post-dose, Day
1, 12 h post-dose, Day 2, 24 h post-dose, and Day 5. [0340] Day 22
pre-dose, Day 22, 3 h post-dose, Day 22, 12 h post-dose, Day 23, 24
h post-dose, and Day 26 [0341] Day 43 pre-dose, Day 43, 3 h
post-dose, Day 43, 12 h post-dose, Day 44, 24 h post-dose, and Day
47
T Cell Responses
[0342] The following cytokine release profiles are assessed HPV-16
E7 stimulated T cells of patients: IFN-.gamma., TNF-.alpha., IL-2
& IL-4
[0343] Assays are performed on cells sampled from patients at the
following times: Screening, Day 1 pre-dosing, day 22 pre-dosing,
day 43 pre-dosing, day 126, and day 180
Delayed Type Hypersensitivity testing
[0344] DTH testing is conducted on the following study days:
Screening, Day 5, Day 26, Day 47, Day 126 and Day 180.
Macrophage Activation
[0345] Samples for the assessment of macrophage activation are
collected on the following study days and times: [0346] Day 1
pre-dose, Day 1, 3 h post-dose, Day 1, 12 h post-dose, Day 2, 24 h
post-dose, and Day 5. [0347] Day 22 pre-dose, Day 22, 3 h
post-dose, Day 22, 12 h post-dose, Day 23, 24 h post-dose, and Day
26. [0348] Day 43 pre-dose, Day 43, 3 h post-dose, Day 43, 12 h
post-dose, Day 44, 24 h post-dose, and Day 47.
Vaccine Administration
[0349] LM-LLO-E7 is administered as a 30 min i v infusion with each
dose freshly thawed and diluted in 250 ml normal saline.
Safety Review
[0350] Adverse Events are graded based on the National Cancer
Institute (NCI) Common Toxicity Criteria. Dose limiting toxicity is
defined as any of the following:
[0351] Non-Hematologic Toxicity: [0352] 1. Presumptive bacterial
meningitis as determined by symptoms. [0353] 2. Persistent
listeremia at day 5 and 15 after a 10-day course of antibiotics.
[0354] 3. Clinical sepsis requiring ICU admission. [0355] 4. A drop
in blood pressure sufficient to warrant therapeutic intervention,
[0356] 5. Hepatitis as evidenced by grade 3-4 elevation in
transaminases for a minimum of 7 days. [0357] 6. Gastrointestinal
toxicity of grade 3-4 despite adequate medical intervention. [0358]
7. Any Grade 3 injection site reaction. [0359] 8. Any Grade 3 or
higher adverse event that cannot be attributed to cervical cancer
or other concurrent illnesses.
[0360] Hematologic Toxicity: [0361] 1. Absolute neutrophil count
(ANC) grade 4 for a minimum of 7 days or neutropenic fever defined
as Grade 4 neutropenia with temperature of >38.5.degree. C.
[0362] 2. Platelet count grade 4 or bleeding with Grade 3 platelet
count.
[0363] Dose escalation to the next cohort proceeds in each case,
provided that there are no Grade 3 or higher adverse events related
to the therapeutic vaccine.
Results
[0364] Women are enrolled that have stage II or stage III Cervical
Intraepithelial Neoplasia (CIN II/III) who have disease that is
sufficiently indolent to allow for a 6 month period of treatment
and evaluation to occur prior to surgery. Patients receive 3 doses
of LM-LLO-E7 at 3 week intervals as inpatients and return for
follow up visits to assess their response to the vaccine, collect
samples for analysis, and assess their disease. Samples for
immunologic analysis are collected throughout the trial and assayed
upon the completion of the study.
[0365] Safety is assessed through standard physical, hematologic
and serum chemistry measures, and by blood cultures to assess serum
Listeria Immunologic activity is assessed in the areas of serum
cytokine release, activated T cell responses to tumor antigen,
macrophage activation, and delayed hypersensitivity responses (DTH)
to tumor antigen.
[0366] Clinically, patients are grouped by primary endpoints.
Namely, whether patients exhibit sufficient remission of their
disease to make surgery unnecessary. Patients that do require
surgery, are grouped regarding whether they exhibit lesser disease
than the control group. LM-LLO-E7 reduces the fraction of women
that subsequently require surgery and/or the degree of disease
among those that require surgery.
Example 12
Passaging of Listeria Vaccine Vectors Through Mice Elicits
Increased Immune Responses to Heterologous and Endogenous
Antigens
Materials and Experimental Methods
Bacterial Strains
[0367] L. monocytogenes strain 10403S, serotype 1 (ATCC, Manassas,
Va.) was the wild type organism used in these studies and the
parental strain of the constructs described below. Strain 10403S
has an LD.sub.50 of approximately 5.times.10.sup.4 CFU when
injected intraperitoneally into BALB/c mice. "Lm-Gag" is a
recombinant LM strain containing a copy of the HIV-1 strain HXB
(subtype B laboratory strain with a syncytia-forming phenotype) gag
gene stably integrated into the listerial chromosome using a
modified shuttle vector pKSV7. Gag protein was expressed and
secreted by the strain, as determined by Western blot. All strains
were grown in brain-heart infusion (BHI) broth or agar plates
(Difco Labs, Detroit, Mich.).
Bacterial Culture
[0368] Bacteria from a single clone expressing the passenger
antigen and/or fusion protein were selected and cultured in BHI
broth overnight. Aliquots of this culture were frozen at .sup.-
70.degree. C. with no additives. From this stock, cultures were
grown to 0.1-0.2 O.D. at 600 nm, and aliquots were again frozen at
-70.degree. C. with no additives. To prepare cloned bacterial
pools, the above procedure was used, but after each passage a
number of bacterial clones were selected and checked for expression
of the target antigen, as described herein. Clones in which
expression of the foreign antigen was confirmed were used for the
next passage.
Passage of Bacteria in Mice
[0369] 6-8 week old female BALB/c (H-2d) mice were purchased from
Jackson Laboratories (Bar Harbor, Me.) and were maintained in a
pathogen-free microisolator environment. The titer of viable
bacteria in an aliquot of stock culture, stored frozen at
-70.degree. C., was determined by plating on BHI agar plates on
thawing and prior to use. In all, 5.times.10.sup.5 bacteria were
injected intravenously into BALB/c mice. After 3 days, spleens were
harvested, homogenized, and serial dilutions of the spleen
homogenate were incubated in BHI broth overnight and plated on BHI
agar plates. For further passage, aliquots were again grown to
0.1-0.2 O.D., frozen at -70.degree. C., and bacterial titer was
again determined by serial dilution. After the initial passage
(passage 0), this sequence was repeated for a total of 4 times.
Intracellular Cytokine Stain for IFN-Gamma
[0370] Lymphocytes were cultured for 5 hours in complete RPMI-10
medium supplemented with 50 U/ml human recombinant IL-2 and 1
microliter/ml Brefeldin A (Golgistop.TM.; PharMingen, San Diego,
Calif.) in the presence or absence of either the cytotoxic T-cell
(CTL) epitope for HIV-GAG (AMQMLKETI; SEQ ID No: 24), Listeria LLO
(GYKDGNEYI; SEQ ID No: 25) or the HPV virus gene E7 (RAHYNIVTF (SEQ
ID No: 14), at a concentration of 1 micromole. Cells were first
surface-stained, then washed and subjected to intracellular
cytokine stain using the Cytofix/Cytoperm kit in accordance with
the manufacturer's recommendations (PharMingen, San Diego, Calif.).
For intracellular IFN-gamma stain, FITC-conjugated rat anti-mouse
IFN-gamma monoclonal antibody (clone XMG 1.2) and its isotype
control Ab (rat IgG1; both from PharMingen) was used. In all,
10.sup.6 cells were stained in PBS containing 1% Bovine Serum
Albumin and 0.02% sodium azide (FACS Buffer) for 30 minutes at
4.degree. C. followed by 3 washes in FACS buffer. Sample data were
acquired on either a FACScan.TM. flowcytometer or FACSCalibur.TM.
instrument (Becton Dickinson, San Jose, Calif.). Three-color flow
cytometry for CD8 (PERCP conjugated, rat anti-mouse, clone 53-6.7
Pharmingen, San Diego, Calif.), CD62L (APC conjugated, rat
anti-mouse, clone MEL-14), and intracellular IFN-gamma was
performed using a FACSCalibur.TM. flow cytometer, and data were
further analyzed with CELLQuest software (Becton Dickinson,
Mountain View, Calif.). Cells were gated on CD8 high and
CD62L.sup.1' before they were analyzed for CD8.sup.+ and
intracellular IFN-gamma staining.
Results
Passaging in Mice Increases the Virulence of Recombinant Listeria
Monocytogenes
[0371] Three different constructs were used to determine the impact
of passaging on recombinant Listeria vaccine vectors. Two of these
constructs carry a genomic insertion of the passenger antigen: the
first comprises the HIV gag gene (Lm-Gag), and the second comprises
the HPV E7 gene (Lm-E7). The third (Lm-LLO-E7) comprises a plasmid
with the fusion gene for the passenger antigen (HPV E7) fused with
a truncated version of LLO and a gene encoding prfA, the positive
regulatory factor that controls Listeria virulence factors. This
plasmid was used to complement a prfA negative mutant so that in a
live host, selection pressures would favor conservation of the
plasmid, because without it the bacterium is avirulent. All 3
constructs had been propagated extensively in vitro for many
bacterial generations.
[0372] Passaging the bacteria resulted in an increase in bacterial
virulence, as measured by numbers of surviving bacteria in the
spleen, with each of the first 2 passages. For Lm-Gag and
Lm-LLO-E7, virulence increased with each passage up to passage 2
(FIG. 11A). The plasmid-containing construct, Lm-LLO-E7,
demonstrated the most dramatic increase in virulence. Prior to
passage, the initial immunizing dose of Lm-LLO-E7 had to be
increased to 10.sup.7 bacteria and the spleen had to be harvested
on day 2 in order to recover bacteria (whereas an initial dose of
10.sup.5 bacteria for Lm-Gag was harvested on day 3). After the
initial passage, the standard dosage of Lm-LLO-E7 was sufficient to
allow harvesting on day 3. For Lm-E7, virulence increased by 1.5
orders of magnitude over unpassaged bacteria (FIG. 11B).
[0373] Thus, passage through mice increases the virulence of
Listeria vaccine strains.
Passaging Increases the Ability of L. monocytogenes to Induce
CD8.sup.+ T Cells
[0374] Next, the effect of passaging on induction of
antigen-specific CD8.sup.+ T cells was determined by intracellular
cytokine staining with immunodominant peptides specific for
MHC-class I using HIV-Gag peptide AMQMLKETI (SEQ ID No: 24) and LLO
91-99 (GYKDGNEYI; SEQ ID No: 25). Injection of 10.sup.3 CFU
passaged bacteria (Lm-Gag) into mice elicited significant numbers
of HIV-Gag-specific CD8.sup.+ T cells, while the same dose of
non-passaged Lm-Gag induced no detectable Gag-specific CD8.sup.+ T
cells. Even increasing the dose of unpassaged bacteria 100-fold did
not compensate for their relative avirulence; in fact, no
detectable Gag-specific CD8.sup.+ T cells were elicited even at the
higher dose. The same dose increase with passaged bacteria
increased Gag-specific T cell induction by 50% (FIG. 12). The same
pattern of induction of antigen-specific CD8.sup.+ T cells was
observed with LLO-specific CD8.sup.+ T cells, showing that these
results were not caused by the properties of the passenger antigen,
since they were observed with LLO, an endogenous Listeria
antigen.
[0375] Thus, passage through mice increases the immunogenicity of
Listeria vaccine strains.
Example 13
A PrfA-Containing Plasmid is Stable in an Lm Strain with a PrfA
Deletion in the Absence of Antibiotics
Materials and Experimental Methods
Bacteria
[0376] L. monocytogenes strain XFL7 contains a 300 base pair
deletion in the prfA gene XFL7 carries pGG55 which partially
restores virulence and confers CAP resistance, and is described in
United States Patent Application Publication No. 200500118184.
Development of Protocol for Plasmid Extraction from Listeria
[0377] 1 mL of Listeria monocytogenes Lm-LLO-E7 research working
cell bank vial was inoculated into 27 mL BH1 medium containing 34
.mu.g/mL CAP and grown for 24 hours at 37.degree. C. and 200
rpm.
[0378] Seven 2.5 mL samples of the culture were pelleted (15000 rpm
for 5 minutes), and pellets were incubated at 37.degree. C. with 50
.mu.l lysozyme solution for varying amounts of time, from 0-60
minutes.
[0379] Lysozyme solution: [0380] 29 .mu.l 1 M dibasic Potassium
Phosphate [0381] 21 .mu.l 1 M monobasic Potassium Phosphate [0382]
500 .mu.l 40% Sucrose (filter sterilized through 0.45/.mu.m filter)
[0383] 450 .mu.l water [0384] 60 .mu.l lysozyme (50 mg/mL)
[0385] After incubation with the lysozyme, the suspensions were
centrifuged as before and the supernatants discarded. Each pellet
was then subjected to plasmid extraction by a modified version of
the QIAprep Spin Miniprep Kit.RTM. (Qiagen, Germantown, Md.)
protocol. The changes to the protocol were as follows: [0386] 1.
The volumes of buffers P1, P2 and N3 were all increased threefold
to allow complete lysis of the increased biomass. [0387] 2. 2 mg/mL
of lysozyme was added to the resuspended cells before the addition
of P2. The lysis solution was then incubated at 37.degree. C. for
15 minutes before neutralization. [0388] 3. The plasmid DNA was
resuspended in 30 .mu.L rather than 50 .mu.L to increase the
concentration.
[0389] In other experiments, the cells were incubated for 15 min in
P1 buffer+Lysozyme, then incubated with P2 (lysis buffer) and P3
(neutraliztion buffer) at room temperature.
[0390] Equal volumes of the isolated plasmid DNA from each
subculture were run on an 0.8% agarose gel stained with ethidium
bromide and visualized for any signs of structural or segregation
instability.
[0391] The results showed that plasmid extraction from L.
monocytogenes Lm-LLO-E7 increases in efficiency with increasing
incubation time with lysozyme, up to an optimum level at
approximately 50 minutes incubation.
[0392] These results provide an effective method for plasmid
extraction from Listeria vaccine strains.
Replica Plating
[0393] Dilutions of the original culture were plated onto plates
containing LB or TB agar in the absence or presence of 34 .mu.g/mL
CAP. The differences between the counts on selective and
non-selective agar were used to determine whether there was any
gross segregational instability of the plasmid.
Results
[0394] The genetic stability (i.e. the extent to which the plasmid
is retained by or remains stably associated with the bacteria in
the absence of selection pressure; e.g. antibiotic selection
pressure) of the pGG55 plasmid in L. monocytogenes strain XFL7 in
the absence of antibiotic was assessed by serial sub-culture in
both Luria-Bertani media (LB: 5 g/L NaCl, 10 g/ml soy peptone, 5
g/L yeast extract) and Terrific Broth media (TB: 10 g/L glucose,
11.8 g/L soy peptone, 23.6 g/L yeast extract, 2.2 g/L
KH.sub.2PO.sub.4, 9.4 g/L K.sub.2HPO.sub.4), in duplicate cultures.
50 mL of fresh media in a 250 mL baffled shake flask was inoculated
with a fixed number of cells (1 ODmL), which was then subcultured
at 24 hour intervals. Cultures were incubated in an orbital shaker
at 37.degree. C. and 200 rpm. At each subculture the OD.sub.600 was
measured and used to calculate the cell doubling time (or
generation) elapsed, until 30 generations were reached in LB and 42
in TB. A known number of cells (15 ODmL) at each subculture stage
(approximately every 4 generations) were pelleted by
centrifugation, and the plasmid DNA was extracted using the Qiagen
QIAprep Spin Miniprep.RTM. protocol described above. After
purification, plasmid DNA was subjected to agarose gel
electrophoresis, followed by ethidium bromide staining. While the
amount of plasmid in the preps varied slightly between samples, the
overall trend was a constant amount of plasmid with respect to the
generational number of the bacteria (FIGS. 13A-B). Thus, pGG55
exhibited stability in strain XFL7, even in the absence of
antibiotic.
[0395] Plasmid stability was also monitored during the stability
study by replica plating on agar plates at each stage of the
subculture. Consistent with the results from the agarose gel
electrophoresis, there was no overall change in the number of
plasmid-containing cells throughout the study in either LB or TB
liquid culture (FIGS. 14 and 15, respectively).
[0396] These findings demonstrate that prfA-encoding plasmids
exhibit stability in the absence of antibiotic in Listeria strains
containing mutations in prfA.
Example 14
Optimization of Cryopreservation Conditions for Listeria Vaccine
Strains
Materials and Experimental Methods
[0397] An LB Research Working Cell Bank (RWCB) was produced by the
following protocol: 5 ODmL samples were taken from 200 mL cultures
grown in LB or TB with 34 .mu.g/mL CAP in 2 L shake flasks at
several different OD.sub.600. The 5 ODmL samples were cryopreserved
using 20% v/v glycerol and frozen at less than -70.degree. C. for
one day, then were thawed and used to inoculate 50 mL of the same
media used for the starter cultures. The initial growth kinetics of
these cultures was measured by monitoring the OD.sub.600 and
comparing the growth curves for any sign of lag phase.
[0398] An RWCB containing 50 vials of Lm-LLO-E7, cryopreserved in
mid-log phase, was produced. Cells from the original glycerol
stocks, CTL 2003#0810N, were streaked out onto an LB-agar plate
with 34 .mu.g/mL CAP. After a 24-hour incubation, single colonies
were selected and grown in 5 mL of LB-CAP for 24 hours at
37.degree. C., which was then used to inoculate 50 mL of LB-CAP. At
an OD.sub.600 of 0.7, cells were cryopreserved after adding
glycerol to 20% v/v. The culture was 1-mL aliquots were placed into
fifty sterile cryovials and stored below -70.degree. C.
Results
[0399] In order to determine the optimum culture density at which
to cryopreserve the L. monocytogenes strain XFL7 carrying the pGG55
plasmid (which will be referred to as Lm-LLO-E7), bacteria were
grown in 200 mL (milliliter) baffled shake flasks in either LB or
TB. At various 600 .ANG. optical densities (OD.sub.600), 5 ODmL
(i.e. the product of the OD.sub.600 reading and the volume of
culture in ml) aliquots were removed, glycerol was added to 20%
v/v, and the cells were frozen at -70.degree. C. After 24 h (hours)
storage at -70.degree. C., the 5 ODmL samples were thawed and used
to inoculate 50 mL of fresh media of the same type (LB or TB), and
initial growth kinetics of the cultures were monitored. All the
cultures immediately entered exponential growth without showing any
signs of a lag phase (FIG. 16). Thus, among the OD.sub.600
utilized, the highest OD.sub.600 (0.8 for LB and 1.1 for TB) were
determined to be optimum for short-term cryopreservation.
[0400] Next, an LB Research Working Cell Bank (RWCB) was produced
by adding 20% v/v glycerol to an 0.8 OD.sub.600 culture and storing
below -70.degree. C. (see Materials and Experimental Methods
section above). Viability of the RWCB was determined before
freezing by replica plating as described for Example 13. Vials of
the RWCB were thawed after defined intervals, and viability was
determined. As depicted in FIG. 17, the viability in the first LB
cell bank appeared to decrease from 1.times.10.sup.9 to
3.times.10.sup.8 CFU/mL following storage at -70.degree. C.
[0401] A second and a third LB RWCB were generated, this time at
OD.sub.600 of 0.72 and 0.74, respectively. These two RWCB exhibited
viabilities ranging between 8 and 12.times.10.sup.8 CFU/mL, with no
decrease in viability, throughout the course of the study. The
difference between these RWCB and first are likely due to
difference in the OD.sub.600 at the time of cryopreservation. Thus,
an optical density of 0.8 likely corresponds to the end of
exponential growth and the beginning of stationary phase of
Lm-LLO-E7 in. Consequently, an OD.sub.600 of 0.7 was used
subsequently. The second RWCB was assigned the number 2003#0933A
and was utilized to inoculate the cultures used in subsequent
experiments.
[0402] In addition, a TB RWCB was generated from cultures at an
OD.sub.600 of 1.1. The number of viable cells remained stable at
1.times.10.sup.9 CFU/mL (FIG. 18).
[0403] These findings demonstrate that methods of the present
invention (e.g. conditions of 20% glycerol and OD.sub.600 of 0.7)
have utility in generating cryopreserved Listeria vaccine strains
and stocks with stable long-term viability.
Example 15
Optimization of Media for Growth of Listeria Vaccine Strains in
Shake Flask Fermentations
Materials and Experimental Methods
Cultures
[0404] 50 mL volumes of each of the four different defined media
were inoculated with 250 .mu.L aliquots of the LB RWCB and
incubated in 250 mL shake flasks at 37.degree. C. overnight. 20
ODmL of the 50 mL culture were then used to inoculate 200 mL of the
same media in 2 L shake flasks. This type of cell propagation
procedure encourages viability and exponential growth of the
bacteria.
Results
[0405] The growth curves of the Listeria vaccine strain in LB and
TB were investigated in more detail in order to assess its growth
potential. The maximum OD.sub.600 reached in TB and LB were 4 and
0.8 units, which correspond to about 1.times.10.sup.10 and
9.times.10.sup.8 CFU/mL, respectively (FIG. 19).
[0406] Experiments were then performed to develop a defined
synthetic medium that could support a similar growth to that of TB.
A MOPS pH buffer was used instead of a phosphate buffer because its
superior buffering capacity would be appropriate for the demands of
shake flask growth. The formula outlined in Table 3A below was used
as the starting point. In addition to the pH buffer and standard
components ("basic components"), the medium contained supplements
expected to improve growth of the vaccine strain. These supplements
were divided into four groups: essential compounds, amino acids,
vitamins and trace elements.
TABLE-US-00010 TABLE 3A Original defined media composition. Amount
per Component Litre Basic connponents MOPS 20.93 g KH.sub.2PO.sub.4
0.656 g Na.sub.2HPO.sub.4--7H.sub.2O 1.639 g Glucose 10 g
MgSO.sub.4 0.41 g Supplements Essential components Ferric Citrate
0.1 g Methionine 0.1 g Cysteine 0.1 g Glutamine 0.6 g Riboflavin 5
mg Thioctic acid 5 .mu.g Amino acids Leucine 0.1 g Isoleucine 0.1 g
Valine 0.1 g Arginine 0.1 g Histidine 0.1 g Tryptophan 0.1 g
Phenylalanine 0.1 g Vitamins Adenine 0.25 mg Biotin 0.5 mg Thiamine
HCl 1 mg Pyridoxal HCl 1 mg Para-aminobenzoic acid 1 mg Calcium
pantothenate 1 mg Nicotinamide 1 mg Trace Elements Cobalt chloride
hexahydrate (CoCl.sub.2.cndot.6H.sub.2O) 0.02 g Copper (II)
chloride dihydrate (CuCl.sub.2.cndot.2H.sub.2O) 0.019 g Boric acid
(H.sub.3BO.sub.3) 0.016 g Manganese sulfate monohydrate
(MnSO.sub.4.cndot.H.sub.2O) 0.016 g Sodium molybdate dihydrate
(Na.sub.2MoO.sub.4.cndot.2H.sub.2O) 0.02 g Zinc chloride
heptahydrate (ZnCl.sub.2.cndot.7H.sub.2O) 0.02 g Ferric Sulfate
(Fe.sub.2(SO.sub.4).sub.3 .times. H.sub.2O) 0.01 g Calcium Chloride
dihydrate (CaCl.sub.2.cndot.2H.sub.20) 0.01 g
[0407] In order to determine whether supplementation with the three
latter groups (amino acids, vitamins, trace elements) improved the
growth of Lm-LL0-E7, bacteria were grown in 50 mL starter cultures,
then in 250 mL cultures, of the following media in shake flasks:
[0408] 1. Bulk medium (i.e. water plus the basic components in
Table 3A), essential components, amino acids, vitamins and trace
elements. [0409] 2. Bulk medium, essential components, amino acids
and vitamins. [0410] 3. Bulk medium, essential components and amino
acids. [0411] 4. Bulk medium and essential components.
[0412] Presence of both AA and vitamins was necessary to support
significant growth in the 50 mL cultures, and the presence of trace
elements enhanced the growth rate (FIG. 20). However, at the 200 mL
stage the presence of trace elements did not influence the growth
rate (FIG. 21). It is possible that the trace elements supported
the adaptation of Lm-LLO-E7 from the LB cell bank into the defined
medium at the 50 mL stage. Based on these results, all four of the
groups in Table 3A were included in the defined medium in
subsequent experiments.
[0413] The next experiment investigated the effect of increasing
the concentrations of the 4 groups of supplements of Table 3. The
concentrations of all the components of these four groups were
increased by a factor of 2 or 4 to produce "2.times." and
"4.times." defined media, respectively. In addition, 4.times.
defined media containing 1, 2 or 3 g/L of inorganic nitrogen in the
form of NH.sub.4SO.sub.4 were tested. The growth of these five
cultures was compared to the media of Table 3A ("control") in the
50 mL-200 mL protocol described above.
[0414] All media tested exhibited similar growth for the first four
hours. At this point, the growth in the control media began to
decelerate, stopping completely at 13 hours, while the 2.times. and
4.times. media continued to support exponential growth (FIG. 22).
The flasks containing the 2.times. and 4.times. media reached final
OD.sub.600 of 2.5 units and 3.5, respectively. Inclusion of
NH.sub.4SO.sub.4 slightly increased final biomass concentrations,
but considerably decreased the growth rate.
[0415] Thus, increasing the nutrient level, but not inclusion of
NH.sub.4SO.sub.4, significantly improved the growth of the vaccine
strain in defined media. Based on these results, NH.sub.4SO.sub.4
was not included in subsequent experiments.
[0416] Next, the effect in 50 mL and 200 mL cultures of the
following additional modifications to the media was examined: 1)
further increasing the concentration of the 4 groups of supplements
from Table 3A (to 6 and 8 times the original concentration); 2)
increasing the concentration of glutamine (a source of organic
nitrogen) to 8 times the original concentration; and 3) removing
iron from the media. As depicted in FIG. 23 (results from 200 mL
cultures), further increasing the concentration of either glutamine
or the 4 groups of supplements did not enhance the final biomass
concentration of Lm-LLO-E7. Removal of iron, by contrast, reduced
the maximum biomass concentration.
[0417] The effect of increasing the glucose concentration of the
4.times. media was examined Increasing glucose concentration from
10 to 15 g/L significantly improved growth rate and biomass.
[0418] The final OD.sub.600 of each of the 4.times. supplements was
4.5, which corresponded to 1.1.times.10.sup.10 CFU/mL,
approximately the same as the final biomass obtained with TB. Thus,
a defined media was developed that supported growth of a Listeria
vaccine strain to the same extent as TB.
[0419] In conclusion, media containing 4.times. the original
concentration of the four groups of supplements from Table 3A
(referred to henceforth as "4.times. media") supported optimal
growth of Lm-LLO-E7 in 50 mL and 200 mL shake flask cultures. Iron
was required for optimal growth. Increasing the glucose from 10 to
15 g/L increased the total biomass achieved. The resulting
optimized defined media recipe is depicted in Table 3B.
TABLE-US-00011 TABLE 3B Optimized defined media composition. AMOUNT
PER COMPONENT LITRE BASIC COMPONENTS KH.sub.2PO.sub.4 2.2 g
Na.sub.2HPO.sub.4--7H.sub.2O 10.4 g Glucose 15 g MgSO.sub.4 0.41 g
SUPPLEMENTS Essential components Ferric Citrate 0.4 g Methionine
0.4 g Cysteine 0.4 g Glutamine 2.4 g Riboflavin 20 mg Thioctic acid
20 .mu.g Amino acids Leucine 0.4 g Isoleucine 0.4 g Valine 0.4 g
Arginine 0.4 g Histidine 0.4 g Tryptophan 0.4 g Phenylalanine 0.4 g
Vitamins Adenine 0.25 g Biotin 2 mg Thiamine HCl 4 mg Pyridoxal HCl
4 mg Para-aminobenzoic acid 4 mg Calcium pantothenate 4 mg
Nicotinamide 4 mg Trace Elements Cobalt chloride hexahydrate
(CoCl.sub.2.cndot.6H.sub.2O) 0.02 g Copper (II) chloride dihydrate
(CuCl.sub.2.cndot.2H.sub.2O) 0.019 g Boric acid (H.sub.3BO.sub.3)
0.016 g Manganese sulfate monohydrate (MnSO.sub.4.cndot.H.sub.2O)
0.016 g Sodium molybdate dihydrate
(Na.sub.2MoO.sub.4.cndot.2H.sub.2O) 0.02 g Zinc chloride
heptahydrate (ZnCl.sub.2.cndot.7H.sub.2O) 0.02 g Ferric Sulfate
(Fe.sub.2(SO.sub.4).sub.3 .times. H.sub.2O) 0.01 g Calcium Chloride
dihydrate (CaCl.sub.2.cndot.2H.sub.20) 0.01 g Citric Acid 0.6 g
Example 16
Optimization of Media for Growth of Listeria Vaccine Strains in
Batch Fermentations
Materials and Experimental Methods
[0420] FT Applikon 5/7 L fermenter vessels containing 4500 mL of
either TB or defined medium with 34 .mu.g/mfL CAP were utilized in
this Example. 20 ODmL of Lm-LLO-E7 was used to inoculate a 200 mL
starter culture containing CAP, which was grown at 37.degree. C. in
an orbital shaker at 200 rpm for 10 hours until it reached mid-log
phase; 450 ODmL of this culture was used to inoculate the fermenter
vessels. The temperature, pH and dissolved oxygen concentration
were continuously monitored and controlled during the fermentation
at levels of 37.degree. C., 7.0, and 20% of saturation.
Results
[0421] Factors such as dissolved oxygen concentration or pH likely
limited the growth of Lm-LLO-E7 in the previous Example, as they
are not controlled in shake flasks. Consistent with this
possibility, the pH of the cultures in the shake flasks had
decreased to approximately 5.5 units. In a batch fermenter, by
contrast, pH and dissolved oxygen levels are continuously monitored
and controlled. Thus, separate experiments were performed in this
Example to optimize the media used for batch fermentations.
[0422] 200 mL cultures of Lm-LLO-E7 were grown overnight in either
TB or the defined medium from Table 3B until they reached mid-log
phase (OD.sub.600 of 1-2). 450 ODmLs of the starter culture was
then used to inoculate 5 L batch fermenters containing the same
media. The bacteria grown in the TB culture began to grow
exponentially immediately upon innoculation, with a specific growth
rate of 0.5 h.sup.-1, then entered into a deceleration phase about
7 hours after inoculation, reaching stationary phase at a viable
cell density of 2.1.times.10.sup.10 CFU/mL (FIG. 24A). The bacteria
grown in the defined media also exhibited exponential growth;
however, the growth rate was 0.25 h.sup.-1, and the final viable
cell density was 1.4.times.10.sup.10 CFU/mL. A total yield of
8.9.times.10.sup.13 CFR was obtained from the batch fermentation.
Both batch fermentations entered into stationary phase as a result
of carbon limitation, as evidenced by the finding that the glucose
concentration had reached zero at stationary phase. Since LM cannot
utilize AA as a carbon source, the cells were unable to grow in the
absence of carbohydrate.
[0423] At all densities tested, the bacteria grown in TB retained
their viability throughout subsequent steps in the process (FIG.
24B). Bacteria grown in defined media maintained their viability up
to an OD of 3-4 (FIG. 24C).
[0424] It was further found that, to prevent iron precipitation,
the iron and magnesium salts could be dissolved separately in water
and heated to 60.degree. C., then filter-sterilized and
simultaneously added to the fermenter culture medium.
Example 17
Further Optimization of Cryopreservation Conditions for Listeria
Vaccine Strains
[0425] The next experiment examined the viability of cryopreserved
Lm-LLO-E7 in the presence of each of 4 different additives: namely,
glycerol, mannitol, DMSO and sucrose. PBS was used as a control. In
addition, three different storage methods were compared:
-20.degree. C., -70.degree. C., and snap freezing in liquid
nitrogen followed by storage at -70.degree. C.
[0426] A shake flask containing 200 mL of the 4.times. media from
Table 3B was grown to an OD.sub.600 of 1.6. Fifteen 10 mL samples
were pelleted by centrifugation, the supernatants removed, and the
cells resuspended in 10 mL of PBS containing 2% w/v of the
appropriate cryoprotectant. One mL aliquots of each resuspended
sample were transferred into vials and stored using the appropriate
method. Viability was measured by replica plating (with and without
CAP) before storage and after 3-28 days or storage, and the
percentage of viable cells remaining was calculated. 2% w/v
glycerol at -70.degree. C. was found to be the best short-term
cryopreservation method; with the bacteria exhibiting approximately
100% viability. The cell viability remained high over the 3-28 days
under several of the conditions utilized (FIGS. 25-28).
Conclusion--Examples 13-18
[0427] The genetic stability of the pGG55 plasmid in Lm-LLO-E7
showed no signs of structural or segregational instability after 35
or 42 cell generations. A RWCB was produced, and the viability of
the cells preserved in the RWCB remained constant at approximately
1.times.10.sup.9 CFU/mL after freezing and thawing. The ability of
two complex media to support the growth of Lm-LLO-E7 was assessed.
LB and TB supported growth to maximum cell densities of
approximately 9.times.10.sup.8 and 1.times.10.sup.10 CFU/mL,
corresponding to OD.sub.600 of 0.8 and 4.0 units, respectively. A
defined media that supported growth to an extent similar to TB was
developed and optimized for shake flask cultivations. Lm-LLO-E7
reached a higher biomass concentration in 5 L batch fermenters
compared to shake flask cultivation, likely due to the ability to
control the pH in fermenters. The optimum method for
cryopreservation of the cells was also investigated. Lm-LLO-E7
cryopreserved in PBS containing 2% w/v glycerol exhibited
approximately 100% viability following storage at less than
-70.degree. C. for 3 days.
[0428] Having described the embodiments of the invention with
reference to the accompanying drawings, it is to be understood that
the invention is not limited to the precise embodiments, and that
various changes and modifications may be effected therein by those
skilled in the art without departing from the scope or spirit of
the invention as defined in the appended claims.
Sequence CWU 1
1
25132PRTListeria monocytogenes 1Lys Glu Asn Ser Ile Ser Ser Met Ala
Pro Pro Ala Ser Pro Pro Ala 1 5 10 15 Ser Pro Lys Thr Pro Ile Glu
Lys Lys His Ala Asp Glu Ile Asp Lys 20 25 30 214PRTListeria
monocytogenes 2Lys Thr Glu Glu Gln Pro Ser Glu Val Asn Thr Gly Pro
Arg 1 5 10 328PRTListeria monocytogenes 3Lys Ala Ser Val Thr Asp
Thr Ser Glu Gly Asp Leu Asp Ser Ser Met 1 5 10 15 Gln Ser Ala Asp
Glu Ser Thr Pro Gln Pro Leu Lys 20 25 420PRTListeria monocytogenes
4Lys Asn Glu Glu Val Asn Ala Ser Asp Phe Pro Pro Pro Pro Thr Asp 1
5 10 15 Glu Glu Leu Arg 20 533PRTListeria monocytogenes 5Arg Gly
Gly Ile Pro Thr Ser Glu Glu Phe Ser Ser Leu Asn Ser Gly 1 5 10 15
Asp Phe Thr Asp Asp Glu Asn Ser Glu Thr Thr Glu Glu Glu Ile Asp 20
25 30 Arg 617PRTStreptococcus pyogenes 6Lys Gln Asn Thr Ala Ser Thr
Glu Thr Thr Thr Thr Asn Glu Gln Pro 1 5 10 15 Lys
717PRTStreptococcus equisimilis 7Lys Gln Asn Thr Ala Asn Thr Glu
Thr Thr Thr Thr Asn Glu Gln Pro 1 5 10 15 Lys 822DNAArtificial
SequencePrimer for amplifying E7 8ggctcgagca tggagataca cc
22928DNAArtificial SequencePrimer for amplifying E7 9ggggactagt
ttatggtttc tgagaaca 281031DNAArtificial SequencePrimer for
generating hly promoter and gene fragment 10gggggctagc cctcctttga
ttagtatatt c 311128DNAArtificial SequencePrimer for generating hly
promoter and gene fragment 11ctccctcgag atcataattt acttcatc
281255DNAArtificial SequencePrimer for amplifying PrfA gene
12gactacaagg acgatgaccg acaagtgata acccgggatc taaataaatc cgttt
551327DNAArtificial SequencePrimer for amplifying PrfA gene
13cccgtcgacc agctcttctt ggtgaag 27149PRTArtificial
Sequencephycoerythrin (PE)-conjugated E7 peptide 14Arg Ala His Tyr
Asn Ile Val Thr Phe 1 5 15441PRTListeria monocytogenes 15Met Lys
Lys Ile Met Leu Val Phe Ile Thr Leu Ile Leu Val Ser Leu 1 5 10 15
Pro Ile Ala Gln Gln Thr Glu Ala Lys Asp Ala Ser Ala Phe Asn Lys 20
25 30 Glu Asn Ser Ile Ser Ser Val Ala Pro Pro Ala Ser Pro Pro Ala
Ser 35 40 45 Pro Lys Thr Pro Ile Glu Lys Lys His Ala Asp Glu Ile
Asp Lys Tyr 50 55 60 Ile Gln Gly Leu Asp Tyr Asn Lys Asn Asn Val
Leu Val Tyr His Gly 65 70 75 80 Asp Ala Val Thr Asn Val Pro Pro Arg
Lys Gly Tyr Lys Asp Gly Asn 85 90 95 Glu Tyr Ile Val Val Glu Lys
Lys Lys Lys Ser Ile Asn Gln Asn Asn 100 105 110 Ala Asp Ile Gln Val
Val Asn Ala Ile Ser Ser Leu Thr Tyr Pro Gly 115 120 125 Ala Leu Val
Lys Ala Asn Ser Glu Leu Val Glu Asn Gln Pro Asp Val 130 135 140 Leu
Pro Val Lys Arg Asp Ser Leu Thr Leu Ser Ile Asp Leu Pro Gly 145 150
155 160 Met Thr Asn Gln Asp Asn Lys Ile Val Val Lys Asn Ala Thr Lys
Ser 165 170 175 Asn Val Asn Asn Ala Val Asn Thr Leu Val Glu Arg Trp
Asn Glu Lys 180 185 190 Tyr Ala Gln Ala Tyr Ser Asn Val Ser Ala Lys
Ile Asp Tyr Asp Asp 195 200 205 Glu Met Ala Tyr Ser Glu Ser Gln Leu
Ile Ala Lys Phe Gly Thr Ala 210 215 220 Phe Lys Ala Val Asn Asn Ser
Leu Asn Val Asn Phe Gly Ala Ile Ser 225 230 235 240 Glu Gly Lys Met
Gln Glu Glu Val Ile Ser Phe Lys Gln Ile Tyr Tyr 245 250 255 Asn Val
Asn Val Asn Glu Pro Thr Arg Pro Ser Arg Phe Phe Gly Lys 260 265 270
Ala Val Thr Lys Glu Gln Leu Gln Ala Leu Gly Val Asn Ala Glu Asn 275
280 285 Pro Pro Ala Tyr Ile Ser Ser Val Ala Tyr Gly Arg Gln Val Tyr
Leu 290 295 300 Lys Leu Ser Thr Asn Ser His Ser Thr Lys Val Lys Ala
Ala Phe Asp 305 310 315 320 Ala Ala Val Ser Gly Lys Ser Val Ser Gly
Asp Val Glu Leu Thr Asn 325 330 335 Ile Ile Lys Asn Ser Ser Phe Lys
Ala Val Ile Tyr Gly Gly Ser Ala 340 345 350 Lys Asp Glu Val Gln Ile
Ile Asp Gly Asn Leu Gly Asp Leu Arg Asp 355 360 365 Ile Leu Lys Lys
Gly Ala Thr Phe Asn Arg Glu Thr Pro Gly Val Pro 370 375 380 Ile Ala
Tyr Thr Thr Asn Phe Leu Lys Asp Asn Glu Leu Ala Val Ile 385 390 395
400 Lys Asn Asn Ser Glu Tyr Ile Glu Thr Thr Ser Lys Ala Tyr Thr Asp
405 410 415 Gly Lys Ile Asn Ile Asp His Ser Gly Gly Tyr Val Ala Gln
Phe Asn 420 425 430 Ile Ser Trp Asp Glu Val Asn Tyr Asp 435 440
16416PRTListeria monocytogenes 16Met Lys Lys Ile Met Leu Val Phe
Ile Thr Leu Ile Leu Val Ser Leu 1 5 10 15 Pro Ile Ala Gln Gln Thr
Glu Ala Lys Asp Ala Ser Ala Phe Asn Lys 20 25 30 Glu Asn Ser Ile
Ser Ser Val Ala Pro Pro Ala Ser Pro Pro Ala Ser 35 40 45 Pro Lys
Thr Pro Ile Glu Lys Lys His Ala Asp Glu Ile Asp Lys Tyr 50 55 60
Ile Gln Gly Leu Asp Tyr Asn Lys Asn Asn Val Leu Val Tyr His Gly 65
70 75 80 Asp Ala Val Thr Asn Val Pro Pro Arg Lys Gly Tyr Lys Asp
Gly Asn 85 90 95 Glu Tyr Ile Val Val Glu Lys Lys Lys Lys Ser Ile
Asn Gln Asn Asn 100 105 110 Ala Asp Ile Gln Val Val Asn Ala Ile Ser
Ser Leu Thr Tyr Pro Gly 115 120 125 Ala Leu Val Lys Ala Asn Ser Glu
Leu Val Glu Asn Gln Pro Asp Val 130 135 140 Leu Pro Val Lys Arg Asp
Ser Leu Thr Leu Ser Ile Asp Leu Pro Gly 145 150 155 160 Met Thr Asn
Gln Asp Asn Lys Ile Val Val Lys Asn Ala Thr Lys Ser 165 170 175 Asn
Val Asn Asn Ala Val Asn Thr Leu Val Glu Arg Trp Asn Glu Lys 180 185
190 Tyr Ala Gln Ala Tyr Ser Asn Val Ser Ala Lys Ile Asp Tyr Asp Asp
195 200 205 Glu Met Ala Tyr Ser Glu Ser Gln Leu Ile Ala Lys Phe Gly
Thr Ala 210 215 220 Phe Lys Ala Val Asn Asn Ser Leu Asn Val Asn Phe
Gly Ala Ile Ser 225 230 235 240 Glu Gly Lys Met Gln Glu Glu Val Ile
Ser Phe Lys Gln Ile Tyr Tyr 245 250 255 Asn Val Asn Val Asn Glu Pro
Thr Arg Pro Ser Arg Phe Phe Gly Lys 260 265 270 Ala Val Thr Lys Glu
Gln Leu Gln Ala Leu Gly Val Asn Ala Glu Asn 275 280 285 Pro Pro Ala
Tyr Ile Ser Ser Val Ala Tyr Gly Arg Gln Val Tyr Leu 290 295 300 Lys
Leu Ser Thr Asn Ser His Ser Thr Lys Val Lys Ala Ala Phe Asp 305 310
315 320 Ala Ala Val Ser Gly Lys Ser Val Ser Gly Asp Val Glu Leu Thr
Asn 325 330 335 Ile Ile Lys Asn Ser Ser Phe Lys Ala Val Ile Tyr Gly
Gly Ser Ala 340 345 350 Lys Asp Glu Val Gln Ile Ile Asp Gly Asn Leu
Gly Asp Leu Arg Asp 355 360 365 Ile Leu Lys Lys Gly Ala Thr Phe Asn
Arg Glu Thr Pro Gly Val Pro 370 375 380 Ile Ala Tyr Thr Thr Asn Phe
Leu Lys Asp Asn Glu Leu Ala Val Ile 385 390 395 400 Lys Asn Asn Ser
Glu Tyr Ile Glu Thr Thr Ser Lys Ala Tyr Thr Asp 405 410 415
17529PRTListeria monocytogenes 17Met Lys Lys Ile Met Leu Val Phe
Ile Thr Leu Ile Leu Val Ser Leu 1 5 10 15 Pro Ile Ala Gln Gln Thr
Glu Ala Lys Asp Ala Ser Ala Phe Asn Lys 20 25 30 Glu Asn Ser Ile
Ser Ser Met Ala Pro Pro Ala Ser Pro Pro Ala Ser 35 40 45 Pro Lys
Thr Pro Ile Glu Lys Lys His Ala Asp Glu Ile Asp Lys Tyr 50 55 60
Ile Gln Gly Leu Asp Tyr Asn Lys Asn Asn Val Leu Val Tyr His Gly 65
70 75 80 Asp Ala Val Thr Asn Val Pro Pro Arg Lys Gly Tyr Lys Asp
Gly Asn 85 90 95 Glu Tyr Ile Val Val Glu Lys Lys Lys Lys Ser Ile
Asn Gln Asn Asn 100 105 110 Ala Asp Ile Gln Val Val Asn Ala Ile Ser
Ser Leu Thr Tyr Pro Gly 115 120 125 Ala Leu Val Lys Ala Asn Ser Glu
Leu Val Glu Asn Gln Pro Asp Val 130 135 140 Leu Pro Val Lys Arg Asp
Ser Leu Thr Leu Ser Ile Asp Leu Pro Gly 145 150 155 160 Met Thr Asn
Gln Asp Asn Lys Ile Val Val Lys Asn Ala Thr Lys Ser 165 170 175 Asn
Val Asn Asn Ala Val Asn Thr Leu Val Glu Arg Trp Asn Glu Lys 180 185
190 Tyr Ala Gln Ala Tyr Pro Asn Val Ser Ala Lys Ile Asp Tyr Asp Asp
195 200 205 Glu Met Ala Tyr Ser Glu Ser Gln Leu Ile Ala Lys Phe Gly
Thr Ala 210 215 220 Phe Lys Ala Val Asn Asn Ser Leu Asn Val Asn Phe
Gly Ala Ile Ser 225 230 235 240 Glu Gly Lys Met Gln Glu Glu Val Ile
Ser Phe Lys Gln Ile Tyr Tyr 245 250 255 Asn Val Asn Val Asn Glu Pro
Thr Arg Pro Ser Arg Phe Phe Gly Lys 260 265 270 Ala Val Thr Lys Glu
Gln Leu Gln Ala Leu Gly Val Asn Ala Glu Asn 275 280 285 Pro Pro Ala
Tyr Ile Ser Ser Val Ala Tyr Gly Arg Gln Val Tyr Leu 290 295 300 Lys
Leu Ser Thr Asn Ser His Ser Thr Lys Val Lys Ala Ala Phe Asp 305 310
315 320 Ala Ala Val Ser Gly Lys Ser Val Ser Gly Asp Val Glu Leu Thr
Asn 325 330 335 Ile Ile Lys Asn Ser Ser Phe Lys Ala Val Ile Tyr Gly
Gly Ser Ala 340 345 350 Lys Asp Glu Val Gln Ile Ile Asp Gly Asn Leu
Gly Asp Leu Arg Asp 355 360 365 Ile Leu Lys Lys Gly Ala Thr Phe Asn
Arg Glu Thr Pro Gly Val Pro 370 375 380 Ile Ala Tyr Thr Thr Asn Phe
Leu Lys Asp Asn Glu Leu Ala Val Ile 385 390 395 400 Lys Asn Asn Ser
Glu Tyr Ile Glu Thr Thr Ser Lys Ala Tyr Thr Asp 405 410 415 Gly Lys
Ile Asn Ile Asp His Ser Gly Gly Tyr Val Ala Gln Phe Asn 420 425 430
Ile Ser Trp Asp Glu Val Asn Tyr Asp Pro Glu Gly Asn Glu Ile Val 435
440 445 Gln His Lys Asn Trp Ser Glu Asn Asn Lys Ser Lys Leu Ala His
Phe 450 455 460 Thr Ser Ser Ile Tyr Leu Pro Gly Asn Ala Arg Asn Ile
Asn Val Tyr 465 470 475 480 Ala Lys Glu Cys Thr Gly Leu Ala Trp Glu
Trp Trp Arg Thr Val Ile 485 490 495 Asp Asp Arg Asn Leu Pro Leu Val
Lys Asn Arg Asn Ile Ser Ile Trp 500 505 510 Gly Thr Thr Leu Tyr Pro
Lys Tyr Ser Asn Lys Val Asp Asn Pro Ile 515 520 525 Glu
1825DNAArtificial SequencePrimer for amplifying E7 18gcggatccca
tggagataca cctac 251922DNAArtificial SequencePrimer for amplifying
E7 19gctctagatt atggtttctg ag 222098PRTHuman papillomavirus type 16
20Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln 1
5 10 15 Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser
Ser 20 25 30 Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala
Glu Pro Asp 35 40 45 Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys
Lys Cys Asp Ser Thr 50 55 60 Leu Arg Leu Cys Val Gln Ser Thr His
Val Asp Ile Arg Thr Leu Glu 65 70 75 80 Asp Leu Leu Met Gly Thr Leu
Gly Ile Val Cys Pro Ile Cys Ser Gln 85 90 95 Lys Pro 21105PRTHuman
papillomavirus type 16 21Met His Gly Pro Lys Ala Thr Leu Gln Asp
Ile Val Leu His Leu Glu 1 5 10 15 Pro Gln Asn Glu Ile Pro Val Asp
Leu Leu Cys His Glu Gln Leu Ser 20 25 30 Asp Ser Glu Glu Glu Asn
Asp Glu Ile Asp Gly Val Asn His Gln His 35 40 45 Leu Pro Ala Arg
Arg Ala Glu Pro Gln Arg His Thr Met Leu Cys Met 50 55 60 Cys Cys
Lys Cys Glu Ala Arg Ile Glu Leu Val Val Glu Ser Ser Ala 65 70 75 80
Asp Asp Leu Arg Ala Phe Gln Gln Leu Phe Leu Asn Thr Leu Ser Phe 85
90 95 Val Cys Pro Trp Cys Ala Ser Gln Gln 100 105 22158PRTHuman
papillomavirus type 16 22Met His Gln Lys Arg Thr Ala Met Phe Gln
Asp Pro Gln Glu Arg Pro 1 5 10 15 Arg Lys Leu Pro Gln Leu Cys Thr
Glu Leu Gln Thr Thr Ile His Asp 20 25 30 Ile Ile Leu Glu Cys Val
Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu 35 40 45 Val Tyr Asp Phe
Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly 50 55 60 Asn Pro
Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile 65 70 75 80
Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu 85
90 95 Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile
Asn 100 105 110 Cys Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His
Leu Asp Lys 115 120 125 Lys Gln Arg Phe His Asn Ile Arg Gly Arg Trp
Thr Gly Arg Cys Met 130 135 140 Ser Cys Cys Arg Ser Ser Arg Thr Arg
Arg Glu Thr Gln Leu 145 150 155 23158PRTHuman papillomavirus type
16 23Met Ala Arg Phe Glu Asp Pro Thr Arg Arg Pro Tyr Lys Leu Pro
Asp 1 5 10 15 Leu Cys Thr Glu Leu Asn Thr Ser Leu Gln Asp Ile Glu
Ile Thr Cys 20 25 30 Val Tyr Cys Lys Thr Val Leu Glu Leu Thr Glu
Val Phe Glu Phe Ala 35 40 45 Phe Lys Asp Leu Phe Val Val Tyr Arg
Asp Ser Ile Pro His Ala Ala 50 55 60 Cys His Lys Cys Ile Asp Phe
Tyr Ser Arg Ile Arg Glu Leu Arg His 65 70 75 80 Tyr Ser Asp Ser Val
Tyr Gly Asp Thr Leu Glu Lys Leu Thr Asn Thr 85 90 95 Gly Leu Tyr
Asn Leu Leu Ile Arg Cys Leu Arg Cys Gln Lys Pro Leu 100 105 110 Asn
Pro Ala Glu Lys Leu Arg His Leu Asn Glu Lys Arg Arg Phe His 115 120
125 Asn Ile Ala Gly His Tyr Arg Gly Gln Cys His Ser Cys Cys Asn Arg
130 135 140 Ala Arg Gln Glu Arg Leu Gln Arg Arg Arg Glu Thr Gln Val
145 150 155 249PRTHuman immunodeficiency virus 24Ala Met Gln Met
Leu Lys Glu Thr Ile 1 5 259PRTListeria monocytogenes 25Gly Tyr Lys
Asp Gly
Asn Glu Tyr Ile 1 5
* * * * *